<SEC-DOCUMENT>0001193125-22-082798.txt : 20220323
<SEC-HEADER>0001193125-22-082798.hdr.sgml : 20220323
<ACCEPTANCE-DATETIME>20220323163727
ACCESSION NUMBER:		0001193125-22-082798
CONFORMED SUBMISSION TYPE:	POSASR
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20220323
DATE AS OF CHANGE:		20220323
EFFECTIVENESS DATE:		20220323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POSASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-253851
		FILM NUMBER:		22763619

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>POSASR
<SEQUENCE>1
<FILENAME>d280081dposasr.htm
<DESCRIPTION>POSASR
<TEXT>
<HTML><HEAD>
<TITLE>POSASR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on March&nbsp;23, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-253851</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>POST-EFFECTIVE
AMENDMENT NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">87-0233535</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>951 Yamato Road, Suite 220 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boca Raton, Florida 33431 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(561) <FONT STYLE="white-space:nowrap">961-1900</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Hugh O&#146;Dowd </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>951 Yamato Road, Suite 220 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boca Raton, Florida 33431 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(561) <FONT STYLE="white-space:nowrap">961-1900</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Joshua
M. Samek, Esq. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DLA Piper LLP (US) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>200 South Biscayne Boulevard, Suite 2500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Miami, Florida 33131 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(305)
<FONT STYLE="white-space:nowrap">423-8500</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of
commencement of proposed sale to the public</B>: From time to time after the effective date of this registration statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the only securities being
registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of
the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans,
check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the
Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a registration
statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act. &#9744; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Post-Effective Amendment No.&nbsp;1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Commission file <FONT
STYLE="white-space:nowrap">No.&nbsp;333-253851)</FONT> (the &#147;Registration Statement&#148;) of TherapeuticsMD, Inc. (the &#147;Registrant&#148;) is being filed because the Registrant expects that it will no longer be a well-known seasoned issuer
(as such term is defined in Rule 405 of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;)) when it files its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021.
This Post-Effective Amendment No.&nbsp;1 adds disclosure to Registration Statement required for a registrant other than a well-known seasoned issuer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This registration statements contains two prospectuses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a base prospectus that covers the offering, issuance and sale of by us of up to $209,377,660 of the securities
described therein from time to time in one or more offerings; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a sales agreement prospectus that covers the offering, issuance and sale by us of up to a maximum aggregate
offering price of $59,377,660 of our common stock that may be issued and sold under a Controlled Equity OfferingSM Sales Agreement, or the sales agreement, with Cantor Fitzgerald&nbsp;&amp; Co. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus other than
the shares of our common stock to be offered, issued and sold under the sales agreement will be specified in a prospectus supplement to the base prospectus. The specific terms of the shares of our common stock to be offered, issued and sold under
the sales agreement are specified in the sales agreement prospectus that immediately follows the base prospectus. The $59,377,660 of our common stock that may be offered, issued and sold under the sales agreement prospectus is included in the
$209,377,660 of securities that may be offered, issued and sold by us under the base prospectus. Upon termination of the sales agreement, any portion of the $59,377,660 included in the sales agreement prospectus that is not sold pursuant to the
sales agreement will be available for sale in other offerings pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $59,377,660 of securities may be sold in other offerings pursuant to the base prospectus.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g280081g03s03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$209,377,660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Purchase
Contracts </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and
sell up to $209,377,660 in the aggregate of securities from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer and sell. We will provide specific terms of any offering in a
supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents
incorporated or deemed to be incorporated by reference in this prospectus before you invest in any of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell in the same
offering or in separate offerings; to or through underwriters, dealers and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities and any applicable fees, commissions, or discounts
will be described in the applicable prospectus supplement. Our net proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus may not be used to consummate a sale of our securities unless accompanied by the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See the &#147;<U><A HREF="#cova280081_200">Risk Factors</A></U>&#148; section beginning on
page&nbsp;2 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We
may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendment or supplements, any free writing prospectuses, and any documents incorporated by
reference carefully before you make your investment decision. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March&nbsp;23, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_3">CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_4">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_7">DESCRIPTION OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_8">DESCRIPTION OF PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_10">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_11">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_12">DESCRIPTION OF PURCHASE CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_13">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_14">CERTAIN PROVISIONS OF NEVADA LAW AND OUR CHARTER AND
BYLAWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_15">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_16">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_17">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_18">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_19">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca280081_20">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &#147;shelf&#148;
registration process. Under this shelf registration process, we may sell, from time to time, any combination of the securities described in this prospectus in one or more offerings for an aggregate initial offering price of up to $209,377,660. This
prospectus provides you with general information regarding the securities we may offer. We will provide a prospectus supplement that contains specific information about any offering by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement also may add, update, or change information contained in the prospectus. You should read both this prospectus and the prospectus
supplement related to any offering as well as additional information described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus or any
accompanying prospectus supplement or any &#147;free writing prospectus.&#148; We are offering to sell securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus and in any accompanying
prospectus supplement is accurate only as of the dates of their covers, regardless of the time of delivery of this prospectus or any prospectus supplement or of any sale of our securities. Our business, financial condition, results of operations,
and prospects may have changed since those dates. You should rely only on the information contained or incorporated by reference in this prospectus or any accompanying prospectus supplement. To the extent there is a conflict between the information
contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later
date &#151; for example, a document incorporated by reference into this prospectus or any prospectus supplement &#151; the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references in this prospectus to &#147;TherapeuticsMD,&#148; &#147;TXMD,&#148; &#147;Company,&#148; &#147;our
company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, BocagreenMD, Inc., a Nevada corporation, and vitaCare
Prescription Services, Inc., a Florida corporation (&#147;vitaCare&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>,
vitaMedMD<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>, BocaGreenMD<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>, IMVEXXY<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>,
BIJUVA<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT> and ANNOVERA<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT> are registered trademarks of our company. Solely for convenience, trademarks, trade
names and service marks referred to in this prospectus supplement and the accompanying prospectus may appear without the <FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>,
<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable
licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with,
or endorsement or sponsorship of us by, these other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_2"></A><A NAME="cova280081_200"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the discussion of risks and
uncertainties under the heading &#147;Risk Factors&#148; contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020 and our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, June&nbsp;30 and September&nbsp;30, 2021, respectively, which are incorporated by reference in this prospectus, and under similar headings in our subsequently filed annual
reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> , as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing
prospectus and in the other documents incorporated by reference in this prospectus. See the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus. The
risks and uncertainties we discuss in this prospectus, in any applicable prospectus supplement or free writing prospectus and in the other documents incorporated by reference in this prospectus are not the only ones facing our company. Additional
risks and uncertainties not presently known to us or that we currently believe are immaterial also may materially and adversely affect our business, financial condition and results of operations. Please also refer to the section of this prospectus
titled &#147;Cautionary Statement About Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_3"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, any applicable prospectus supplement and the documents and information incorporated by reference herein and therein may contain
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements may include, but are not
limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events, or developments that we intend, expect, project, believe or anticipate will or may occur in
the future. These statements are often characterized by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148;
&#147;target,&#148; &#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. You should not place
undue reliance on these forward-looking statements, which reflect our view only as of the date of this prospectus, and we undertake no obligation to update these forward-looking statements in the future, except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of important factors could cause actual results to differ materially from those indicated by the forward-looking statements, including, without
limitation, those factors described under the caption &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020 and our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, June&nbsp;30 and September&nbsp;30, 2021, respectively, which are incorporated by reference in this prospectus, and under similar headings in our subsequently filed annual
reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> , as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing
prospectus and in the other documents incorporated by reference in this prospectus. Some of the key factors that could cause actual results to differ from our expectations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain or increase sales of our approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and commercialize IMVEXXY, ANNOVERA, BIJUVA and our hormone therapy drug candidates and
obtain additional financing necessary therefor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our common stock on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the closing of the divestiture of vitaCare and the timing thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing, and manufacturing capabilities and strategy for our approved products; the size
of markets and the potential market opportunity for which our products are approved and our ability to penetrate such markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of healthcare providers to prescribe and patients to use our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain additional financing when needed and to service our debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the success of competing products that are or become available for the indications
that we are pursuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will be able to comply with the covenants and conditions under our term loan facility;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of management transitions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully implement cost savings initiatives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential of adverse side effects or other safety risks that could adversely affect the commercialization of
our current or future approved products or preclude the approval of our future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length, cost and uncertain results of future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials, research and development and manufacturing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our licensees to commercialize and distribute our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of laws, regulations and enforcement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive nature of the industries in which we conduct our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement from government authorities and health insurance companies for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of product liability lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the influence of extensive and costly government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the concentration of power in our stock ownership. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_4"></A>OUR COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a women&#146;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a
patient-controlled, long-lasting contraceptive to advanced U.S. Food and Drug Administration (&#147;FDA&#148;) approved <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy pharmaceutical products for the treatment of vasomotor
symptoms and dyspareunia. We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our women&#146;s healthcare focus. Our portfolio of products focused on women&#146;s
health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. Beginning in 2018, the FDA approval of our pharmaceutical products transitioned our company from predominately focused on conducting
research and development to one focused on commercializing our pharmaceutical products. In July 2018, we launched our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, IMVEXXY (estradiol vaginal inserts) for the treatment of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was approved by the FDA
in May 2018. In April 2019, we launched our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of <FONT STYLE="white-space:nowrap">bio-identical</FONT>
17&szlig;-estradiol and <FONT STYLE="white-space:nowrap">bio-identical</FONT> progesterone in a single, oral softgel capsule, for the treatment of <FONT STYLE="white-space:nowrap">moderate-to</FONT> severe vasomotor symptoms, or VMS, due to
menopause in women with a uterus, which was approved by the FDA in October 2018. In October 2019, we began a test and learn market introduction for our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product ANNOVERA (segesterone acetate and
ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was approved by the FDA in August 2018 and which we have licensed for commercialization in
the U.S. with the Population Council, Inc. (the &#147;Population Council&#148;) pursuant to an exclusive license agreement with the Population Council. We paused the full commercial launch of ANNOVERA in March 2020 due to the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and resumed this initiative in July 2020. In addition, in July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc. (&#147;Knight&#148;) pursuant to which we granted
Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In June 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited (&#147;Theramex&#148;) to commercialize BIJUVA and IMVEXXY
outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation. We maintain our principal executive offices at 951 Yamato Road, Suite 220, Boca&nbsp;Raton, Florida 33431. Our telephone number
is (561) <FONT STYLE="white-space:nowrap">961-1900.</FONT> We maintain websites at <I>www.therapeuticsmd.com</I> as well as various product websites. The information contained on our websites or that can be accessed through our websites does not
constitute part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as may be otherwise set forth in any prospectus supplement accompanying this prospectus, we will use the net proceeds we receive from sales of
securities offered hereby to fund the commercialization of our IMVEXXY, BIJUVA and ANNOVERA products and for general corporate purposes, which may include the repayment of indebtedness outstanding from time to time and for working capital, capital
expenditures, acquisitions and repurchases of our common stock or other securities. Pending these uses, the net proceeds may also be temporarily invested in cash equivalents or short-term securities. When specific securities are offered, the
prospectus supplement relating thereto will set forth our intended use of the net proceeds that we receive from the sale of such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of investors purchasing
securities in an offering under this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net tangible book value per share of our equity securities before and after the offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the increase in such net tangible book value per share attributable to the cash payments made by
purchasers of the equity interests being offered; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_7"></A>DESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section describes the general terms of our common stock. A prospectus supplement may provide information that is different from this prospectus. If the
information in the prospectus supplement with respect to our common stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and restated articles of incorporation, as
amended, has been incorporated by reference from our filings with the SEC as an exhibit to the registration statement of which this prospectus forms a part. Our common stock and the rights of the holders of our common stock are subject to the
applicable provisions of the Nevada Private Corporation Code, which we refer to as &#147;Nevada law,&#148; our amended and restated articles of incorporation, as amended, our bylaws, as amended, and the rights of the holders of our preferred stock,
if any, as well as some of the terms of our outstanding indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of incorporation, as amended, we have the
authority to issue 600,000,000 shares of common stock, par value $0.001 per share. As of March&nbsp;17, 2022, we had 433,427,878 shares of common stock outstanding. As of March&nbsp;17, 2022, there were 128 stockholders of record of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our common stock, and any description of our common stock in a prospectus supplement, may not be complete and is
subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of incorporation and our bylaws, each as amended from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding share of our common stock
is entitled to one vote per share of record on all matters submitted to a vote of stockholders and to vote together as a single class for the election of directors and in respect of other corporate matters. At a meeting of stockholders at which a
quorum is present, for all matters other than the election of directors, an affirmative vote of the majority of shares entitled to vote on a matter and that are represented either in person or by proxy at a meeting of stockholders decides all
questions, unless the matter is one upon which a different vote is required by express provision of law or our amended and restated articles incorporation or our bylaws, each as may be amended from time to time. Directors will be elected by a
plurality of the votes of the shares present at a meeting. Holders of shares of common stock do not have cumulative voting rights with respect to the election of directors or any other matter. The Company has adopted a majority voting policy as part
of its Corporate Governance Guidelines. The majority voting policy is applicable solely to uncontested elections, which are those elections in which the number of nominees for election is less than or equal to the number of directors to be elected.
Under the majority voting policy, any nominee for director who receives more &#147;withheld&#148; votes than &#147;for&#148; votes in an uncontested election must submit a written offer to resign as director. Any such resignation will be reviewed by
the Nominating and Corporate Governance Committee and, within 90 days after the election, the independent members of the Company&#146;s board of directors will determine whether to accept, reject or take other appropriate action with respect to, the
resignation, in furtherance of the best interests of the Company and its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to receive dividends or other distributions when, as and if declared by our board of directors. The right of our board
of directors to declare dividends, however, is subject to any rights of the holders of other classes of our capital stock, any indebtedness outstanding from time to time and the availability of sufficient funds, as determined under Nevada law, to
pay dividends. In addition, the Financing Agreement, dated as of April&nbsp;24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, various lenders from time to time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors contains covenants that limit our ability to pay dividends or make other distributions on our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preemptive Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our common stock do not have preemptive rights to purchase or subscribe for any of our capital stock or other securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of our common stock are not subject to
redemption by operation of a sinking fund or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution, or winding up of our company, subject to the rights, if any, of the holders of other classes of our capital
stock, the holders of shares of our common stock are entitled to receive any of our assets available for distribution to our stockholders ratably in proportion to the number of shares held by them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options, Warrants and Other Stock-Based Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time
to time, we have issued and expect to continue to issue options, warrants and other stock-based rights to various lenders, investors, consultants, employees, officers and directors of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;17, 2022 we had: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding options representing the right to purchase a total of 16,174,918 shares of common stock at a weighted
average exercise price of $4.59 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,812,855 shares of common stock underlying outstanding restricted stock units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 9,139,956 shares of common stock underlying outstanding performance stock units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding warrants representing the right to purchase a total of 5,127,116 shares of common stock at a
weighted-average exercise price of $1.52 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,245,373 shares of common stock reserved for future issuance under our share-based payment award plans; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,063,944 shares of common stock reserved for future issuance under our employee stock purchase plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A., 350 Indiana Street, Suite 800, Golden, Colorado 80401. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_8"></A>DESCRIPTION OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section describes the general terms of our preferred stock to which any prospectus supplement may relate. A prospectus supplement will describe the terms
relating to any preferred stock to be offered by us in greater detail and may provide information that is different from terms described in this prospectus. If the information in the prospectus supplement with respect to the particular preferred
stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and restated articles of incorporation, as amended, has been incorporated by reference from our filings with the
SEC as an exhibit to the registration statement of which this prospectus forms a part. A certificate of designation or amendment to the amended and restated articles of incorporation, as amended, will specify the terms of the preferred stock being
offered, and will be filed or incorporated by reference as an exhibit to the registration statement before the preferred stock is issued. The following description of our preferred stock, and any description of the preferred stock in a prospectus
supplement may not be complete and is subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of incorporation, as amended, and bylaws, each as amended
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of incorporation, as amended, we have the authority to issue 10,000,000 shares of preferred
stock, par value $0.001 per share, which are issuable in series on terms to be determined by our board of directors. Accordingly, our board of directors is authorized, without action by the stockholders, to issue preferred stock from time to time
with such dividend, liquidation, conversion, voting, redemption, sinking fund and other rights, preferences, privileges and restrictions as it may determine. All shares of any one series of our preferred stock will be identical, except that shares
of any one series issued at different times may differ as to the dates from which dividends may be cumulative. All series will rank equally and will provide for other terms as described in the applicable prospectus supplement. As of the date of this
prospectus, there were no outstanding shares of our preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless provided in a prospectus supplement, the shares of our preferred stock to be issued will have no preemptive rights. Any prospectus supplement offering
our preferred stock will furnish the following information with respect to the preferred stock offered by that prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of preferred stock to be issued and the offering price of the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any dividend rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any dividend rates, periods, or payment dates, or methods of calculating dividends applicable to the preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date from which distributions on the preferred stock will accumulate, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into our common
stock, including the conversion price (or manner of calculation thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any right to convert the preferred stock into a different type of security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any voting rights attributable to the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any rights and preferences upon our liquidation, dissolution, or winding up of our affairs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any terms of redemption; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any procedures for any auction and remarketing for the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for a sinking fund for the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of material U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to distribution rights (including whether any
liquidation preference as to the preferred stock will be treated as a liability for purposes of determining the availability of assets for distributions to holders of stock ranking junior to the shares of preferred stock as to distribution rights);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any series of preferred stock ranking senior to or on a parity with the series of
preferred stock being offered as to distribution rights and rights upon the liquidation, dissolution, or winding up or our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, limitations, or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rank </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated
in the applicable prospectus supplement, shares of our preferred stock will rank, with respect to payment of distributions and rights upon our liquidation, dissolution, or winding up, and allocation of our earnings and losses as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the
preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity
securities rank on a parity with the preferred stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities
rank senior to the preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to any preferential rights of any outstanding stock or series of stock, our preferred stockholders will be entitled to receive distributions, in
accordance with the applicable terms of each series of preferred stock, when, as, and if declared by our board of directors, out of legally available funds, and to share pro rata based on the number of preferred shares, common stock, and other
parity equity securities outstanding. The rates and dates of payment of dividends, if any, will be set forth in the prospectus supplement relating to the applicable series of preferred stock. Dividends, if any, will be payable to holders of record
of preferred stock as they appear on our books or, if applicable, the records of the depositary, if any, referred to below on the record dates fixed by our board of directors. Dividends on a series of preferred stock may be cumulative or
noncumulative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not declare, pay, or set apart for payment dividends on the preferred stock unless full dividends on other series of preferred
stock that rank on an equal or senior basis have been paid or sufficient funds have been set apart for payment for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all prior dividend periods of other series of preferred stock that pay dividends on a cumulative basis; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the immediately preceding dividend period of other series of preferred stock that pay dividends on a
noncumulative basis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partial dividends declared on shares of preferred stock and each other series of preferred stock ranking on an
equal basis as to dividends will be declared pro rata. A pro rata declaration means that the ratio of dividends declared per share to accrued dividends per share will be the same for each series of preferred stock. Similarly, we may not declare,
pay, or set apart for payment <FONT STYLE="white-space:nowrap">non-stock</FONT> dividends or make other payments on the common stock or any other of our stock ranking junior to the preferred stock until full dividends on the preferred stock have
been paid or set apart for payment for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all prior dividend periods if the preferred stock pays dividends on a cumulative basis; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the immediately preceding dividend period if the preferred stock pays dividends on a noncumulative basis.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, or as required by Nevada law, holders of our preferred stock will not have any voting
rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the voluntary
or involuntary liquidation, dissolution, or winding up of our affairs, then, before any distribution or payment will be made to the holders of any common stock or any other class or series of stock ranking junior to the preferred stock in our
distribution of assets upon any liquidation, dissolution, or winding up, the holders of each series of our preferred stock will be entitled to receive, after payment or provision for payment of our debts and other liabilities, out of our assets
legally available for distribution to stockholders, liquidating distributions in the amount of the liquidation preference per share (set forth in the applicable prospectus supplement), plus an amount, if applicable, equal to all distributions
accrued and unpaid thereon (which will not include any accumulation in respect of unpaid distributions for prior distribution periods if the preferred stock is not entitled to a cumulative distribution). Unless otherwise specified in the applicable
prospectus supplement, after payment of the full amount of the liquidating distributions to which they are entitled, the holders of preferred stock will have no right or claim to any of our remaining assets. In the event that, upon our voluntary or
involuntary liquidation, dissolution, or winding up, the legally available assets are insufficient to pay the amount of the liquidating distributions on all of our outstanding preferred stock and the corresponding amounts payable on all of our other
classes or series of equity securities ranking on a parity with the preferred stock in the distribution of assets upon liquidation, dissolution, or winding up, then the holders of our preferred stock and all other such classes or series of equity
securities will share ratably in the distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the liquidating distributions are made in full to all holders of preferred stock, our remaining assets will be distributed among the holders of any other
classes or series of equity securities ranking junior to the preferred stock upon our liquidation, dissolution, or winding up, according to their respective rights and preferences and in each case according to their respective number of shares of
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms and conditions,
if any, upon which shares of any series of preferred stock are to be convertible into other securities will be set forth in the applicable prospectus supplement. These terms will include the amount and type of security into which the shares of
preferred stock are convertible, the conversion price (or manner of calculation thereof), the conversion period, provisions as to whether conversion will be at the option of the holders of the preferred stock or us, the events requiring an
adjustment of the conversion price, and provisions affecting conversion in the event of the redemption of that preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so provided in the applicable prospectus supplement, our preferred stock will be subject to mandatory redemption or redemption at our option, in whole or in
part, in each case upon the terms, at the times and at the redemption prices set forth in such prospectus supplement. Unless we default in the payment of the redemption price, dividends will cease to accrue after the redemption date on shares of
preferred stock called for redemption and all rights of holders of such shares will terminate, except for the right to receive the redemption price. No series of preferred stock will receive the benefit of a sinking fund except as set forth in the
applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registrar and Transfer Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registrar and transfer agent for our preferred stock will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our board of directors decides to issue any shares of preferred stock, it may discourage or make more difficult a merger, tender offer, business
combination or proxy contest, assumption of control by a holder of a large block of our securities, or the removal of incumbent management, even if these events were favorable to the interests of stockholders. Our board of directors, without
stockholder approval, may issue preferred stock with voting and conversion rights and dividend and liquidation preferences that may adversely affect the holders of our other equity or debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes certain general terms and provisions of the debt securities that we may offer under this prospectus and one or more prospectus
supplements. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a prospectus supplement. The following description of debt securities will apply to the debt securities offered by this
prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of debt securities may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue &#147;senior,&#148; &#147;senior subordinated,&#148; or &#147;subordinated&#148; debt securities. &#147;Senior securities&#148; will be direct
obligations of ours and will rank equally and ratably in right of payment with other indebtedness of ours that is not subordinated. &#147;Senior subordinated securities&#148; will be subordinated in right of payment to the prior payment in full of
senior indebtedness, as defined in the applicable prospectus supplement, and may rank equally and ratably with any other senior subordinated indebtedness. &#147;Subordinated securities&#148; will be subordinated in right of payment to senior
subordinated securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We need not issue all debt securities of one series at the same time. Unless we provide otherwise, we may reopen a series,
without the consent of the holders of such series, for issuances of additional securities of that series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the senior debt securities and
senior subordinated debt securities under a senior indenture, which we will enter into with a trustee to be named in the senior indenture, and we will issue the subordinated debt securities under a subordinated indenture, which we will enter into
with a trustee to be named in the subordinated indenture. We use the term &#147;indenture&#148; or &#147;indentures&#148; to refer to both the senior indenture and the subordinated indenture. Each indenture will be subject to and governed by the
Trust Indenture Act of 1939, as amended, or the Trust Indenture Act, and we may supplement the indenture from time to time. Any trustee under any indenture may resign or be removed with respect to one or more series of debt securities, and we may
appoint a successor trustee to act with respect to that series. We have filed a form of indenture as an exhibit to this registration statement, of which this prospectus forms a part. The terms of the senior indenture and subordinated indenture will
be substantially similar, except that the subordinated indenture will include provisions pertaining to the subordination of the subordinated debt securities and senior subordinated debt securities to the senior debt securities and any other of our
senior securities. The following statements relating to the debt securities and the indenture are summaries only, are subject to change, and are qualified in their entirety to the detailed provisions of the indenture, any supplemental indenture, and
the discussion contained in any prospectus supplements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be our direct obligations. We may issue debt securities from time to time and in one or more series as our board of directors may
establish by resolution or as we may establish in one or more supplemental indentures. The particular terms of each series of debt securities will be described in a prospectus supplement relating to the series. We may issue debt securities with
terms different from those of debt securities that we previously issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time and in one or more series with
the same or various maturities, at par, at a premium, or at a discount. We will set forth in a prospectus supplement, relating to any series of debt securities being offered, the initial offering price, and the following terms of the debt
securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the series designation and whether they are senior securities, senior subordinated securities, or subordinated
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities and any limit on the aggregate amount of the series of debt
securities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the aggregate principal amount) at which we will issue the debt
securities and, if other than the principal amount of the debt securities, the portion of the principal amount of the debt securities payable upon the maturity of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which we will pay the principal on the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) or the method used to determine the rate or rates (including
any commodity, commodity index, stock exchange index, or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable, and any
regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal, premium, if any, and any interest will be payable or the method of such
payment and where the debt securities can be surrendered for transfer, exchange, or conversion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms, if any, by which holders of the debt securities may convert or exchange the debt securities for our
common stock, preferred stock, or any other security or property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if convertible, the initial conversion price, the conversion period, and any other terms governing such
conversion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any subordination provisions or limitations relating to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sinking fund requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem, purchase or repay the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the price or prices at which and the period and periods within which and the terms and conditions upon which debt securities of the series shall be redeemed, purchased, or repaid
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase the debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will issue the debt securities in certificated or book-entry form; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which (if any), the period or periods within which (if any), and the terms and conditions
upon which (if other than as provided herein) the debt securities may be redeemed, in whole or in part, at the option, or as an obligation, of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities shall be issued in whole or in part in the form of a global security or securities;
the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual debt securities, and the depositary for such global security and securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be in registered or bearer form and, if in registered form, whether the
securities will be issuable, in whole or in part, in the form of a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies, or currency units in which payment of principal of, premium, and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, and interest and any additional amounts on the debt securities will be made in one
or more currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium or interest on the debt securities will be
determined, if these amounts may be determined by reference to an index based on a currency or currencies other than that in which the debt securities are denominated or designated to be payable or by reference to a commodity, commodity index, stock
exchange index, or financial index; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicability of the defeasance provisions described in this prospectus or any prospectus supplement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities in respect of
any tax, assessment, or governmental charge and, if so, whether we will have the option to redeem the debt securities instead of making this payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the events of default described in this prospectus or in the indenture with respect
to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the covenants described in this prospectus or in the indenture with respect to the
debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are to be issued upon the exercise of debt warrants, the time, manner, and place for them
to be authenticated and delivered; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange on which we will list the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale, or other assignment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any guarantee of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may modify or delete any provision of the indenture as it applies
to that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents, or other agents with
respect to the debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that are exchangeable for or convertible into shares of our common stock
or other securities or property. The terms, if any, on which the debt securities may be exchanged for or converted into shares of our common stock or other securities or property will be set forth in the applicable prospectus supplement. Such terms
may include provisions for conversion, either mandatory, at the option of the holder or at our option, in which case the number of shares of common stock or other securities or property to be received by the holders of debt securities would be
calculated as of a time and in the manner stated in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities at less than the principal amount payable
upon maturity. We refer to these securities as &#147;original issue discount securities.&#148; If material or applicable, we will describe in the applicable prospectus supplement special U.S. federal income tax, accounting, and other considerations
applicable to original issue discount securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and interest and any additional amounts on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will describe the
restrictions, elections, general tax considerations, specific terms, and provide other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as may be set forth in any prospectus supplement relating to the debt securities, no indenture will
contain any other provisions that would limit our ability to incur indebtedness or that would afford holders of the debt securities protection in the event of a highly leveraged or similar transaction involving us or in the event of a change in
control. You should review carefully the applicable prospectus supplement for information with respect to events of default and any covenants applicable to the debt securities being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payments and Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate
in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of
business on the regular record date for the interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay principal of, and interest and any additional amounts on, the debt securities of a
particular series at the office of the paying agents designated by us, except that, unless we otherwise indicate in the applicable prospectus supplement, we may make interest payments by check, which we will mail to the holder, or by wire transfer
to certain holders. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the
applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Transfer,
and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, as
depositary, or a nominee of the depositary (as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (as a &#147;certificated debt security&#148;), as described in the applicable prospectus supplement. Except
as described under &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certificated Debt Securities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of our debt
securities may transfer or exchange certificated debt securities at the trustee&#146;s office or paying agencies in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt
securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of our debt securities may transfer certificated debt securities and the right to receive the principal of, and interest and any additional amounts
on, certificated debt securities only by surrendering the old certificate representing those certificated debt securities and either we or the trustee will reissue the old certificate to the new holder, or we or the trustee will issue a new
certificate to the new holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Global Debt Securities and Book-Entry System </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the depositary, and registered in the name of the
depositary or a nominee of the depositary. Ownership of beneficial interests in book-entry debt securities will be limited to persons that have accounts with the depositary for the related global debt security, whom we refer to as participants, or
persons that may hold interests through participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described in this prospectus or any applicable prospectus supplement, beneficial owners
of book-entry debt securities will not be entitled to have securities registered in their names, will not receive or be entitled to receive physical delivery of a certificate in definitive form representing securities, and will not be considered the
owners or holders of those securities under the indenture. Accordingly, to exercise any rights of a holder under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the indenture, each person beneficially owning book-entry debt securities must rely on the procedures of the depositary for the related global debt security and, if that person is not a
participant, on the procedures of the participant through which that person owns its interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand, however, that under existing industry
practice, the depositary will authorize the persons on whose behalf it holds a global debt security to exercise certain rights of holders of debt securities, and the indenture provides that we, the trustee, and our respective agents will treat as
the holder of a debt security the persons specified in a written statement of the depositary with respect to that global debt security for purposes of obtaining any consents or directions required to be given by holders of the debt securities
pursuant to the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will make payments of principal of, and interest and any additional amounts on, book-entry debt securities to the
depositary or its nominee, as the case may be, as the registered holder of the related global debt security. We, the trustee, and any other agent of ours or agent of the trustee will not have any responsibility or liability for any aspect of the
records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising, or reviewing any records relating to such beneficial ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any certificated debt securities issued in exchange for a global debt security will be registered in such name or names as the depositary shall instruct the
trustee. We expect that such instructions will be based upon directions received by the depositary from participants with respect to ownership of book-entry debt securities relating to such global debt security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional discussion of book entry and certificated securities, see the section entitled &#147;Legal Ownership of Securities&#148; included in this
prospectus. We have obtained the foregoing information in this section and the &#147;Legal Ownership of Securities&#148; section concerning the depositary and the depositary&#146;s book-entry system from sources we believe to be reliable. We take no
responsibility for the depositary&#146;s performance of its obligations under the rules and regulations governing its operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the
Event of a Change in Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions
that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable
prospectus supplement, the debt securities will not contain any restrictive covenants, including covenants restricting us or any of our subsidiaries from incurring, issuing, assuming, or guaranteeing any indebtedness secured by a lien on any of our
or our subsidiaries&#146; property or capital stock or restricting us or any of our subsidiaries from entering into any sale and leaseback transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger, Consolidation, and Sale of Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we
provide otherwise in the applicable prospectus supplement, we may not merge with or into or consolidate with, or convey, transfer, or lease all or substantially all of our properties and assets to, any person (a &#147;successor person&#148;), unless
the following applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either (a)&nbsp;the company is the surviving entity or (b)&nbsp;the successor person is a corporation,
partnership, trust, or other entity organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no event of default, and no event that, after notice or lapse
of time, or both, would become an event of default, will have occurred and be continuing under the indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other conditions that may be set forth in the applicable prospectus supplement are met.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This covenant would not apply to any recapitalization transaction, a change in control of us, or a
transaction in which we incur a large amount of additional debt unless the transactions or change in control included a merger, consolidation, or transfer or lease of substantially all of our assets. Except as may be described in the applicable
prospectus supplement, there are no covenants or other provisions in the indenture providing for a &#147;put&#148; right or increased interest or that would otherwise afford holders of debt securities additional protection in the event of a
recapitalization transaction, a change in control of us, or a transaction in which we incur a large amount of additional debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default Under
the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, an &#147;event of default&#148; will mean, with respect to any
series of debt securities, any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable and
continuance of that default for a period of 30 days (unless the entire amount of such payment is deposited by us with the trustee or with a paying agent before the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of, and any other amounts due on, any debt security of that series when due
and payable either at maturity, redemption, or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the deposit of any sinking fund payment, when and as due in respect of any debt security of that
series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series) or in the debt security, which default continues uncured for a period of 60 days after we receive written
notice from the trustee or we and the trustee receive written notice from the holders of not less than a majority in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, pursuant to or within the meaning of any applicable bankruptcy law, commence a voluntary case, consent to the
entry of an order for relief against us in an involuntary case, consent to the appointment of a custodian for all or substantially all of our property, make a general assignment for the benefit of our creditors, or admit in writing our inability
generally to pay our debts as they become due; or, similarly, a court enters an order or decree under any applicable bankruptcy law that provides for relief against us in an involuntary case, appoints a custodian for all or substantially all of our
properties, or orders our liquidation (and the order remains in effect for 60 days); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided with respect to debt securities of that series that is included in any
supplemental indenture or is described in the applicable prospectus supplement accompanying this prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No event of default with
respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency, or reorganization) necessarily will constitute an event of default with respect to any other series of debt securities. An event of default may
also be an event of default under our bank credit agreements or other debt securities in existence from time to time and under certain guaranties by us of any subsidiary indebtedness. In addition, certain events of default or an acceleration under
the indenture may also be an event of default under some of our other indebtedness outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the
applicable prospectus supplement, if an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing (other than certain events of our bankruptcy, insolvency, or reorganization), then the trustee or
the holders of not less than a majority in principal amount of the outstanding debt securities of that series may, by written notice to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal (or, if
the debt securities of that series are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discount securities, that portion of the principal amount as may be specified in the terms of that series) of and accrued and unpaid interest, if any, of all debt securities of that series. In
the case of an event of default resulting from certain events of bankruptcy, insolvency, or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, of all outstanding debt securities will become and be
immediately due and payable without any declaration or other act by the trustee or any holder of outstanding debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time after an
acceleration with respect to debt securities of a series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of not less than a majority in principal amount of the outstanding
debt securities of that series may cancel the acceleration and annul its consequences if the rescission would not conflict with any judgment or decree and if all existing events of default with respect to that series have been cured or waived except
nonpayment of principal (or such lesser amount) or interest that has become due solely because of the acceleration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture also provides that the
holders of not less than a majority in principal amount of the outstanding debt securities of any series may waive any past default with respect to that series and its consequences, except a default involving the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay the principal of, and interest and any additional amounts on, any debt security; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covenant or provision contained in the indenture that cannot be modified or amended without the consent of the
holders of each outstanding debt security affected by the default. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trustee is generally required to give notice to the holders of
debt securities of each affected series within 90 days of a default actually known to a responsible officer of the trustee unless the default has been cured or waived. The indenture provides that the trustee may withhold notice to the holders of
debt securities of any series of any default or event of default (except in payment on any debt securities of that series) with respect to debt securities of that series if it in good faith determines that withholding notice is in the interest of
the holders of those debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the indenture will provide that the trustee
will be under no obligation to exercise any of its rights or powers under the indenture at the request or discretion of any holder of any such outstanding debt securities unless the trustee receives indemnity satisfactory to it against any loss,
liability, or expense. Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place of conducting any proceeding
for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. The trustee may, however, refuse to follow any discretion that conflicts with the indenture or any
law or which may be unduly prejudicial to the holders of the debt securities of the applicable series not joining in the discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, no holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or
for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing event of default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered reasonable indemnity, to the trustee to institute such proceeding as trustee, and the trustee will not have received from the holders of a majority in principal amount of the outstanding debt securities of that series a
direction inconsistent with that request and has failed to institute the proceeding within 60 days. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing,
except as provided in the subordination provisions, if any, the holder of any debt security will have an absolute and unconditional right to receive payment of the principal of, and any interest or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional amounts on, that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a certificate as to compliance with the indenture, or,
in the event of noncompliance, specify the noncompliance and the nature and status of the noncompliance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as specified below, modifications and amendments to the indenture require the approval of not less than a majority in principal amount of our
outstanding debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes Requiring the Unanimous Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may not make any modification or amendment to the indenture without the consent of the holder of each affected debt security then
outstanding if that amendment will have any of the following results: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest on any debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or change the fixed maturity of any debt security or waive a redemption payment or alter
the redemption provisions on any debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation
with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal, interest, or any additional amounts on any debt security, except
a rescission of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from that
acceleration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of, or interest or any additional amounts on, any debt security payable in currency other than
that stated in the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the place of payment on a debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the currency or currencies of payment of the principal of, and any premium, make-whole payment, interest,
or additional amounts on, any debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair the right to initiate suit for the enforcement of any payment on or with respect to any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of holders of debt securities whose consent is needed to modify or amend an indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of the holders of outstanding debt securities of any series necessary to modify or amend
the indenture, to waive compliance with provisions of the indenture or defaults and their consequences under the indenture, or to reduce the quorum or voting requirements contained in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that adversely affects the right to convert or exchange any debt security other than as permitted
by the indenture or decrease the conversion or exchange rate or increase the conversion or exchange price of any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, and interest and any additional amount on, those debt securities, the right of holders to institute suit for the enforcement of any payment or the right of holders to waive past defaults.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes Not Requiring Approval of Debt Holders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify or amend an indenture, without the consent of any holder of debt securities, for any of the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of another person to us as obligor under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our existing covenants additional covenants for the benefit of the holders of all or any series of debt
securities, or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add events of default for the benefit of the holders of all or any series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add or change any provisions of the indenture to facilitate the issuance of, or to liberalize the terms of,
debt securities in bearer form, or to permit or facilitate the issuance of debt securities in uncertificated form, provided that this action will not adversely affect the interests of the holders of the debt securities of any series in any material
respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add, change, or eliminate any provisions of the indenture, provided that any addition, change, or elimination
(a)&nbsp;shall neither (i)&nbsp;apply to any debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of such provision nor (ii)&nbsp;modify the rights of the holder of any debt security
with respect to such provision, or (b)&nbsp;shall become effective only when there are no outstanding debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish additional series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to secure previously unsecured debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form or terms of debt securities of any series, including the provisions and procedures, if
applicable, for the conversion or exchange of the debt securities into our common stock, preferred stock, or other securities or property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance or appointment of a successor trustee or facilitate the administration
of the trusts under the indenture by more than one trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any provision with respect to the conversion or exchange of rights of holders pursuant to the
requirements of the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect, or inconsistency in the indenture, provided that the action does not adversely
affect the interests of holders of debt securities of any series issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to close the indenture with respect to the authentication and delivery of additional series of debt securities or
to qualify, or maintain qualification of, the indenture under the Trust Indenture Act; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to supplement any of the provisions of the indenture to the extent necessary to permit or facilitate defeasance
and discharge of any series of debt securities, provided that the action shall not adversely affect the interests of the holders of the debt securities of any series in any material respect. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A vote by holders of debt securities will not be required for clarifications and certain other changes that would not adversely affect holders of the debt
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the terms of the applicable
series of debt securities provide otherwise, we may be discharged from any and all obligations in respect of the debt securities of any series (except for certain obligations to register the transfer or exchange of debt securities of the series; to
replace stolen, lost, or mutilated debt securities of the series; and to maintain paying agencies and certain provisions relating to the treatment of funds held by paying agents). We will be so discharged upon the deposit with the trustee, in trust,
of money and/or U.S. government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, foreign government obligations (as described at the end of this section), that, through
the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient to pay and discharge each installment of principal, interest, and any additional amounts on and any mandatory sinking fund payments in
respect of the debt securities of that series on the stated maturity of such payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an officers&#146; certificate and an opinion of counsel stating that we
have received from, or there has been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that
holders of the debt securities of such series will not recognize income, gain, or loss for U.S. federal income tax purposes as a result of the deposit, defeasance, and discharge and will be subject to U.S. federal income tax on the same amount and
in the same manner and at the same times as would have been the case if the deposit, defeasance, and discharge had not occurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain
Covenants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the terms of the applicable series of debt securities provide otherwise, upon compliance with certain conditions, we may omit to
comply with the restrictive covenants contained in the indenture (except for certain obligations to maintain paying agencies and certain provisions relating to the treatment of funds held by paying agents), as well as any additional covenants
contained in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. dollars, foreign government obligations, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient, in the opinion of a nationally
recognized firm of independent public accountants, to pay principal, interest, and any additional amounts on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in
accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain, or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax in the same amount and in the same manner and at the same
times as would have been the case if the deposit and related covenant defeasance had not occurred. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Covenant Defeasance and Events of
Default </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we exercise our option, as described above, not to comply with certain covenants of the indenture with respect to any series of debt
securities, and the debt securities of that series are declared due and payable because of the occurrence of any event of default, the amount of money and/or U.S. government obligations or foreign government obligations on deposit with the trustee
will be sufficient to pay amounts due on the debt securities of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the debt securities of that series at the time of the acceleration resulting from the
event of default. However, we will remain liable for those payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Foreign government obligations&#148; means, with respect to debt securities of
any series that are denominated in a currency other than U.S. dollars: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct obligations of the government that issued or caused to be issued such currency for the payment of which
obligations its full faith and credit is pledged, which are not callable or redeemable at the option of the issuer thereof; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obligations of a person controlled or supervised by or acting as an agency or instrumentality of that government,
the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government, which are not callable or redeemable at the option of the issuer thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guarantees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our payment obligations under any series of
debt securities may be guaranteed by us or one or more of our subsidiaries. The terms of any such guarantee will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable
prospectus supplement the terms and conditions, if any, upon which any series of senior subordinated securities or subordinated securities is subordinated to debt securities of another series or to other indebtedness of ours. The terms will include
a description of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indebtedness ranking senior to the debt securities being offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on payments to the holders of the debt securities being offered while a default with respect to
the senior indebtedness is continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on payments to the holders of the debt securities being offered following an event of default;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions requiring holders of the debt securities being offered to remit some payments to holders of senior
indebtedness. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion and Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms on which debt securities of any series may be convertible into or exchangeable for our common stock, preferred stock, or other securities or property
of our company will be described in the applicable prospectus supplement. These terms will include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion or exchange price, or the manner of calculating the price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exchange or conversion period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the conversion or exchange is mandatory, or voluntary at the option of the holder, or at our option;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on conversion or exchange in the event of redemption of the debt securities and any restrictions
on conversion or exchange; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the means of calculating the number of shares of our common stock, preferred stock, or other securities or
property of our company to be received by the holders of debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion or exchange price of any debt securities of
any series that are convertible into our common stock or preferred stock may be adjusted for any stock dividends, stock splits, reclassification, combinations, or similar transactions, as set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities may be
subject to optional or mandatory redemption on terms and conditions described in the applicable prospectus supplement. Subject to such terms, we may opt at any time to redeem the debt securities in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If less than all the debt securities of any series are to be redeemed or purchased in an offer to purchase at any time, the trustee will select the debt
securities of that series to be redeemed or purchased as follows: (1)&nbsp;if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities of such series are listed on any national securities exchange, in compliance with the requirements of the principal national securities exchange on which the debt securities of that
series are listed, or, (2)&nbsp;if the debt securities of that series are not listed on a national securities exchange, on a pro rata basis, by lot, or by such other method as the trustee deems fair and appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided as to any particular series of debt securities, at least 30 days but not more than 60 days before a redemption date, we or the
trustee will mail a notice of redemption to each holder whose debt securities are to be redeemed. From and after notice has been given as provided in the applicable indenture, if funds for the redemption of any debt securities called for redemption
shall have been made available on the redemption date, the debt securities will cease to bear interest on the date fixed for the redemption specified in the notice, and the only right of the holders of the debt securities will be to receive payment
of the redemption price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
indentures and the debt securities will be governed by and construed in accordance with the laws of the state of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_10"></A>DESCRIPTION OF DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue receipts for depositary shares representing fractional shares of preferred stock. The fractional share of the applicable series of preferred
stock represented by each depositary share will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of any series of preferred stock
underlying any depositary shares that we may sell under this prospectus will be deposited under a deposit agreement between us and a depositary selected by us. Subject to the terms of the deposit agreement, each holder of a depositary share will be
entitled, in proportion to the applicable fraction of a share of the preferred stock underlying the depositary share, to all of the rights, preferences, and privileges, and will be subject to the qualifications and restrictions, of the preferred
stock underlying that depositary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary shares will be evidenced by depositary receipts issued under the deposit agreement. Depositary
receipts will be distributed to the holders of the depositary shares that are sold in the applicable offering. We will incorporate by reference into the registration statement of which this prospectus forms a part the form of any deposit agreement,
including a form of depositary receipt, that describes the terms of any depositary shares we are offering before the issuance of the related depositary shares. The following summaries of material provisions of the deposit agreement, the depositary
shares and the depositary receipts are subject to, and qualified in their entirety by reference to, all of the provisions of the deposit agreement applicable to a particular offering of depositary shares. We urge you to read the prospectus
supplements relating to any depositary shares that are sold under this prospectus, as well as the complete deposit agreement and depositary receipt. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the preparation of definitive depositary
receipts, the depositary may, upon our written order, issue temporary depositary receipts substantially identical to the definitive depositary receipts but not in definitive form. These temporary depositary receipts will entitle their holders to all
of the rights of definitive depositary receipts. Temporary depositary receipts will then be exchangeable for definitive depositary receipts at our expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will
distribute all cash dividends or other cash distributions received with respect to the underlying preferred stock to the record holders of depositary shares in proportion to the number of depositary shares owned by those holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is a distribution other than in cash, the depositary will distribute property received by it to the record holders of depositary shares in proportion
to the number of depositary shares owned by those holders, unless the depositary determines that it is not feasible to do so. If this occurs, the depositary may, with our approval, sell the property and distribute the net proceeds from the sale to
those holders in proportion to the number of depositary shares owned by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount distributed to holders of depositary shares will be reduced by
any amounts required to be withheld by us or the preferred stock depositary on account of taxes or other governmental charges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of our voluntary or involuntary
liquidation, dissolution, or winding up, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Underlying Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a prospectus supplement, holders may surrender depositary receipts at the principal office of the depositary and, upon payment
of any unpaid amount due to the depositary, be entitled to receive the number of whole shares of underlying preferred stock and all money and other property represented by the related depositary shares. We will not issue any partial shares of
preferred stock. If the holder delivers depositary receipts evidencing a number of depositary shares that represent more than a whole number of shares of preferred stock, the depositary will issue a new depositary receipt evidencing the excess
number of depositary shares to the holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Depositary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the preferred stock underlying any depositary shares we may sell under this prospectus is subject to redemption, the depositary shares will be redeemed from
the proceeds received by the depositary resulting from any such redemption, in whole or in part, of that underlying preferred stock. The redemption price per depositary share will be equal to the applicable fraction of the redemption price per share
payable with respect to the underlying preferred stock. Whenever we redeem shares of underlying preferred stock that are held by the depositary, the depositary will redeem, as of the same redemption date, the number of depositary shares representing
the shares of underlying preferred stock so redeemed. If fewer than all of the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or proportionately, as may be determined by the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the date fixed for redemption, the depositary shares called for redemption will no longer be deemed to be outstanding, and all rights of the holders of
the depositary shares will cease, except the right to receive the monies payable and any other property to which the holders were entitled upon the redemption upon surrender to the preferred stock depositary of the depositary receipts evidencing the
depositary shares. Any funds deposited by us with the preferred stock depositary for any depositary shares that the holders fail to redeem will be returned to us after a period of two years from the date the funds are deposited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any meeting at which
holders of the preferred stock underlying any depositary shares that we may sell under this prospectus are entitled to vote, the depositary will mail the information contained in the notice to the record holders of the depositary shares. Each record
holder of the depositary shares on the record date, which will be the same date as the record date for the underlying preferred stock, will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the amount of
the underlying preferred stock represented by the holder&#146;s depositary shares. The depositary will then try, as far as practicable, to vote the number of shares of preferred stock underlying those depositary shares in accordance with those
instructions, and we will agree to take all reasonable actions which may be deemed necessary by the depositary to enable the depositary to do so. The depositary will not vote the underlying preferred stock to the extent it does not receive specific
instructions with respect to the depositary shares representing such preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion of Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the prospectus supplement relating to any depositary shares that we may sell under this prospectus states that the underlying preferred stock is convertible
into our common stock or other securities, the following will apply. The depositary shares, as such, will not be convertible into any of our securities. Rather, any holder of the depositary shares may surrender the related depositary receipts to the
depositary with written instructions that direct us to cause conversion of the preferred stock represented by the depositary shares into or for whole shares of our common stock or other securities, as applicable. Upon receipt of those instructions
and any amounts payable by the holder in connection with the conversion, we will cause the conversion using the same procedures as those provided for conversion of the underlying preferred stock. If only some of a holder&#146;s depositary shares are
converted, a new depositary receipt or receipts will be issued to the holder for any depositary shares not converted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of the Deposit Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may at any time be amended by agreement between us
and the depositary. However, any amendment which materially and adversely alters the rights of the holders of depositary shares will not be effective until 90 days after notice of that amendment has been given to the holders. Each holder of
depositary shares at the time any amendment becomes effective shall be deemed to consent and agree to that amendment and to be bound by the deposit agreement as so amended. The deposit agreement may be terminated by us or by the depositary only if
all outstanding depositary shares have been redeemed or converted into any other securities into which the underlying preferred stock is convertible or there has been a final distribution, including to holders of depositary receipts, of the
underlying preferred stock in connection with our liquidation, dissolution, or winding up. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangement. We will also pay charges of
the depositary in connection with the initial deposit of the preferred stock, the initial issuance of the depositary shares, any redemption of the preferred stock, and all withdrawals of preferred stock by owners of depositary shares. Holders of
depositary receipts will pay transfer, income, and other taxes and governmental charges and other specified charges as provided in the deposit arrangement for their accounts. If these charges have not been paid, the depositary may refuse to transfer
depositary shares, withhold dividends and distributions, and sell the depositary shares evidenced by the depositary receipt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the depositary will be liable if either of us is prevented or delayed by law or any circumstance beyond our control in performing our
respective obligations under the deposit agreement. Our obligations and those of the depositary will be limited to performance of our respective duties under the deposit agreement without, in our case, negligence or bad faith or, in the case of the
depositary, negligence or willful misconduct. We and the depositary may rely upon advice of counsel or accountants, or upon information provided by persons presenting the underlying preferred stock for deposit, holders of depositary receipts, or
other persons believed by us in good faith to be competent and on documents believed to be genuine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Trust Office of Preferred Stock
Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred stock depositary&#146;s corporate trust office will be set forth in the applicable prospectus supplement relating to a series
of depositary shares. The preferred stock depositary will act as transfer agent and registrar for depositary receipts, and, if shares of a series of preferred stock are redeemable, the preferred stock depositary will act as redemption agent for the
corresponding depositary receipts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and Removal of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may resign at any time by delivering notice to us of its election to resign. We may remove the depositary at any time. Any resignation or
removal will take effect upon the appointment of a successor depositary and its acceptance of the appointment. The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and must be a bank or
trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reports to Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will deliver all required reports and communications to holders of the preferred stock to the preferred stock depositary, and it will forward those
reports and communications to the holders of depositary shares. Upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
request, the preferred stock depositary will provide for inspection to the holders of depositary shares the transfer books of the depositary and the list of holders of receipts; provided that any
requesting holder certifies to the preferred stock depositary that such inspection is for a proper purpose reasonably related to such person&#146;s interest as an owner of depositary shares evidenced by the receipts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_11"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase common stock,
which we refer to as common stock warrants, preferred stock, which we refer to as preferred stock warrants, debt securities, which we refer to as debt security warrants, or depositary shares, which we refer to as depositary share warrants. Any of
these warrants may be issued independently or together with any other securities offered by this prospectus and may be attached to or separate from those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the terms we have summarized below will generally apply to any future warrants we may offer under this prospectus, we will describe the particular terms
of any warrants that we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under a prospectus supplement may differ from the terms we describe below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue the warrants under a warrant agreement, which we will enter into with a warrant agent to be selected by us. Each warrant agent will act solely as
our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A
warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us.
Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of warrant agreement, including a form of
warrant certificate, that describes the terms of the series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to,
and qualified in their entirety by reference to, all the provisions of the warrant agreement applicable to a particular series of warrants. We urge you to read the applicable prospectus supplements related to the warrants that we sell under this
prospectus, as well as the complete warrant agreements that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement
the terms of the warrants in respect of which this prospectus is being delivered, including, when applicable, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the warrants will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, number, and terms of the securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the other securities, if any, with which the warrants are issued and the number of
warrants issued with each such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related underlying securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which each underlying security purchasable upon exercise of the warrants may be purchased;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which such right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the minimum amount of the warrants that may be exercised at any one time; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any information with respect to book-entry procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale, or other disposition of our business on the warrant agreement and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the warrants, including terms, procedures, and limitations relating to the transferability,
exchange, and exercise of such warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants begins and the date on which that right expires;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal income tax consequences of holding or exercising the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, or limitations of, or restrictions on, the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless specified in an applicable prospectus supplement, common stock warrants, preferred stock warrants, debt security warrants, or
depositary shares warrants will be in registered form only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new certificates of different
denominations, present them for registration of transfer, and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any common stock warrants, preferred stock
warrants, debt security warrants, or depositary shares warrants are exercised, holders of the warrants will not have any rights of holders of the underlying common stock, preferred stock, debt securities, or depositary shares, including any rights
to receive dividends or to exercise any voting rights, except to the extent set forth under the heading &#147;Warrant Adjustments&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the
holder to purchase for cash shares of common stock, preferred stock, debt securities, or depositary shares at the applicable exercise price set forth in, or determined as described in, the applicable prospectus supplement. Warrants may be exercised
at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants may be exercised by delivering to the corporation trust office of the warrant agent or any other officer indicated in the applicable prospectus
supplement (a)&nbsp;the warrant certificate properly completed and duly executed and (b)&nbsp;payment of the amount due upon exercise. As soon as practicable following exercise, we will forward the shares of common stock, preferred stock, debt
securities, or depositary shares. If less than all of the warrants represented by a warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. If we so indicate in the applicable prospectus supplement,
holders of the warrants may surrender securities as all or a part of the exercise price for the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Supplements to the Warrant
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may amend or supplement a warrant agreement without the consent of the holders of the applicable warrants to cure ambiguities in the
warrant agreement, to cure or correct a defective provision in the warrant agreement, or to provide for other matters under the warrant agreement that we and the warrant agent deem necessary or desirable, so long as, in each case, such amendments or
supplements do not materially and adversely affect the interests of the holders of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, the exercise price of, and the number of securities covered by, a common stock warrant, preferred
stock warrant, debt security warrant, or depositary share warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be adjusted proportionately if we subdivide or combine our common stock, preferred stock, debt securities, or depositary shares, as applicable. In addition, unless the prospectus supplement
states otherwise, if we, without payment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue capital stock or other securities convertible into or exchangeable for common stock or preferred stock, or
any rights to subscribe for, purchase, or otherwise acquire any of the foregoing, as a dividend or distribution to holders of our common stock or preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay any cash to holders of our common stock or preferred stock other than a cash dividend paid out of our current
or retained earnings or other than in accordance with the terms of the preferred stock; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue any evidence of our indebtedness or rights to subscribe for or purchase our indebtedness to holders of our
common stock or preferred stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue common stock or preferred stock or additional stock or other securities or property to holders of our
common stock or preferred stock by way of spinoff, <FONT STYLE="white-space:nowrap">split-up,</FONT> reclassification, combination of shares, or similar corporate rearrangement, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then the holders of common stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants, as applicable, will be entitled to
receive upon exercise of the warrants, in addition to the securities otherwise receivable upon exercise of the warrants and without paying any additional consideration, the amount of stock and other securities and property such holders would have
been entitled to receive had they held the common stock, preferred stock, debt securities, or depositary shares, as applicable, issuable under the warrants on the dates on which holders of those securities received or became entitled to receive such
additional stock and other securities and property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as stated above, the exercise price and number of securities covered by a common stock
warrant, preferred stock warrant, debt security warrant, and depositary share warrant, and the amounts of other securities or property to be received, if any, upon exercise of those warrants, will not be adjusted or provided for if we issue those
securities or any securities convertible into or exchangeable for those securities, or securities carrying the right to purchase those securities or securities convertible into or exchangeable for those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of common stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants may have additional rights under the
following circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain reclassifications, capital reorganizations, or changes of the common stock, preferred stock, or
depositary shares, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain share exchanges, mergers, or similar transactions involving us and which result in changes of the common
stock, preferred stock, or depositary shares, as applicable; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain sales or dispositions to another entity of all or substantially all of our property and assets.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If one of the above transactions occurs and holders of our common stock, preferred stock, debt securities, or depositary shares are
entitled to receive stock, securities, or other property with respect to or in exchange for their securities, the holders of the common stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants then outstanding,
as applicable, will be entitled to receive upon exercise of their warrants the kind and amount of shares of stock and other securities or property that they would have received upon the applicable transaction if they had exercised their warrants
immediately before the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_12"></A>DESCRIPTION OF PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific or varying number of
debt securities, shares of common stock or preferred stock, depositary shares, warrants, or any combination of the above, at a future date or dates. Alternatively, the purchase contracts may obligate us to purchase from holders, and obligate holders
to sell to us, a specific or varying number of debt securities, shares of common stock or preferred stock, depositary shares, warrants, or any combination of the above. The price of the securities subject to the purchase contracts may be fixed at
the time the purchase contracts are issued or may be determined by reference to a specific formula described in the purchase contracts. We may issue purchase contracts separately or as a part of units each consisting of a purchase contract and one
or more of the other securities described in this prospectus or securities of third parties, including U.S. Treasury securities, securing the holder&#146;s obligations under the purchase contract. If we issue a purchase contract as part of a unit,
the applicable prospectus supplement will state whether the purchase contract will be separable from the other securities in the unit before the purchase contract settlement date. The purchase contracts may require us to make periodic payments to
holders or vice versa and the payments may be unsecured or <FONT STYLE="white-space:nowrap">pre-funded</FONT> on some basis. The purchase contracts may require holders to secure the holder&#146;s obligations in a manner specified in the applicable
prospectus supplement, and in certain circumstances, we may deliver newly issued prepaid purchase contracts, often known as prepaid securities, upon release to a holder of any collateral securing such holder&#146;s obligations under the original
purchase contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of purchase contract
we are offering before the issuance of the purchase contract. The following summaries of material provisions of the purchase contract are subject to, and qualified in their entirety by reference to, all the provisions of the purchase contract. We
urge you to read the applicable prospectus supplements related to the purchase contracts that we sell under this prospectus, as well as the complete purchase contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the terms of any purchase contracts in respect of which this prospectus is being delivered, including, to
the extent applicable, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the
securities subject to purchase under the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the purchase contracts are to be prepaid or not; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the purchase contracts will be issued as part of a unit and, if so, the other securities comprising the
unit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value,
performance, or level of the securities subject to purchase under the purchase contract; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any acceleration, cancellation, termination, or other provisions relating to the settlement of the purchase
contracts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the purchase contracts will be issued in fully registered or global form. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Material U.S. federal income tax consideration applicable to the purchase contracts and the purchase units will also be discussed in the applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_13"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and
provisions of the units that we may offer under this prospectus. Units may be offered independently or together with common stock, preferred stock, debt securities, depositary shares, and warrants offered by any prospectus supplement, and may be
attached to or separate from those securities. While the terms we have summarized below will generally apply to any future units that we may offer under this prospectus, we will describe the particular terms of any series of units that we may offer
in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of unit agreement, including a form of unit
certificate, if any, that describes the terms of the series of units we are offering before the issuance of the related series of units. The following summaries of material provisions of the units and the unit agreements are subject to, and
qualified in their entirety by reference to, all the provisions of the unit agreement applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the units that we sell under this prospectus, as
well as the complete unit agreements that contain the terms of the units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of common stock, preferred stock, debt securities, depositary shares, and warrants in any combination. Each unit will be issued
so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may
provide that the securities included in the unit may not be held or transferred separately, at any time, or at any time before a specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
describe in the applicable prospectus supplement the terms of the series of units, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement that differ from those described below; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities
comprising the units. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;Description of Common
Stock,&#148; &#147;Description of Preferred Stock,&#148; &#147;Description of Debt Securities,&#148; &#147;Description of Depositary Shares,&#148; and &#147;Description of Warrants,&#148; will apply to each unit and to any common stock, preferred
stock, debt security, depositary share, or warrant included in each unit, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units in such amounts and in such numerous distinct series as we determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Units </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each unit
agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series
of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us.
Any holder of a unit, without the consent of the related unit agent or the holder of any other unit, may enforce by appropriate legal action its rights as holder under any security included in the unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the unit agent, and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that
certificate for any purposes and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_14"></A>CERTAIN PROVISIONS OF NEVADA LAW AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR CHARTER AND BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
paragraphs summarize certain provisions of Nevada law and our amended and restated articles of incorporation, as amended, and bylaws. The summary does not purport to be complete and is subject to and qualified in its entirety by reference to Nevada
law and to our amended and restated articles of incorporation, as amended, and bylaws, as amended, copies of which are on file with the SEC as exhibits to reports previously filed by us. See &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our amended and restated
articles of incorporation, as amended, and bylaws and Nevada law could make our acquisition by a third party, a change in our incumbent management, or a similar change in control more difficult, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an acquisition of us by means of a tender or exchange offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an acquisition of us by means of a proxy contest or otherwise; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the removal of a majority or all of our incumbent officers and directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, which are summarized below, are likely to discourage certain types of coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that these provisions help to protect our potential ability to negotiate with the proponent of an
unfriendly or unsolicited proposal to acquire or restructure us, and that this benefit outweighs the potential disadvantages of discouraging such a proposal because our ability to negotiate with the proponent could result in an improvement of the
terms of the proposal. The existence of these provisions which are described below could limit the price that investors might otherwise pay in the future for our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of Incorporation and Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized But
Unissued Capital Stock. </I>We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of any securities exchange on which our stock may
be listed. We may utilize these additional shares for a variety of corporate purposes, including for future public offerings to raise additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more
difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest, or otherwise. In addition, if we issue preferred stock, the
issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Blank Check Preferred Stock</I>. Our board of directors, without stockholder approval, has the authority under our amended and restated articles of
incorporation, as amended, to issue preferred stock with rights superior to the rights of the holders of common stock. As a result, preferred stock could be issued quickly and easily, could impair the rights of holders of common stock, and could be
issued with terms calculated to delay or prevent a change in control or make removal of management more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Election of Directors</I>. Our
bylaws provide that a majority of directors then in office may fill any vacancy occurring on our board of directors, even though less than a quorum may then be in office. These provisions may discourage a third party from voting to remove incumbent
directors and simultaneously gaining control of our board of directors by filling the vacancies created by that removal with its own nominees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors</I>. Except in certain cases for directors elected by the holders of any series of
preferred stock, a director may be removed only by the affirmative vote of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the combined voting power of the then issued and outstanding shares of our capital stock entitled to vote in the
election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings</I>. Our bylaws do not permit stockholders to call a special meeting of
stockholders. Rather, only our board of directors or such person or persons authorized by our board of directors will be able to call special meetings of stockholders. This provision may discourage another person or entity from making a tender
offer, even if it acquired a majority of our outstanding voting stock, because the person or entity could only take action at a duly called stockholders&#146; meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Nevada Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business
Combinations with Interested Stockholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;business combination with interested stockholders&#148; provisions of Sections 78.411 to 78.444,
inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200 stockholders of record from engaging in various &#147;combination&#148; transactions with any interested stockholder for a period of
two&nbsp;years after the date of the transaction in which the person became an interested stockholder, unless the combination is approved by our board of directors prior to the date the interested stockholder obtained such status or the combination
is approved by our board of directors and at such time or thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders,
and extends beyond the expiration of the <FONT STYLE="white-space:nowrap">two-year</FONT> period, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the combination was approved by our board of directors prior to the person becoming an interested stockholder or
the transaction by which the person first became an interested stockholder was approved by our board of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by
disinterested stockholders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a)&nbsp;the
highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher;
(b)&nbsp;the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher; or (c)&nbsp;for holders of preferred stock, the highest liquidation
value of the preferred stock, if it is higher. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, NRS 78.411 to 78.444, inclusive, do not apply to any
combination of a resident domestic corporation with an interested stockholder after the expiration of four years after the person first became an interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;combination&#148; is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other
disposition, in one transaction or a series of transactions, with an &#147;interested stockholder&#148; having: (a)&nbsp;an aggregate market value equal to more than 5% of the aggregate market value of the assets of the corporation, (b)&nbsp;an
aggregate market value equal to more than 5% of the aggregate market value of all outstanding voting shares of the corporation, (c)&nbsp;more than 10% of the earning power or net income of the corporation, and (d)&nbsp;certain other transactions
with an interested stockholder or an affiliate or associate of an interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, an &#147;interested stockholder&#148; is a person
who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&#146;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may
discourage attempts to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Control Share Acquisitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;control share&#148; provisions of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &#147;issuing corporations&#148; that are Nevada
corporations with at least 200 stockholders of record, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The control share statute prohibits an acquirer, under certain
circumstances, from voting its shares of a target corporation&#146;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&#146;s disinterested stockholders. The statute
specifies three thresholds: <FONT STYLE="white-space:nowrap">one-fifth</FONT> or more but less than <FONT STYLE="white-space:nowrap">one-third,</FONT> <FONT STYLE="white-space:nowrap">one-third</FONT> but less than a majority, and a majority or
more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become &#147;control shares&#148; and such control shares are
deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all
other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters&#146; rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A corporation may elect to not be governed by, or &#147;opt out&#148; of, the control share provisions by making an election in its articles of incorporation
or bylaws, provided that the <FONT STYLE="white-space:nowrap">opt-out</FONT> election must be in place on the 10th&nbsp;day following the date an acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds
described above. We have not opted out of the control share statutes, and will be subject to these statutes if we are an &#147;issuing corporation&#148; as defined in such statutes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect of the Nevada control share statutes is that the acquiring person, and those acting in association with the acquiring person, will obtain only such
voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable, could have the effect of discouraging takeovers of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, limit the liability of directors and provides that no director or officer of ours will be
personally liable to us or any of our stockholders for damages for breach of fiduciary duty as a director or officer involving any act or omission of any act by such director or officer, other than (i)&nbsp;for acts or omissions which involve
intentional misconduct, fraud, or a known violation of the law, or (ii)&nbsp;the payment of dividends in violation of Section&nbsp;78.300 of the NRS. In addition, our amended and restated articles of incorporation, as amended, provide that we will
indemnify our directors and officers to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation and generally governed by the Nevada Private
Corporations Code, Chapter 78 of the Nevada Revised Statutes, or NRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.138 of the NRS provides that, unless the corporation&#146;s
articles of incorporation provide otherwise, a director or officer is not individually liable to the corporation or its stockholders or creditors for damages as a result of any action or omission to act as a director or officer unless the
presumption that the director or officer acted in good faith, on an informed basis and with a view to the interests to the corporation is rebutted and it is proven that (i)&nbsp;the director&#146;s or officer&#146;s acts or omissions constituted a
breach of his or her fiduciary duties, and (ii)&nbsp;such breach involved intentional misconduct, fraud, or a knowing violation of the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.7502 of the NRS permits a company to indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement
actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding, if the officer or director (i)&nbsp;is not liable pursuant to Section&nbsp;78.138 of the NRS, or (ii)&nbsp;acted in good faith and
in a manner the officer or director reasonably believed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be in or not opposed to the best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. A
discretionary indemnification pursuant to Section&nbsp;78.7502 may be made as authorized in the specific case upon a determination by the stockholders, the disinterested board members, or, under certain circumstances, by independent legal counsel.
Indemnification under Section&nbsp;78.7502 of the NRS may not be made the corporation if the officer or director has been adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable to the corporation or for amounts
paid in settlement to the corporation, unless and only to the extent that the court determines that in view of all the circumstances, the person is fairly and reasonably entitled to indemnity for such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS requires a corporation to indemnify its officers and directors to the extent that they have been successful on the merits or
otherwise in defense of any action, suit or proceeding (whether civil, criminal, administrative or investigative) or any claim, issue or matter therein, but also provides that discretionary indemnification may not be made under Section&nbsp;78.7502
of a director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable for intentional misconduct, fraud or a knowing violation of law, and such misconduct, fraud or violation was material to
the cause of action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS permits a Nevada corporation to indemnify its officers and directors against expenses incurred in
defending a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof. Section&nbsp;78.751 of the NRS provides that, unless restricted by the articles of incorporation, the bylaws or an agreement
made by the corporation, the corporation may (or shall, if required by the articles of incorporation, bylaws or an agreement) pay expenses as incurred and in advance of final disposition of the action, suit or proceeding, upon receipt of an
undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be indemnified by the corporation. Section&nbsp;78.751 of
the NRS further permits the corporation to grant its directors and officers additional rights of indemnification under its articles of incorporation, bylaws, or other agreement. We have entered into indemnification agreements with our directors and
executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.752 of the NRS provides that a Nevada corporation may purchase and maintain insurance or make other financial
arrangements on behalf of any person who is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another company, partnership, joint
venture, trust, or other enterprise, for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee, or agent, or arising out of his status as such, whether or not the corporation
has the authority to indemnify him against such liability and expenses. We have obtained primary and excess insurance policies insuring our directors and officers and our subsidiaries against certain liabilities they may incur in their capacity as
directors and officers. Under such policies, the insurer, on our behalf, may also pay amounts for which we have granted indemnification to the directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of indemnification merely summarizes certain aspects of indemnification provisions and is limited by reference to the above discussed
sections of the Nevada Private Corporations Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, provide that we shall, to the fullest
extent permitted by the provisions of the Nevada Private Corporations Code, indemnify any and all persons whom we have the power to indemnify from and against any and all expenses, liabilities and other matters referred to in or covered by such
provisions. We have entered into indemnification agreements with each of our directors and certain officers, in addition to the indemnification provided for in our amended and restated articles of incorporation, as amended. Insofar as
indemnification by our company for liabilities arising under the Securities Act may be permitted to officers and directors of our company pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification for Securities Act Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted for directors, officers, or controlling persons pursuant to the
provisions described in the preceding paragraph, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_15"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We refer to those persons who have securities registered in their
own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal holders of the securities. We refer to those persons who,
indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss below, indirect holders are not legal holders, and investors in
securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See also the section entitled &#147;Description of Debt Securities
&#151; Form, Transfer, and Exchange&#148; above for additional discussion of book entry and certificated form of ownership as such forms of ownership impact the rights and obligations of purchasers of debt securities to be issued under this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. Upon the issuance of a global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the respective principal amounts of the book-entry securities
represented by the global security beneficially owned by such participants. The accounts to be credited will be designated by any dealers, underwriters, or agents participating in the distribution of the book-entry securities. Ownership of
book-entry securities will be shown on, and the transfer of the ownership interests will be effected only through, records maintained by the depositary for the related global security (with respect to interests of participants) and on the records of
participants (with respect to interests of persons holding through participants). The laws of some states may require that certain purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the
ability to own, transfer, or pledge beneficial interests in book-entry securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized
as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the
securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The
depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a
bank, broker, or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not
holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an
investor in street name would be registered in the name of a bank, broker, or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he, she, or it
maintains at that institution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For securities held in street name, we will recognize only the intermediary banks, brokers, and other
financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the
beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the
obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name,
or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is
required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Whether and how the holders contact the indirect holders is up to the holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold
securities through a bank, broker, or other financial institution, either in book-entry form or in street name, you should check with your own institution to determine the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. Each security issued in book-entry
form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we
specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee, or a successor depositary, unless
special termination situations arise. We describe those situations below under &#147;Special Situations When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be the sole registered
owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests must be held by means of an account with a broker, bank, or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an
investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented
by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any
book-entry clearing system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may at any time and in our sole discretion determine not to have any of the book-entry securities of any series
represented by one or more global securities and, in that event, we will issue certificated securities in exchange for the global securities of that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights
of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect
holder as a holder of securities and instead deal only with the depositary that holds the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a
global security, an investor should be aware of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his, her, or its name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his, her, or its interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his, her, or its own bank or broker for payments on the
securities and protection of his, her, or its legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his, her, or its interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges,
and other matters relating to an investor&#146;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in a global security, may also have their own policies affecting payments, notices, and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any
of those intermediaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing
those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred
to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable, or no longer qualified under the Exchange Act to
continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement may also list additional situations for terminating a global security that would apply
only to the particular types and series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions
that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_16"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities described in this prospectus from time to time in one or more of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more purchasers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of those methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the offered securities will describe the terms of the offering, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceeds from such sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any underwriting discounts or agency fees and other items constituting underwriters&#146; or agents&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchanges on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may distribute the securities from time to time in one or more of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed public offering price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices relating to prevailing market prices at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at varying prices determined at the time of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, if we use underwriters for a sale of securities, the underwriters will acquire the
securities for their own account. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price, or at varying prices determined at the time of sale. The obligations of
the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. Unless otherwise indicated in a prospectus supplement, the underwriters will be obligated to purchase all the
securities of the series offered if they purchase any of the securities of that series. We may change from time to time any initial public offering price and any discounts or concessions the underwriters allow or reallow or pay to dealers. We may
use underwriters with whom we or they have a material relationship. We will describe in the prospectus supplement naming the underwriter the nature of any such relationship. We may designate agents who agree to use their reasonable efforts to
solicit purchases for the period of their appointment or to sell securities on a continuing basis. We may also sell securities directly to one or more purchasers without using underwriters or agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers, or agents may receive compensation in the form of discounts, concessions, or commissions from us or from purchasers of the securities
as their agents in connection with the sale of the securities. These underwriters, dealers, or agents may be considered to be underwriters under the Securities Act. As a result, discounts, commissions, or profits on resale received by underwriters,
dealers, or agents may be treated as underwriting discounts and commissions. Each prospectus supplement will identify any underwriter, dealer, or agent and describe any compensation received by them from us. Any initial public offering price and any
discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will
be a new issue with no established trading market, other than our common stock, which is listed on the Nasdaq Global Select Market. We may elect to apply for listing of our common stock on another securities exchange or to list any other class or
series of securities on any exchange, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any
market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with any offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids in accordance with Regulation M under the Exchange Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not
exceed a specified maximum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over-allotment involves sales by the underwriters of shares of our common stock in excess of the number of shares
the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares of our common stock
over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares of our common stock involved is greater than the number of shares in the
over-allotment option. The underwriters may close out any covered short position by either exercising their over-allotment option or purchasing shares of our common stock in the open market. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Syndicate covering transactions involve purchases of our common stock in the open market after the distribution
has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares of our common stock available for purchase
in the open market as compared to the price at which they may purchase shares through the over-allotment option so that if there is a naked short position, the position can only be closed out by buying shares in the open market. A naked short
position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares of our common stock in the open market after the pricing of any offering that could adversely affect investors
who purchase in that offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Penalty bids permit the representatives of the underwriters to reclaim a selling concession from a syndicate
member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, over-allotments, syndicate covering transactions, and penalty bids may have the effect of raising or maintaining the market
price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. These transactions may be
effected on the Nasdaq Global Select Market or otherwise and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings
into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale
transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those
derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement. In addition, we may
otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our
securities or in connection with a concurrent offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT>
provisions in respect of any given offering will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers, and agents may be entitled
under agreements entered into with us to indemnification against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments they may be required to make in respect of these liabilities
thereof. Underwriters, dealers, and agents and their affiliates may be customers of, may engage in transactions with, or perform services for us in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_17"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock and preferred stock offered under this prospectus and certain other legal matters will be passed upon for us by
Greenberg Traurig, LLP, Las Vegas, Nevada. The validity of the debt securities, depositary shares, warrants, purchase contracts and units offered under this prospectus and certain other legal matters will be passed upon for us by will be passed upon
for us by DLA Piper LLP (US), Miami, Florida. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_18"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audited financial statements incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by
reference in reliance upon the report of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_19"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Through our website at <I>www.therapeuticsmd.com</I>, you
may access, free of charge, our filings, as soon as reasonably practical after we electronically file them with or furnish them to the SEC. The information contained in our website is not incorporated by reference in, and should not be considered a
part of, this prospectus or any accompanying prospectus supplement. Our SEC filings are also available to the public at the SEC&#146;s website at <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC to register the securities
to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from
the SEC at the address listed above or from the SEC&#146;s website listed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_20"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information that we incorporate by reference is considered to be part of this prospectus. Information that we file with the SEC in the future and incorporate by reference in this prospectus automatically updates and
supersedes previously filed information as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus the following documents filed by us with the SEC,
other than any portion of any such documents that is not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;3, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2021, June&nbsp;30, 2021, and September&nbsp;30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000119312521153419/d148297d10q.htm">May&nbsp;
6, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021040907/txmd-10q_20210630.htm">August&nbsp;
4, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021056434/txmd-10q_20210930.htm">November&nbsp;12, 2021</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312521116458/d152560ddef14a.htm">Definitive Proxy Statement
on Schedule 14A</A>, filed with the SEC on April&nbsp;14, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121000535/txmd-8k_011321.htm">January&nbsp;13,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121002393/txmd-8k_021121.htm">February&nbsp;
16, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121004324/txmd-8k_040821.htm">April&nbsp;
12, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000119312521177164/d160590d8k.htm">May&nbsp;
28, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021042695/txmd-8k_20210803.htm">August&nbsp;
9, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021047142/txmd-8k_20210902.htm">September&nbsp;
7, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021048250/txmd-8k_20210915.htm">September&nbsp;
17, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021049852/txmd-8k_20210930.htm">October&nbsp;
1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021056427/txmd-8k_20211111.htm">November&nbsp;
12, 2021</A> as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021057142/txmd-8ka_20211111.htm">November&nbsp;
16, 2021</A>,<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021059685/txmd-8k_20211207.htm"> December&nbsp;
8, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021060036/txmd-8k_20211210.htm">December&nbsp;
10, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021060654/txmd-8k_20211213.htm">December&nbsp;
17, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021060676/txmd-8k_20211214.htm">December&nbsp;
20, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022000008/txmd-8k_20211228.htm">January&nbsp;
3, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022005710/txmd-8k_20220217.htm">February&nbsp;
18, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022009476/txmd-8k_20220306.htm">March&nbsp;
10, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022011090/txmd-8k_20220314.htm">March&nbsp;18, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock included under the heading &#147;Description of Common Stock&#148; in the
prospectus forming a part of the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312515368426/d71137ds3.htm">Form <FONT STYLE="white-space:nowrap">S-3</FONT></A> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-207837),</FONT> as filed with the SEC on November&nbsp;
5, 2015, which description has been incorporated by reference in Item 1 of the Registrant&#146;s <A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713117004988/txmd-8a12b_100617.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;001-00100),</FONT> as filed with the SEC on October&nbsp;6, 2017, including any amendment or report filed with the SEC for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (not including any information
furnished under Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any other information that is identified as &#147;furnished&#148; rather than filed, which information is not incorporated by reference herein),
including those filings made after the date of the initial filing of the registration statement of which this prospectus forms a part, prior to the termination of the offering, will be deemed to be incorporated herein by reference and to be a part
of this prospectus from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained
herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request of that
person, a copy of any and all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus (excluding exhibits unless specifically incorporated by reference into those documents). Please direct
requests to us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">951
Yamato Road, Suite 220 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Boca Raton, Florida 33431 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(561) <FONT STYLE="white-space:nowrap">961-1900</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g280081g51s75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$209,377,660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Purchase
Contracts </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;23, 2022 </B></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g280081g51s75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $59,377,660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a
Controlled Equity OfferingSM Sales Agreement, or sales agreement, dated March&nbsp;3, 2021, with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor Fitzgerald, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus.
In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $59,377,660 from time to time through or to Cantor Fitzgerald, acting as sales agent. We originally
filed a prospectus, dated March&nbsp;3, 2021, or the prior prospectus, for the offer and sale of up to $100,000,000 of shares of our common stock pursuant to the sales agreement under the registration statement of which this prospectus forms a part.
The prior prospectus provided for sales of shares of our common stock having an aggregate offering price of up to $100,000,000. As of the date of this prospectus, we have issued and sold an aggregate of 33,705,315 shares of common stock pursuant to
the sales agreement and the prior prospectus, for which we have received gross proceeds of approximately $40.8&nbsp;million. We will not make any further offers or sales of our common stock pursuant to the prior prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; On March&nbsp;22, 2022, the
last reported sale price of our common stock on the Nasdaq Global Select Market was $0.40. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus may
be made in sales deemed to be &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to the terms of the sales agreement, Cantor Fitzgerald is not
required to sell any specific number or dollar amounts of securities but will act as sales agent and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal
trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust, or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will be entitled to compensation at a fixed commission rate of 3.0% of the aggregate gross sales price per share sold. In connection with
the sale of our common stock on our behalf, Cantor Fitzgerald will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or
discounts. See &#147;Plan of Distribution&#148; beginning on page&nbsp;20 for additional information regarding the compensation to be paid to Cantor Fitzgerald. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<U><A HREF="#covb280081_400">Risk Factors</A></U>&#148; on page&nbsp;5 of this
prospectus and in the documents we incorporate by reference in this prospectus to read about factors you should consider before buying shares of our common stock. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus,
any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g280081g52s52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March&nbsp;23, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca280081_toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_4">Cautionary Statement About Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_7">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_8">Certain Provisions of Nevada Law and our Charter and
Bylaws</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_9">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb280081_13">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the sales agent has not, authorized anyone to provide any information or to make any representations other
than those contained or incorporated by reference in this prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of the date of this
prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references in this prospectus to &#147;TherapeuticsMD,&#148; &#147;TXMD,&#148; &#147;Company,&#148; &#147;our
company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, VitaMedMD, LLC, a Delaware limited liability company, BocagreenMD, Inc., a Nevada corporation, and VitaCare
Prescription Services, Inc., a Florida corporation (&#147;vitaCare&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus forms part of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission, or SEC, using a &#147;shelf&#148; registration process. To the extent that any statement we make in this prospectus is inconsistent with statements made
in any documents incorporated by reference herein, the statements made in this prospectus will be deemed to modify or supersede those made in such documents incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offering of shares of our common stock. Before buying any shares of our common stock offered hereby, we urge you to carefully
read this prospectus, together with the information incorporated herein by reference as described under the headings &#147;Where you can find more information&#148; and &#147;Incorporation of certain information by reference.&#148; These documents
contain important information that you should consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or
incorporated by reference into this prospectus and any free writing prospectus authorized by us. To the extent the information contained in this prospectus differs or varies from the information contained in any document filed prior to the date of
this prospectus and incorporated by reference, the information in this prospectus will control. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we have authorized
for use in connection with this offering, in their entirety before making an investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The industry and market data and other statistical
information contained in the documents we incorporate by reference are based on management&#146;s own estimates, independent publications, government publications, reports by market research firms or other published independent sources and, in each
case, are believed by management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>,
vitaMedMD<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>, BocaGreenMD<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>, IMVEXXY<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>,
BIJUVA<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT> and ANNOVERA<FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT> are registered trademarks of our company. Solely for convenience, trademarks, trade
names and service marks referred to in this prospectus may appear without the <FONT STYLE="font-family:Times New Roman; font-size:7.5pt">&reg;</FONT>, <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> or SM symbols, but such references are
not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of
other parties&#146; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus. Because
this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus, including the documents incorporated by reference herein and therein, which are described under
&#147;Incorporation of Certain Information by Reference&#148; in this prospectus. You should also carefully consider the matters discussed in the section in this prospectus entitled &#147;Risk Factors&#148;, in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, and in other documents incorporated herein by reference. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a women&#146;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women
from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions
range from a patient-controlled, long-lasting contraceptive to advanced U.S. Food and Drug Administration (&#147;FDA&#148;) approved <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy pharmaceutical products for the treatment of
vasomotor symptoms and dyspareunia. We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our women&#146;s healthcare focus. Our portfolio of products focused on
women&#146;s health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. Beginning in 2018, the FDA approval of our pharmaceutical products transitioned our company from predominately focused on
conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we launched our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, IMVEXXY (estradiol vaginal inserts) for the treatment of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was approved by the FDA
in May 2018. In April 2019, we launched our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of <FONT STYLE="white-space:nowrap">bio-identical</FONT>
17&szlig;-estradiol and <FONT STYLE="white-space:nowrap">bio-identical</FONT> progesterone in a single, oral softgel capsule, for the treatment of <FONT STYLE="white-space:nowrap">moderate-to</FONT> severe vasomotor symptoms, or VMS, due to
menopause in women with a uterus, which was approved by the FDA in October 2018. In October 2019, we began a test and learn market introduction for our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product ANNOVERA (segesterone acetate and
ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was approved by the FDA in August 2018 and which we have licensed for commercialization in
the U.S. with the Population Council, Inc. (the &#147;Population Council&#148;) pursuant to an exclusive license agreement with the Population Council. We paused the full commercial launch of ANNOVERA in March 2020 due to the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and resumed this initiative in July 2020. In addition, in July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc. (&#147;Knight&#148;) pursuant to which we granted
Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In June 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited (&#147;Theramex&#148;) to commercialize BIJUVA and IMVEXXY
outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation. We maintain our principal executive offices at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431. Our telephone number is
(561) <FONT STYLE="white-space:nowrap">961-1900.</FONT> We maintain websites at<I> www.therapeuticsmd.com</I> as well as various product websites. The information contained on our websites or that can be accessed through our websites does not
constitute part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us pursuant to this prospectus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of our common stock having an aggregate offering price of up to $59,377,660.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock to be outstanding after this offering(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 578,251,439 shares (as more fully described in the notes following this table), assuming sales of 144,823,561 shares of our common stock in this offering at an offering price of $0.41 per share, which was the last reported
sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;18, 2022. The actual number of shares issued will vary depending on the sales price under this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan of Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;At the market offering&#148; that may be made from time to time through or to our sales agent, Cantor Fitzgerald. See &#147;Plan of Distribution&#148; on page&nbsp;20 of this prospectus.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We intend to use a portion of the net proceeds from this offering for commercialization of IMVEXXY, BIJUVA and ANNOVERA. We additionally intend to use a portion of the net proceeds from this offering for working capital and general
corporate purposes. We may also use a portion of the net proceeds from this offering to discharge certain indebtedness currently outstanding under our Financing Agreement, dated as of April&nbsp;24, 2019, as amended, with our senior lender, or the
Financing Agreement. Please see the section entitled &#147;Use of Proceeds&#148; on page&nbsp;10 of this prospectus.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk Factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing in our common stock involves a high degree of risk. You should carefully read and consider the information set forth under &#147;Risk Factors&#148; on page 5 of this prospectus and in the documents incorporated by
reference herein and therein to read about factors you should consider before buying shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock symbol</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TXMD.&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1)
The number of shares of common stock to be outstanding immediately after this offering is based on 433,427,878 shares outstanding on March&nbsp;17, 2022 and excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding options representing the right to purchase a total of 16,174,918 shares of common stock at a weighted
average exercise price of $4.59 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,812,855 shares of common stock underlying outstanding restricted stock units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 9,139,956 shares of common stock underlying outstanding performance stock units; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding warrants representing the right to purchase a total of 5,127,116 shares of common stock at a
weighted-average exercise price of $1.52 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,245,373 shares of common stock reserved for future issuance under our share-based payment award plans; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,063,944 shares of common stock reserved for future issuance under our employee stock purchase plan.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_3"></A><A NAME="covb280081_400"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully consider the
risks described below and the risks described under &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December</I><I></I><I>&nbsp;31, 2020</I> and our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, June&nbsp;30 and September&nbsp;30, 2021, respectively, which are incorporated by reference in this prospectus, and under similar headings in our subsequently filed annual
reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT><I>, as well as the other risks and uncertainties described in the other documents incorporated by reference in
this prospectus and the information contained in our other filings with the SEC, which are incorporated by reference in this prospectus in their entirety, and in any free writing prospectus that we have authorized for use in connection with this
offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part
of your investment. </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Risks Related to this Offering and our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock, or the perception that such sales might occur, could adversely affect the trading price of
our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;17, 2022, we had 433,427,878 shares of our common stock outstanding. Also, we had, as of March&nbsp;17, 2022,
up to 42,254,845 shares of our common stock issuable upon the exercise of outstanding options, restricted stock units, performance stock units and warrants. Sales of a substantial number of shares of our common stock in the public market following
this offering could cause the market price of our common stock to decline. Although there can be no assurance that any of the $59,377,660 worth of shares being offered under this prospectus will be sold or the price at which any such shares might be
sold, assuming that an aggregate of 144,823,561 shares of our common stock are sold during the term of the sales agreement with Cantor Fitzgerald, in each case, for example, at a price of $0.41 per share, the last reported sale price of our common
stock on the Nasdaq Global Select Market on March&nbsp;18, 2022, upon completion of this offering, based on our shares outstanding as of March&nbsp;17, 2022, we will have outstanding an aggregate of 578,251,439 shares of common stock, assuming no
exercise or settlement, as the case may be, of our outstanding stock options, restricted stock units, performance stock units or warrants. Sales of a substantial number of shares of our common stock, or the perception that such sales might occur,
could adversely affect the trading price of our common stock. Further, sales of shares underlying stock options, restricted stock units, performance stock units and warrants, or the perception in the market that the holders of a large number of
shares intend to sell shares, could reduce the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution in the book
value per share of the common stock you purchase and may experience further dilution in the future as a result of equity offerings and other issuances of our common stock or other securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming
that an aggregate of 144,823,561 shares of our common stock are sold in this offering at a price of $0.41 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;18, 2022, for aggregate gross
proceeds of $59,377,660, and after deducting commissions and estimated offering expenses payable by us, you will experience immediate dilution of $0.54 per share, representing the difference between our as adjusted net tangible book value per share
as of December&nbsp;31, 2021 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options and warrants and the settlement of outstanding restricted stock units and performance stock units will
result, and the issuances of additional shares of our common stock subsequent to December&nbsp;31, 2021 have resulted, in further dilution of your investment. See the section entitled &#147;Dilution&#148; below for a more detailed illustration of
the dilution you would incur if you participate in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To raise additional capital, we may in the future offer additional shares of our common stock or other
securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We cannot assure you that we will be able to sell shares or other securities in any other offering at a
price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 17, 2022, there were outstanding options representing the right to purchase a total of 16,174,918 shares of our common stock at a weighted average
exercise price of $4.59 per share, 11,812,855 shares of common stock underlying outstanding restricted stock units, up to 9,139,956 shares of common stock underlying outstanding performance stock units, outstanding warrants representing the right to
purchase a total of 5,127,116 shares of our common stock at a weighted-average exercise price of $1.52 per share, 15,245,373 shares of our common stock reserved for future issuance under our share-based payment award plans and 5,063,944 shares of
common stock reserved for future issuance under our employee stock purchase plan. You will incur dilution upon exercise of any outstanding stock options or warrants or upon the issuance of shares of common stock under our stock incentive programs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market, or the
perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will
have on the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion to determine how to use the proceeds raised in this offering, and we may not
use the proceeds effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion over the use of proceeds from this offering, and we could spend the
proceeds from this offering in ways with which you may not agree or that do not yield a favorable return. We intend to use a portion of the net proceeds from this offering for commercialization of IMVEXXY, BIJUVA and ANNOVERA. We additionally intend
to use a portion of the net proceeds from this offering for working capital and general corporate purposes. In addition, we may use a portion of the net proceeds from this offering to discharge certain indebtedness currently outstanding under our
Financing Agreement. If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the aggregate proceeds resulting from sales made under the sales agreement. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Cantor
Fitzgerald at any time throughout the term of the sales agreement. The number of shares that are sold through Cantor Fitzgerald after delivering a placement notice will fluctuate based on a number of factors, including the market price of our common
stock during the sales period, any limits we may set with Cantor Fitzgerald in any applicable placement notice and the demand for our common stock. Because this offering can be terminated at any time and the price per share of each share sold
pursuant to the sales agreement will fluctuate over time, it is not currently possible to predict the aggregate proceeds to be raised in connection with sales under the sales agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of common stock offered hereby will be in &#147;at the market offerings,&#148; and investors who buy shares at different times will likely pay
different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may
experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering. In addition, subject to the final
determination by our board of directors or any restrictions we may place in any applicable placement notice delivered to Cantor Fitzgerald, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a
decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not have a sufficient number of authorized and unissued shares of common stock to sell the full
amount of shares registered hereunder.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, authorizes the issuance of 600,000,000
shares of common stock. As of March&nbsp;17, 2022, we had 433,427,878 shares of common stock issued and outstanding, and we have reserved for issuance outstanding options representing the right to purchase a total of 16,174,918 shares of common
stock, outstanding warrants representing the right to purchase a total of 5,127,116 shares of common stock, 11,812,855 shares of common stock underlying outstanding restricted stock units, up to 9,139,956 shares of common stock underlying
outstanding performance stock units, 15,245,373 shares of common stock reserved for future issuance under our share-based payment award plans, and 5,063,944 shares of common stock reserved for future issuance under our employee stock purchase plan.
As a result, after giving effect to the outstanding shares of common stock and 62,564,162 shares reserved for issuance pursuant to options warrants, restricted stock units, performance stock units and shares reserved for issuance under our
share-based payment award plans and employee stock purchase plan, we only have 104,007,960 shares of common stock available for issuance in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on an offering price of $0.41 per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;18,
2022, the sale of the full $59,377,660 in shares registered hereunder would result in the issuance of 144,823,561 shares of our common stock. As a result, we may not be able to sell the full amount of shares of common stock registered hereunder if
we sell shares of common stock at prices that are not higher than the current market price of our common stock. In such an event, we may choose to seek stockholder approval to authorize additional shares of common stock, which could result in
further dilution of your investment, and there is no guarantee that any such increase in authorized shares of common stock will be approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_4"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the documents and information incorporated by reference herein and therein may contain &#147;forward-looking statements&#148; within the
meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;). Forward-looking statements may include, but are not limited to,
statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.
These statements are often characterized by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148; &#147;target,&#148;
&#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. You should not place
undue reliance on these forward-looking statements, which reflect our view only as of the date of this prospectus, and we undertake no obligation to update these forward-looking statements in the future, except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of important factors could cause actual results to differ materially from those indicated by the forward-looking statements, including, without
limitation, those factors described under the caption &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020 and our Quarterly Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarters ended March&nbsp;31, June&nbsp;30 and September&nbsp;30 2021, which are incorporated by reference in this prospectus and under similar headings in our subsequently filed quarterly
reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as the other risks and uncertainties described herein and in the other documents incorporated by reference
in this prospectus. Some of the key factors that could cause actual results to differ from our expectations include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will be able to comply with the covenants and conditions under the Financing Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the closing of the divestiture of our vitaCare business, the timing thereof and how the proceeds that may be
generated by such divestiture are utilized; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain or increase sales of our approved products, including the ability of our marketing
contractors to market ANNOVERA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and commercialize IMVEXXY, ANNOVERA, BIJUVA and our hormone therapy drug candidates and
obtain additional financing necessary therefor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our common stock on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing, and manufacturing capabilities and strategy for our approved products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of markets and the potential market opportunity for which our products are approved and our ability to
penetrate such markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of healthcare providers to prescribe and patients to use our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain additional financing when needed and to service our debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the success of competing products that are or become available for the indications
that we are pursuing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will be able to comply with the covenants and conditions under our term loan facility;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of management transitions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully implement cost savings initiatives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential of adverse side effects or other safety risks that could adversely affect the commercialization of
our current or future approved products or preclude the approval of our future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length, cost and uncertain results of future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials, research and development and manufacturing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property, including with respect to the Paragraph IV notice letters we
received regarding IMVEXXY and BIJUVA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our licensees to commercialize and distribute our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of laws, regulations and enforcement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive nature of the industries in which we conduct our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement from government authorities and health insurance companies for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of product liability lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the influence of extensive and costly government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the FDA will approve a lower dose of BIJUVA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the concentration of power in our stock ownership. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There
can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Cantor Fitzgerald as a source of financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use a portion of the net proceeds from this offering for commercialization of IMVEXXY, BIJUVA and ANNOVERA. We additionally intend to use a
portion of the net proceeds from this offering for working capital and general corporate purposes. In addition, we may use a portion of the net proceeds from this offering to discharge certain indebtedness currently outstanding under our Financing
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the proceeds from this offering. The amounts
and timing of our actual expenditures will depend on numerous factors, including the progress of commercialization activities, the timing of our revenue and the amount of cash used by our operations. Accordingly, we will retain broad discretion over
the use of such proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchasers of common stock in this offering will experience immediate dilution to the extent of the difference between the purchase price per share of common
stock, and the net tangible book value per share of common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value (deficit) as of
December&nbsp;31, 2021 was approximately ($133.9) million, or $(0.31) per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding
as of December&nbsp;31, 2021. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common
stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of shares of common stock offered by the prospectus at an assumed purchase price
of $0.41 per share (the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;18, 2022), and after deducting the commissions and estimated aggregate offering expenses payable by us, our net tangible book value
(deficit) as of December&nbsp;31, 2021 would have been approximately $(76.3) million, or $(0.13) per share of common stock. This represents an immediate increase in net tangible book value of $0.18 per share to our existing stockholders and an
immediate dilution of $0.54 per share of common stock issued to the new investors purchasing securities in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates
this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed purchase price per share of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value (deficit) per share as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value (deficit) per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 144,823,561 shares of our common stock are sold at a
price of $0.41 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;18, 2022, for aggregate gross proceeds of approximately $59,377,660. The shares sold in this offering, if any, will be sold
from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $0.41 per share shown in the table above, assuming all of our common stock in the aggregate amount of
$59,377,660 is sold at that price, would result in an as adjusted net tangible book value (deficit) per share after this offering of approximately $(0.16) per share and would increase the dilution in net tangible book value per share to new
investors to $1.57 per share, after deducting commissions and estimated aggregate offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information discussed above is
illustrative only and may differ based on the actual offering price and the actual number of shares offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be
outstanding immediately after this offering is based on 429,886,212 shares outstanding on December&nbsp;31, 2021 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding options representing the right to purchase a total of 17,654,668 shares of common stock at a weighted
average exercise price of $4.52 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,583,079 shares of common stock underlying outstanding restricted stock units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 11,687,530 shares of common stock underlying outstanding performance stock units; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding warrants representing the right to purchase a total of 5,127,116 shares of common stock at a
weighted-average exercise price of $1.52 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,054,491 shares of common stock reserved for future issuance under our share-based payment award plans; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,063,944 shares of common stock reserved for future issuance under our employee stock purchase plan
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or warrants are exercised or we issue shares of common stock under our stock incentive plans,
investors purchasing our common stock in this offering will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our
current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_7"></A>DESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section describes the general terms of our common stock. A prospectus supplement may provide information that is different from this prospectus. If the
information in the prospectus supplement with respect to our common stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and restated articles of incorporation, as
amended, has been incorporated by reference from our filings with the SEC as an exhibit to the registration statement of which this prospectus forms a part. Our common stock and the rights of the holders of our common stock are subject to the
applicable provisions of the Nevada Private Corporation Code, which we refer to as &#147;Nevada law,&#148; our amended and restated articles of incorporation, as amended, our bylaws, as amended, and the rights of the holders of our preferred stock,
if any, as well as some of the terms of our outstanding indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of incorporation, as amended, we have the
authority to issue 600,000,000 shares of common stock, par value $0.001 per share. As of March&nbsp;17, 2022, there were 433,427,878 shares of our common stock outstanding. As of March&nbsp;17, 2022, there were 128 stockholders of record of our
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our common stock, and any description of our common stock in a prospectus supplement, may not be complete and
is subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of incorporation and our bylaws, each as amended from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding share of our common stock
is entitled to one vote per share of record on all matters submitted to a vote of stockholders and to vote together as a single class for the election of directors and in respect of other corporate matters. At a meeting of stockholders at which a
quorum is present, for all matters other than the election of directors, an affirmative vote of the majority of shares entitled to vote on a matter and that are represented either in person or by proxy at a meeting of stockholders decides all
questions, unless the matter is one upon which a different vote is required by express provision of law or our amended and restated articles incorporation or our bylaws, each as may be amended from time to time. Directors will be elected by a
plurality of the votes of the shares present at a meeting. Holders of shares of common stock do not have cumulative voting rights with respect to the election of directors or any other matter. The Company has adopted a majority voting policy as part
of its Corporate Governance Guidelines. The majority voting policy is applicable solely to uncontested elections, which are those elections in which the number of nominees for election is less than or equal to the number of directors to be elected.
Under the majority voting policy, any nominee for director who receives more &#147;withheld&#148; votes than &#147;for&#148; votes in an uncontested election must submit a written offer to resign as director. Any such resignation will be reviewed by
the Nominating and Corporate Governance Committee and, within 90 days after the election, the independent members of the Company&#146;s board of directors will determine whether to accept, reject or take other appropriate action with respect to, the
resignation, in furtherance of the best interests of the Company and its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to receive dividends or other distributions when, as and if declared by our board of directors. The right of our board
of directors to declare dividends, however, is subject to any rights of the holders of other classes of our capital stock, any indebtedness outstanding from time to time and the availability of sufficient funds, as determined under Nevada law, to
pay dividends. In addition, the Financing Agreement, dated as of April&nbsp;24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, various lenders from time to time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors contains covenants that limit our ability to pay dividends or make other distributions on our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preemptive Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our common stock do not have preemptive rights to purchase or subscribe for any of our capital stock or other securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of our common stock are not subject to
redemption by operation of a sinking fund or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution, or winding up of our company, subject to the rights, if any, of the holders of other classes of our capital
stock, the holders of shares of our common stock are entitled to receive any of our assets available for distribution to our stockholders ratably in proportion to the number of shares held by them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options, Warrants and Other Stock-Based Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time
to time, we have issued and expect to continue to issue options, warrants and other stock-based rights to various lenders, investors, consultants, employees, officers and directors of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;17, 2022, we had: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding options representing the right to purchase a total of 16,174,918 shares of common stock at a weighted
average exercise price of $4.59 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,812,855 shares of common stock underlying outstanding restricted stock units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 9,139,956 shares of common stock underlying outstanding performance stock units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding warrants representing the right to purchase a total of 5,127,116 shares of common stock at a
weighted-average exercise price of $1.52 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,245,373 shares of common stock reserved for future issuance under our share-based payment award plans; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,063,944 shares of common stock reserved for future issuance under our employee stock purchase plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A., 350 Indiana Street, Suite 800, Golden, Colorado 80401. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_8"></A>CERTAIN PROVISIONS OF NEVADA LAW AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR CHARTER AND BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
paragraphs summarize certain provisions of Nevada law and our amended and restated articles of incorporation, as amended, and bylaws. The summary does not purport to be complete and is subject to and qualified in its entirety by reference to Nevada
law and to our amended and restated articles of incorporation, as amended, and bylaws, as amended, copies of which are on file with the SEC as exhibits to reports previously filed by us. See &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our amended and restated
articles of incorporation, as amended, and bylaws and Nevada law could make our acquisition by a third party, a change in our incumbent management, or a similar change in control more difficult, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an acquisition of us by means of a tender or exchange offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an acquisition of us by means of a proxy contest or otherwise; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the removal of a majority or all of our incumbent officers and directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, which are summarized below, are likely to discourage certain types of coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that these provisions help to protect our potential ability to negotiate with the proponent of an
unfriendly or unsolicited proposal to acquire or restructure us, and that this benefit outweighs the potential disadvantages of discouraging such a proposal because our ability to negotiate with the proponent could result in an improvement of the
terms of the proposal. The existence of these provisions which are described below could limit the price that investors might otherwise pay in the future for our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of Incorporation and Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized But
Unissued Capital Stock. </I>We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of any securities exchange on which our stock may
be listed. We may utilize these additional shares for a variety of corporate purposes, including for future public offerings to raise additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more
difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest, or otherwise. In addition, if we issue preferred stock, the
issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Blank Check Preferred Stock</I>. Our board of directors, without stockholder approval, has the authority under our amended and restated articles of
incorporation, as amended, to issue preferred stock with rights superior to the rights of the holders of common stock. As a result, preferred stock could be issued quickly and easily, could impair the rights of holders of common stock, and could be
issued with terms calculated to delay or prevent a change in control or make removal of management more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Election of Directors</I>. Our
bylaws provide that a majority of directors then in office may fill any vacancy occurring on our board of directors, even though less than a quorum may then be in office. These provisions may discourage a third party from voting to remove incumbent
directors and simultaneously gaining control of our board of directors by filling the vacancies created by that removal with its own nominees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors</I>. Except in certain cases for directors elected by the holders of any series of
preferred stock, a director may be removed only by the affirmative vote of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the combined voting power of the then issued and outstanding shares of our capital stock entitled to vote in the
election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings</I>. Our bylaws do not permit stockholders to call a special meeting of
stockholders. Rather, only our board of directors or such person or persons authorized by our board of directors will be able to call special meetings of stockholders. This provision may discourage another person or entity from making a tender
offer, even if it acquired a majority of our outstanding voting stock, because the person or entity could only take action at a duly called stockholders&#146; meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Nevada Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business
Combinations with Interested Stockholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;business combination with interested stockholders&#148; provisions of Sections 78.411 to 78.444,
inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200 stockholders of record from engaging in various &#147;combination&#148; transactions with any interested stockholder for a period of two
years after the date of the transaction in which the person became an interested stockholder, unless the combination is approved by our board of directors prior to the date the interested stockholder obtained such status or the combination is
approved by our board of directors and at such time or thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders, and
extends beyond the expiration of the <FONT STYLE="white-space:nowrap">two-year</FONT> period, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the combination was approved by our board of directors prior to the person becoming an interested stockholder or
the transaction by which the person first became an interested stockholder was approved by our board of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by
disinterested stockholders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a)&nbsp;the
highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher;
(b)&nbsp;the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher; or (c)&nbsp;for holders of preferred stock, the highest liquidation
value of the preferred stock, if it is higher. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, NRS 78.411 to 78.444, inclusive, do not apply to any
combination of a resident domestic corporation with an interested stockholder after the expiration of four years after the person first became an interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;combination&#148; is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other
disposition, in one transaction or a series of transactions, with an &#147;interested stockholder&#148; having: (a)&nbsp;an aggregate market value equal to more than 5% of the aggregate market value of the assets of the corporation, (b)&nbsp;an
aggregate market value equal to more than 5% of the aggregate market value of all outstanding voting shares of the corporation, (c)&nbsp;more than 10% of the earning power or net income of the corporation, and (d)&nbsp;certain other transactions
with an interested stockholder or an affiliate or associate of an interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, an &#147;interested stockholder&#148; is a person
who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&#146;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may
discourage attempts to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Control Share Acquisitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;control share&#148; provisions of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &#147;issuing corporations&#148; that are Nevada
corporations with at least 200 stockholders of record, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The control share statute prohibits an acquirer, under certain
circumstances, from voting its shares of a target corporation&#146;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&#146;s disinterested stockholders. The statute
specifies three thresholds: <FONT STYLE="white-space:nowrap">one-fifth</FONT> or more but less than <FONT STYLE="white-space:nowrap">one-third,</FONT> <FONT STYLE="white-space:nowrap">one-third</FONT> but less than a majority, and a majority or
more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become &#147;control shares&#148; and such control shares are
deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all
other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters&#146; rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A corporation may elect to not be governed by, or &#147;opt out&#148; of, the control share provisions by making an election in its articles of incorporation
or bylaws, provided that the <FONT STYLE="white-space:nowrap">opt-out</FONT> election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds
described above. We have not opted out of the control share statutes, and will be subject to these statutes if we are an &#147;issuing corporation&#148; as defined in such statutes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect of the Nevada control share statutes is that the acquiring person, and those acting in association with the acquiring person, will obtain only such
voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable, could have the effect of discouraging takeovers of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, limit the liability of directors and provides that no director or officer of ours will be
personally liable to us or any of our stockholders for damages for breach of fiduciary duty as a director or officer involving any act or omission of any act by such director or officer, other than (i)&nbsp;for acts or omissions which involve
intentional misconduct, fraud, or a known violation of the law, or (ii)&nbsp;the payment of dividends in violation of Section&nbsp;78.300 of the NRS. In addition, our amended and restated articles of incorporation, as amended, provide that we will
indemnify our directors and officers to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation and generally governed by the Nevada Private
Corporations Code, Chapter 78 of the Nevada Revised Statutes, or NRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.138 of the NRS provides that, unless the corporation&#146;s
articles of incorporation provide otherwise, a director or officer is not individually liable to the corporation or its stockholders or creditors for damages as a result of any action or omission to act as a director or officer unless the
presumption that the director or officer acted in good faith, on an informed basis and with a view to the interests to the corporation is rebutted and it is proven that (i)&nbsp;the director&#146;s or officer&#146;s acts or omissions constituted a
breach of his or her fiduciary duties, and (ii)&nbsp;such breach involved intentional misconduct, fraud, or a knowing violation of the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.7502 of the NRS permits a company to indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement
actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding, if the officer or director (i)&nbsp;is not liable pursuant to Section&nbsp;78.138 of the NRS, or (ii)&nbsp;acted in good faith and
in a manner the officer or director reasonably believed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be in or not opposed to the best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. A
discretionary indemnification pursuant to Section&nbsp;78.7502 may be made as authorized in the specific case upon a determination by the stockholders, the disinterested board members, or, under certain circumstances, by independent legal counsel.
Indemnification under Section&nbsp;78.7502 of the NRS may not be made the corporation if the officer or director has been adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable to the corporation or for amounts
paid in settlement to the corporation, unless and only to the extent that the court determines that in view of all the circumstances, the person is fairly and reasonably entitled to indemnity for such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS requires a corporation to indemnify its officers and directors to the extent that they have been successful on the merits or
otherwise in defense of any action, suit or proceeding (whether civil, criminal, administrative or investigative) or any claim, issue or matter therein, but also provides that discretionary indemnification may not be made under Section&nbsp;78.7502
of a director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable for intentional misconduct, fraud or a knowing violation of law, and such misconduct, fraud or violation was material to
the cause of action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS permits a Nevada corporation to indemnify its officers and directors against expenses incurred in
defending a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof. Section&nbsp;78.751 of the NRS provides that, unless restricted by the articles of incorporation, the bylaws or an agreement
made by the corporation, the corporation may (or shall, if required by the articles of incorporation, bylaws or an agreement) pay expenses as incurred and in advance of final disposition of the action, suit or proceeding, upon receipt of an
undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be indemnified by the corporation. Section&nbsp;78.751 of
the NRS further permits the corporation to grant its directors and officers additional rights of indemnification under its articles of incorporation, bylaws, or other agreement. We have entered into indemnification agreements with our directors and
executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.752 of the NRS provides that a Nevada corporation may purchase and maintain insurance or make other financial
arrangements on behalf of any person who is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another company, partnership, joint
venture, trust, or other enterprise, for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee, or agent, or arising out of his status as such, whether or not the corporation
has the authority to indemnify him against such liability and expenses. We have obtained primary and excess insurance policies insuring our directors and officers and our subsidiaries against certain liabilities they may incur in their capacity as
directors and officers. Under such policies, the insurer, on our behalf, may also pay amounts for which we have granted indemnification to the directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of indemnification merely summarizes certain aspects of indemnification provisions and is limited by reference to the above discussed
sections of the Nevada Private Corporations Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, provide that we shall, to the fullest
extent permitted by the provisions of the Nevada Private Corporations Code, indemnify any and all persons whom we have the power to indemnify from and against any and all expenses, liabilities and other matters referred to in or covered by such
provisions. We have entered into indemnification agreements with each of our directors and certain officers, in addition to the indemnification provided for in our amended and restated articles of incorporation, as amended. Insofar as
indemnification by our company for liabilities arising under the Securities Act may be permitted to officers and directors of our company pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification for Securities Act Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted for directors, officers, or controlling persons pursuant to the
provisions described in the preceding paragraph, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, dated March&nbsp;3, 2021, with Cantor Fitzgerald&nbsp;&amp; Co.,
or Cantor Fitzgerald, under which we may offer and sell shares of our common stock. Pursuant to this prospectus, we may offer and sell shares of our common stock having an aggregate gross sales price of up to $59,377,660 from time to time through
Cantor Fitzgerald acting as agent. The Sales Agreement has been filed as an exhibit to this Registration Statement. This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald may offer and sell
shares of our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on Nasdaq or any other existing trading
market for our common stock. We may instruct Cantor Fitzgerald not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor Fitzgerald may suspend or terminate the offering of our
common stock upon notice and subject to other conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Cantor Fitzgerald commissions, in cash, for its services in acting as agent in the
sale of our common stock. Cantor Fitzgerald is entitled to compensation at a commission rate of 3.0% of the gross proceeds from each sale of our common stock. Because there is no minimum offering amount required as a condition to this offering, the
actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse a portion of Cantor Fitzgerald&#146;s expenses, including legal fees, in connection with this offering
up in an amount not to exceed $50,000. A financial advisor will receive a cash fee in connection with this offering. The financial advisor is not acting as a sales agent and will not sell or offer to sell any securities and will not identify,
solicit, or engage directly with potential investors. In addition, the financial advisor will not underwrite or purchase any of the offered shares or otherwise participate in any such undertaking. We estimate that the total expenses for the offering
under this prospectus, excluding compensation and reimbursements payable to Cantor Fitzgerald under the terms of the Sales Agreement, will be approximately $0.1 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for sales of shares of common stock will occur on the second business day following the date on which any sales are made, or on some other date
that is agreed upon by us and Cantor Fitzgerald in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The
Depository Trust Company or by such other means as we and Cantor Fitzgerald may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will use its commercially reasonable efforts, consistent with its sales and trading practices and applicable law and regulations, to solicit
offers to purchase the shares of common stock under the terms and subject to the conditions set forth in the Sales Agreement. In connection with the sale of the shares of common stock on our behalf, Cantor Fitzgerald will be deemed to be an
&#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor Fitzgerald
(and its partners, members, directors, officers, employees and agents) against certain civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of shares of our common stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. We
and Cantor Fitzgerald may each terminate the Sales Agreement at any time upon five days&#146; prior notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald and its affiliates may in the future provide various investment banking, commercial
banking and other financial services for us, our subsidiaries and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor Fitzgerald will not engage in any market making
activities involving our common stock while the offering is ongoing under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus in electronic format may be made available on
a website maintained by Cantor Fitzgerald and Cantor Fitzgerald may distribute this prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Greenberg Traurig, LLP, Las Vegas, Nevada. Certain other legal matters
will be passed upon for us by DLA Piper LLP (US), Miami, Florida. Certain legal matters relating to this offering will be passed upon for the sales agent by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_11"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
audited financial statements incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the report of Grant Thornton LLP, independent registered public
accountants, upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_12"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Through our website at
<I>www.therapeuticsmd.com</I>, you may access, free of charge, our filings, as soon as reasonably practical after we electronically file them with or furnish them to the SEC. The information contained in our website is not incorporated by reference
in, and should not be considered a part of, this prospectus or any accompanying prospectus supplement. Our SEC filings are also available to the public at the SEC&#146;s website at <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC to register the securities
to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from
the SEC at the address listed above or from the SEC&#146;s website listed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb280081_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information that we incorporate by reference is considered to be part of this prospectus. Information that we file with the SEC in the future and incorporate by reference in this prospectus automatically updates and
supersedes previously filed information as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus the following documents filed by us with the SEC,
other than any portion of any such documents that is not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121003140/txmd-10k_123120.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;3, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2021, June&nbsp;30, 2021, and September&nbsp;30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000119312521153419/d148297d10q.htm">May&nbsp;
6, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021040907/txmd-10q_20210630.htm">August&nbsp;
4, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021056434/txmd-10q_20210930.htm">November&nbsp;12, 2021</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312521116458/d152560ddef14a.htm">Definitive Proxy Statement
on Schedule 14A</A>, filed with the SEC on April&nbsp;14, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on J<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121000535/txmd-8k_011321.htm">anuary
<U></U>&nbsp;13, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121002393/txmd-8k_021121.htm">February<U></U>&nbsp;
16, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000138713121004324/txmd-8k_040821.htm">April<U></U>&nbsp;
12, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000119312521177164/d160590d8k.htm">May<U></U>&nbsp;
28, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021042695/txmd-8k_20210803.htm">August<U></U>&nbsp;
9, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021047142/txmd-8k_20210902.htm">September<U></U>&nbsp;
7, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021048250/txmd-8k_20210915.htm">September<U></U>&nbsp;
17, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021049852/txmd-8k_20210930.htm">October<U></U>&nbsp;
1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021056427/txmd-8k_20211111.htm">November<U></U>&nbsp;
12, 2021</A> as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021057142/txmd-8ka_20211111.htm">November<U></U>&nbsp;
16, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021059685/txmd-8k_20211207.htm">December<U></U>&nbsp;
8, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021060036/txmd-8k_20211210.htm">December<U></U>&nbsp;
10, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021060654/txmd-8k_20211213.htm">December<U></U>&nbsp;
17, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459021060676/txmd-8k_20211214.htm">December<U></U>&nbsp;
20, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022000008/txmd-8k_20211228.htm">January<U></U>&nbsp;
3, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022005710/txmd-8k_20220217.htm">February<U></U>&nbsp;
18, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022009476/txmd-8k_20220306.htm">March<U></U>&nbsp;
10, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/25743/000156459022011090/txmd-8k_20220314.htm">March<U></U>&nbsp;18, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock included under the heading &#147;Description of Common Stock&#148; in the
prospectus forming a part of the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312515368426/d71137ds3.htm">Form <FONT STYLE="white-space:nowrap">S-3</FONT></A> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-207837),</FONT> as filed with the SEC on November&nbsp;5, 2015, which description has been incorporated by reference in Item&nbsp;
1 of the Registrant&#146;s <A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713117004988/txmd-8a12b_100617.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-00100),</FONT> as
filed with the SEC on October&nbsp;6, 2017, including any amendment or report filed with the SEC for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (not including any information
furnished under Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any other information that is identified as &#147;furnished&#148; rather than filed, which information is not incorporated by reference herein),
including those filings made after the date of the initial filing of the registration statement of which this prospectus forms a part, prior to the termination of the offering, will be deemed to be incorporated herein by reference and to be a part
of this prospectus from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained
herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request of that
person, a copy of any and all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus (excluding exhibits unless specifically incorporated by reference into those documents). Please direct
requests to us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">951
Yamato Road, Suite 220 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Boca Raton, Florida 33431 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(561) <FONT STYLE="white-space:nowrap">961-1900</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:140pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g280081g51s75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $59,377,660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g280081g75s75.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;23, 2022 </B></P>
<P STYLE="font-size:110pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the fees and expenses payable by us in connection with the offerings described in this registration statement. In addition to
the costs and expenses set forth below, the registrant will pay any selling commissions and brokerage fees and any applicable taxes, fees and disbursements with respect to securities registered hereby sold by the registrant. All of the amounts shown
are estimates, except for the SEC registration fee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;19,409.30</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and Engraving Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trust Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>$&nbsp;**</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes an aggregate of $15,394.52 of fees previously paid and offset pursuant to Rule 457(p) under the
Securities Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These fees and expenses are calculated based on the securities offered and the number of issuances and
accordingly are not estimated at this time and will be reflected in the applicable prospectus supplement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation and generally governed by the Nevada Private Corporations Code, Chapter 78 of the Nevada Revised Statutes, or NRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.138 of the NRS provides that, unless the corporation&#146;s articles of incorporation provide otherwise, a director or officer is not
individually liable to the corporation or its stockholders or creditors for damages as a result of any action or omission to act as a director or officer unless the presumption that the director or officer acted in good faith, on an informed basis
and with a view to the interests to the corporation is rebutted and it is proven that (i)&nbsp;the director&#146;s or officer&#146;s acts or omissions constituted a breach of his or her fiduciary duties, and (ii)&nbsp;such breach involved
intentional misconduct, fraud, or a knowing violation of the law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.7502 of the NRS permits a company to indemnify its directors and
officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding, if the officer or director (i)&nbsp;is not liable
pursuant to Section&nbsp;78.138 of the NRS, or (ii)&nbsp;acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the best interests of the corporation and, if a criminal action or proceeding, had no
reasonable cause to believe the conduct of the officer or director was unlawful. A discretionary indemnification pursuant to Section&nbsp;78.7502 may be made as authorized in the specific case upon a determination by the stockholders, the
disinterested board members, or, under certain circumstances, by independent legal counsel. Indemnification under Section&nbsp;78.7502 of the NRS may not be made the corporation if the officer or director has been adjudged by a court of competent
jurisdiction, after exhaustion of any appeals, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court determines that in view of all the circumstances, the person is fairly
and reasonably entitled to indemnity for such expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS requires a corporation to indemnify its officers and directors to the extent
that they have been successful on the merits or otherwise in defense of any action, suit or proceeding (whether civil, criminal, administrative or investigative) or any claim, issue or matter therein, but also provides that discretionary
indemnification may not be made under Section&nbsp;78.7502 of a director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable for intentional misconduct, fraud or a knowing violation of law,
and such misconduct, fraud or violation was material to the cause of action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS permits a Nevada corporation to indemnify its
officers and directors against expenses incurred in defending a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof. Section&nbsp;78.751 of the NRS provides that, unless restricted by the
articles of incorporation, the bylaws or an agreement made by the corporation, the corporation may (or shall, if required by the articles of incorporation, bylaws or an agreement) pay expenses as incurred and in advance of final disposition of the
action, suit or proceeding, upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be
indemnified by the corporation. Section&nbsp;78.751 of the NRS further permits the corporation to grant its directors and officers additional rights of indemnification under its articles of incorporation, bylaws, or other agreement. We have entered
into indemnification agreements with our directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.752 of the NRS provides that a Nevada corporation may purchase
and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or
agent of another company, partnership, joint venture, trust, or other enterprise, for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee, or agent, or arising out of his
status as such, whether or not the corporation has the authority to indemnify him against such liability and expenses. We have obtained primary and excess insurance policies insuring our directors and officers and our subsidiaries against certain
liabilities they may incur in their capacity as directors and officers. Under such policies, the insurer, on our behalf, may also pay amounts for which we have granted indemnification to the directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of indemnification merely summarizes certain aspects of indemnification provisions and is limited by reference to the above discussed
sections of the Nevada Private Corporations Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, provide that we shall, to the fullest
extent permitted by the provisions of the Nevada Private Corporations Code, indemnify any and all persons whom we have the power to indemnify from and against any and all expenses, liabilities and other matters referred to in or covered by such
provisions. We have entered into indemnification agreements with each of our directors and certain officers, in addition to the indemnification provided for in our amended and restated articles of incorporation, as amended. Insofar as
indemnification by our company for liabilities arising under the Securities Act may be permitted to officers and directors of our company pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312521068004/d124843dex12.htm">Controlled Equity OfferingSM Sales Agreement, dated March&nbsp;3, 2021, by and between TherapeuticsMD, Inc. and Cantor Fitzgerald&nbsp;
&amp; Co.(1)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization, dated October&nbsp;25,
2007(2)</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#146;s Minority Health Network, Inc., and
 the Major Shareholders, dated July&nbsp;6, 2009(3)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health
 Network, Inc., dated July&nbsp;11, 2010(4)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC, dated July&nbsp;18, 2011(5)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">Articles of Conversion of AMHN, Inc., dated July&nbsp;20, 2010, filed in the State of Nevada(6)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex3-1.htm">Composite Amended and Restated Articles of Incorporation of the Company, as amended(7)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">Bylaws of AMHN, Inc.(8)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">First Amendment to Bylaws of TherapeuticsMD, Inc.(9)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">Form of Certificate of Common Stock(10)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Certificate of Preferred Stock**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Agreement and Certificate**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Debt Security**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-6.htm">Form of Indenture(11)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Depositary Receipt for Depositary Shares**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Deposit Agreement for Depositary Shares**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Purchase Contract**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Unit Agreement and Unit Certificate**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d280081dex51.htm">Opinion of Greenberg Traurig, LLP*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d280081dex52.htm">Opinion of DLA Piper LLP (US)*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d280081dex51.htm">Consent of Greenberg Traurig, LLP (contained in Exhibit 5.1)*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d280081dex232.htm">Consent of Grant Thornton LLP*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d280081dex52.htm">Consent of DLA Piper LLP (US) (contained in Exhibit 5.2)*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/25743/000119312521068004/d124843ds3asr.htm">Power of Attorney of Directors and Executive Officers (12) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>25.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Statement of Eligibility on Form <FONT STYLE="white-space:nowrap">T-1</FONT> under the Trust Indenture Act of 1939 of the Trustee under the Indenture***</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d280081dexfilingfees.htm">Calculation of Filing Fee Tables</A>*</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment to this registration statement or by a report filed under the Securities Exchange Act
of 1934, as amended, and incorporated herein by reference </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed pursuant to Section&nbsp;305(b)(2) of the Trust Indenture Act of 1939, as amended
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as an exhibit to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with
the Commission on March&nbsp;4, 2021 and incorporated herein by reference (SEC File <FONT STYLE="white-space:nowrap">No.&nbsp;333-253851).</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 33.2 to the Registrant&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-16731)</FONT> for the year ended December&nbsp;31, 2007 with the Commission on May&nbsp;1, 2008 and incorporated herein by reference.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 2.1 to the Registrant&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-16731)</FONT> with the Commission on July&nbsp;10, 2009 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 10.1 to the Registrant&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-16731)</FONT> with the Commission on June&nbsp;14, 2010 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 10.01 to the Registrant&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-16731)</FONT> with the Commission on July&nbsp;21, 2011 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 3.4 to the Registrant&#146;s Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-16731)</FONT> for quarter ended June&nbsp;30, 2010 with the Commission on August&nbsp;3, 2010 and incorporated herein by reference.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 3.1 to the Registrant&#146;s Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-00100)</FONT> for the quarter ended June&nbsp;30, 2020 with the Commission on August&nbsp;7, 2020 and incorporated herein by reference.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit C to the Registrant&#146;s Definitive Information Statement on Schedule 14C (File <FONT
STYLE="white-space:nowrap">No.&nbsp;000-16731)</FONT> with the Commission on June&nbsp;29, 2010 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 3.1 to the Registrant&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-00100)</FONT> with the Commission on December&nbsp;22, 2015 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 4.2 to the Registrant&#146;s Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-186189)</FONT> with the Commission on January&nbsp;25, 2013 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed as Exhibit 4.6 to the Registrant&#146;s Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-186189)</FONT> with the Commission on January&nbsp;25, 2013 and incorporated herein by reference. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included on the signature page to the Registrant&#146;s Registration Statement on Form S-3 filed with the
Commission on March 4, 2021 and incorporated herein by reference (SEC File No. 333-253851) and incorporated herein by reference. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus
required by section 10(a)(3) of the Securities Act of 1933 (the &#147;Securities Act&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set
forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) of this section do not apply if the information required to be included in a
post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section&nbsp;15(d) of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) that are
incorporated by reference into the registration statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any
purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date
the filed prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(B) Each prospectus required to be filed pursuant to Rule
424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the
Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the
securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. <I>Provided</I>, <I>however</I>, that no statement made
in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such effective date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any
purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or
referred to by the undersigned registrant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing prospectus relating to the offering containing material
information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The undersigned registrant hereby undertakes that, for purposes
of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report
pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial <I>bona fide </I>offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection
(a) of section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under section 305(b)(2) of the Trust Indenture Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Post-Effective Amendment No.&nbsp;1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Boca Raton, State of Florida, on the 23rd day of March, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERAPEUTICSMD, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <I>Hugh O&#146;Dowd</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Hugh O&#146;Dowd</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No.&nbsp;1 to the registration statement has been signed by the
following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Position</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>/s/ Hugh O&#146;Dowd</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hugh O&#146;Dowd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer, Director<BR>(Principal Executive
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>/s/ James C. D&#146;Arecca</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James C. D&#146;Arecca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Michael C. Donegan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Accounting Officer<BR>(Principal Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tommy G. Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairman of the Board of<BR>Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paul M. Bisaro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooper C. Collins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Karen L. Ling</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jules A. Musing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gail K. Naughton, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>*</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Angus C. Russell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;23, 2022</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ James C. D&#146;Arecca</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James C. D&#146;Arecca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d280081dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g280081g43s48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 23, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">951 Yamato Road, Suite 220 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, Florida 33431 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Re:&nbsp;&nbsp;&nbsp;&nbsp;Shelf Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as legal
counsel to TherapeuticsMD, Inc., a Nevada corporation (the &#147;<U>Company</U>&#148;), in connection with the preparation of Post-Effective Amendment No.&nbsp;1 to the Company&#146;s Shelf Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (the &#147;<U>Registration Statement</U>&#148;), being filed by the Company with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act of 1933, as amended (the
&#147;<U>Act</U>&#148;), relating to: (i)&nbsp;shares of common stock, par value $0.001 per share, of the Company (&#147;<U>Common Stock</U>&#148;); (ii) one or more classes or series of shares of preferred stock, par value $0.001 per share, of the
Company (&#147;<U>Preferred Stock</U>&#148;); (iii) one or more series of debt securities of the Company (&#147;<U>Debt Securities</U>&#148;); (iv) depositary shares representing interests in Preferred Stock (&#147;<U>Depositary Shares</U>&#148;);
(v) warrants to purchase Common Stock, Preferred Stock, Debt Securities, Depositary Shares, or any combination of those securities (&#147;<U>Warrants</U>&#148;); (vi) contracts to purchase Common Stock, Preferred Stock, Debt Securities, Depositary
Shares, Warrants, or any combination of those securities (&#147;<U>Purchase Contracts</U>&#148;); (vii) units consisting of Common Stock, Preferred Stock, Debt Securities, Depositary Shares, and/or Warrants (&#147;<U>Units</U>&#148;); and
(viii)&nbsp;the Common Stock, Preferred Stock, Debt Securities, or Depositary Shares that may be issued upon the exercise of the Warrants or in connection with Purchase Contracts or Units, as applicable, at an aggregate offering price not to exceed
$209,377,660. The Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants, Purchase Contracts and Units are hereinafter referred to collectively as the &#147;<U>Securities.</U>&#148; The Securities may be issued and sold or
delivered, from time to time, as set forth in the Registration Statement, any amendment thereto, the prospectus contained therein (the &#147;<U>Prospectus</U>&#148;) and any supplements to the Prospectus (the &#147;<U>Prospectus
Supplements</U>&#148; and each, a &#147;<U>Prospectus Supplement</U>&#148;), and pursuant to Rule 415 under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also acted
as legal counsel for the Company in connection with the sales agreement prospectus included in the Registration Statement (the &#147;<U>Sales Agreement Prospectus</U>&#148;) relating to the issuance and sale of shares of Common Stock having an
aggregate offering price of up to $59,377,660 (the &#147;<U>Sales Agreement Shares</U>&#148;) under a Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement, dated March&nbsp;3, 2021, between the Company
and Cantor Fitzgerald&nbsp;&amp; Co. (the &#147;<U>Sales Agreement</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Greenberg Traurig, LLP | Attorneys at Law</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">10845 Griffith Peak Drive | Suite 600 | Las Vegas, Nevada 89135 | T +1 702.792.3773 | F +1 702.792.9002</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">www.gtlaw.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the opinions set forth below, we have examined originals, certified copies,
or copies otherwise identified to our satisfaction as being true copies, of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Amended and Restated Articles of Incorporation of the Company, as amended to date (the
&#147;<U>Charter</U>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Bylaws of the Company, as amended to date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolutions of the Board of Directors of the Company relating to the approval of the Sales Agreement and the
filing of the Registration Statement and the transactions in connection therewith (the &#147;<U>Resolutions</U>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sales Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other documents and records and other certificates and instruments and matters of law as we have deemed
necessary or appropriate to express the opinions set forth below, subject to the assumptions, limitations and qualifications stated herein. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the
authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies and the authenticity of the originals or such latter documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As to matters of fact material to this opinion, we have relied, to the extent we deemed reasonably appropriate, upon representations or
certificates of officers or directors of the Company, without independently verifying the accuracy of such documents, records and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have further assumed that: (i)&nbsp;the Registration Statement and any amendments thereto will be effective under the Act, that no stop
orders will have been issued by the Commission with respect to the Registration Statement and that the Registration Statement will comply with all applicable laws at the time the Securities are offered or issued as contemplated by the Registration
Statement; (ii)&nbsp;an appropriate Prospectus Supplement, free writing prospectus or term sheet relating to the Securities offered thereby will have been prepared and filed with the Commission in compliance with the Act and will comply with all
applicable laws at the time the Securities are offered or issued as contemplated by the Registration Statement; (iii)&nbsp;all Securities will be issued and sold in compliance with the applicable provisions of the Act, the Trust Indenture Act of
1939, as amended, and the securities or blue sky laws of various states and on the terms and in the manner stated in the Registration Statement and the applicable Prospectus Supplement; (iv)&nbsp;any purchase, underwriting or similar agreement
relating to Securities being offered will have been duly authorized, executed and delivered by the Company and the other parties thereto; and (v)&nbsp;in connection with the issuance of any Securities, an adequate number of authorized and unissued
shares of Common Stock or Preferred Stock, as applicable, will be available for issuance under the Charter, as then in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>Greenberg Traurig, LLP | Attorneys at Law</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">www.gtlaw.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based solely upon and subject to the foregoing, and subject to the assumptions, limitations,
and qualifications stated herein, we are of the opinion that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;With respect to the Common Stock other than the
Sales Agreement Shares, assuming (i)&nbsp;the taking by the Board of Directors of the Company of all necessary corporate action to authorize and approve the issuance of the Common Stock; and (ii)&nbsp;the due issuance and delivery of the Common
Stock upon payment therefor in accordance with the applicable definitive purchase, underwriting, or similar agreement, if applicable, or the Prospectus or a Prospectus Supplement approved by the Board of Directors of the Company and otherwise in
accordance with the provisions of such agreement, the Common Stock will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;With respect to the Preferred Stock, assuming (i)&nbsp;the taking by the Board of Directors of the Company of all
necessary corporate action to authorize and approve the issuance and terms of the Preferred Stock and the terms of the offering thereof; (ii)&nbsp;the due filing of the Certificate of Designation with the Nevada Secretary of State setting forth the
terms of such Preferred Stock; and (iii)&nbsp;the due issuance and delivery of the Preferred Stock upon payment therefor in accordance with the applicable definitive purchase, underwriting, or similar agreement, if applicable, or the Prospectus or a
Prospectus Supplement approved by the Board of Directors of the Company and otherwise in accordance with the provisions of such agreement, the Preferred Stock will be validly issued, fully paid, and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;With respect to the Sales Agreement Shares, assuming (i)&nbsp;the Company delivers placement notices under the
Sales Agreement in accordance with the Resolutions and the pricing terms duly approved by the Board of Directors of the Company or a pricing committee duly authorized thereunto; and (ii)&nbsp;the due issuance and delivery of the Sales Agreement
Shares upon payment therefor in accordance with such placement notices, the Sales Agreement and, the Sales Agreement Prospectus or a prospectus supplement thereto approved by the Board of Directors of the Company or a pricing committee duly
authorized thereunto and otherwise in accordance with the provisions of the Sales Agreement, the Sales Agreement Shares will be validly issued, fully paid and nonassessable. This opinion letter is limited to the matters stated herein, and no
opinions may be implied or inferred beyond the matters expressly stated herein. We assume no obligation to supplement this opinion letter if any applicable law changes after the date hereof or if we become aware of any fact that might change the
opinions expressed herein after the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not express any opinion herein concerning any law other than the laws of the State
of Nevada and the federal laws of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>Greenberg Traurig, LLP | Attorneys at Law</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">www.gtlaw.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby expressly consent to (i)&nbsp;any reference to the name of our firm in the
Registration Statement; and (ii)&nbsp;the inclusion of this opinion letter as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section&nbsp;7 of
the Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Greenberg Traurig, LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Greenberg Traurig, LLP</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>Greenberg Traurig, LLP | Attorneys at Law</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">www.gtlaw.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>d280081dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 5.2</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>DLA Piper LLP (US)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">www.dlapiper.com </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g280081g43g40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;23, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">951 Yamato Road, Suite 220 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, FL 33431 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shelf Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special
legal counsel to TherapeuticsMD, Inc., a Nevada corporation (the &#147;<U>Company</U>&#148;), in connection with the preparation of Post-Effective Amendment No.1 to the Company&#146;s Shelf Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> (the &#147;<U>Registration Statement</U>&#148;), being filed by the Company with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act of 1933, as amended (the
&#147;<U>Act</U>&#148;), relating to the proposed issuance and sale by the Company from time to time of: (i)&nbsp;shares of common stock, par value $0.001 per share, of the Company (&#147;<U>Common Stock</U>&#148;); (ii) one or more classes or
series of shares of preferred stock, par value $0.001 per share, of the Company (&#147;<U>Preferred Stock</U>&#148;); (iii) one or more series of debt securities of the Company (&#147;<U>Debt Securities</U>&#148;); (iv) depositary shares
representing interests in Preferred Stock (&#147;<U>Depositary Shares</U>&#148;); (v) warrants to purchase Common Stock, Preferred Stock, Debt Securities, Depositary Shares, or any combination of those securities (&#147;<U>Warrants</U>&#148;); (vi)
contracts to purchase Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants, or any combination of those securities (&#147;<U>Purchase Contracts</U>&#148;); (vii) units consisting of Common Stock, Preferred Stock, Debt
Securities, Depositary Shares, and/or Warrants (&#147;<U>Units</U>&#148;); and (viii)&nbsp;the Common Stock, Preferred Stock, Debt Securities, or Depositary Shares that may be issued upon the exercise of the Warrants or in connection with Purchase
Contracts or Units, as applicable, at an aggregate offering price not to exceed $209,377,660. The Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants, Purchase Contracts and Units are hereinafter referred to collectively as
the &#147;<U>Securities.</U>&#148; The Securities may be issued and sold or delivered, from time to time, as set forth in the Registration Statement, any amendment thereto, the prospectus contained therein (the &#147;<U>Prospectus</U>&#148;) and any
supplements to the Prospectus (the &#147;<U>Prospectus Supplements</U>&#148; and each, a &#147;<U>Prospectus Supplement</U>&#148;), and pursuant to Rule 415 under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Debt Securities will be issued pursuant to one or more indentures (each, an &#147;<U>Indenture</U>&#148;), each to be between the Company
and a financial institution identified therein as the trustee (the &#147;<U>Trustee</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary Shares will be in the form
of depositary receipts and will be issued under one or more Deposit Agreements (each, a &#147;<U>Deposit Agreement</U>&#148;), each to be between the Company and a financial institution identified therein as the depositary (each, a
&#147;<U>Depositary</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants will be issued under one or more Warrant Agreements (each, a &#147;<U>Warrant
Agreement</U>&#148;), each to be between the Company and a counterparty or counterparties identified therein or a financial institution identified therein as the warrant agent (each, a &#147;<U>Warrant Counterparty</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Contracts will be issued under one or more Purchase Contracts or Purchase Agreements (each, a &#147;<U>Purchase
Contract</U>&#148;), each to be between the Company and a counterparty or counterparties identified therein (the &#147;<U>Purchase Contract Counterparty</U>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g280081g43g40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March
23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Units will be issued under one or more Unit Agreements (each, a &#147;<U>Unit
Agreement</U>&#148;), each to be between the Company and a counterparty or counterparties identified therein (the &#147;<U>Unit Counterparty</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the opinions set forth below, we have examined originals, certified copies, or copies otherwise identified to our satisfaction
as being true copies, of such corporate records, documents, instruments and certificates of public officials and of the Company and matters of law that we have deemed necessary or appropriate to express the opinions set forth below, subject to the
assumptions, limitations and qualifications stated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have assumed the genuineness of
all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies and the
authenticity of the originals or such latter documents. We have also assumed that (i)&nbsp;at the time of execution, authentication, issuance and delivery of any Debt Securities, the applicable Indenture will be the valid and legally binding
obligation of the Trustee; (ii)&nbsp;at the time of execution, authentication, issuance and delivery of any Depositary Shares, the applicable Deposit Agreement will be the valid and legally binding obligation of the Depositary; (iii)&nbsp;at the
time of execution, countersignature, issuance and delivery of any Warrants, the applicable Warrant Agreement will be the valid and legally binding obligation of each Warrant Counterparty thereto; (iv)&nbsp;at the time of execution, countersignature,
issuance and delivery of any Purchase Contract, the applicable Purchase Contract will be the valid and legally binding obligation of each Purchase Contract Counterparty thereto; and (v)&nbsp;at the time of execution, countersignature, issuance and
delivery of any Units, the applicable Unit Agreement will be the valid and legally binding obligation of each Unit Counterparty thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As to matters of fact material to this opinion, we have relied, to the extent we deemed reasonably appropriate, upon representations or
certificates of officers or directors of the Company, without independently verifying the accuracy of such documents, records and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Debt Securities, we have assumed further that (i)&nbsp;at the time of execution, authentication,
issuance and delivery of any Debt Securities, the related Indenture will have been duly authorized, executed and delivered by the Company; and (ii)&nbsp;the execution, delivery and performance by the Company of the Indenture and the Debt Securities
will not violate the laws of any jurisdiction (provided that as to the laws of the State of New York and the federal laws of the United States we make no such assumption). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of Depositary Shares, we have assumed further that (i)&nbsp;at the time of execution, countersignature,
issuance and delivery of any Depositary Shares, the related Deposit Agreement will have been duly authorized, executed and delivered by the Company; and (ii)&nbsp;the execution, delivery and performance by the Company of such Deposit Agreement and
such Depositary Shares will not violate the laws of any jurisdiction (provided that as to the laws of the State of New York and the federal laws of the United States we make no such assumption). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of Warrants, we have assumed further that (i)&nbsp;at the time of execution, countersignature, issuance and
delivery of any Warrants, the related Warrant Agreement will have been duly authorized, executed, and delivered by the Company; and (ii)&nbsp;the execution, delivery and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g280081g43g40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March
23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance by the Company of such Warrant Agreement and such Warrants will not violate the laws of any jurisdiction (provided that as to the laws of the State of New York and the federal laws of
the United States we make no such assumption). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of Purchase Contracts, we have assumed further that
(i)&nbsp;at the time of execution, countersignature, issuance and delivery of any Purchase Contracts, the related Purchase Contract will have been duly authorized, executed and delivered by the Company; and (ii)&nbsp;the execution, delivery and
performance by the Company of such Purchase Contract and such Purchase Contracts will not violate the laws of any jurisdiction (provided that as to the laws of the State of New York and the federal laws of the United States we make no such
assumption). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Units, we have assumed further that (i)&nbsp;at the time of execution,
countersignature, issuance and delivery of any Units, the related Unit Agreement will have been duly authorized, executed and delivered by the Company; and (ii)&nbsp;the execution, delivery and performance by the Company of such Unit Agreement and
such Units will not violate the laws of any jurisdiction (provided that as to the laws of the State of New York and the federal laws of the United States we make no such assumption). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have further assumed that: (i)&nbsp;the Registration Statement and any amendments thereto will be effective under the Act, that no stop
orders will have been issued by the Commission with respect to the Registration Statement and that the Registration Statement will comply with all applicable laws at the time the Securities are offered or issued as contemplated by the Registration
Statement; (ii)&nbsp;an appropriate Prospectus Supplement, free writing prospectus or term sheet relating to the Securities offered thereby will have been prepared and filed with the Commission in compliance with the Act and will comply with all
applicable laws at the time the Securities are offered or issued as contemplated by the Registration Statement; (iii)&nbsp;all Securities will be issued and sold in compliance with the applicable provisions of the Act, the Trust Indenture Act of
1939, as amended, and the securities or blue sky laws of various states and in the manner stated in the Registration Statement and the applicable Prospectus Supplement; and (iv)&nbsp;any purchase, underwriting or similar agreement relating to
Securities being offered will have been duly authorized, executed and delivered by the Company and the other parties thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based
solely upon and subject to the foregoing, and subject to the assumptions, limitations, and qualifications stated herein, we are of the opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Debt Securities, assuming (i)&nbsp;the taking of all necessary corporate action to approve
the issuance and terms of the Debt Securities, the terms of the offering thereof and related matters by the Board of Directors of the Company; (ii)&nbsp;the due execution, authentication, issuance and delivery of such Debt Securities upon payment of
the consideration therefor provided for in a definitive purchase, underwriting, or similar agreement, as applicable, or the Prospectus or a Prospectus Supplement approved by the Board of Directors of the Company, and otherwise in accordance with the
provisions of the applicable Indenture and such definitive purchase, underwriting, or similar agreement, as applicable; and (iii)&nbsp;the conditions in the applicable Indenture have been satisfied, such Debt Securities will constitute valid and
legally binding obligations of the Company, enforceable against the Company in accordance with their terms. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g280081g43g40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March
23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Depositary Shares, assuming (i)&nbsp;the taking of all necessary corporate action to
authorize and approve the issuance of the Depositary Shares, the final terms establishing the depositary receipts representing the Depositary Shares (the &#147;<U>Depositary Receipts</U>&#148;) in the form contemplated and authorized by a Deposit
Agreement and related matters by the Board of Directors of the Company; (ii)&nbsp;the due filing of the Certificate of Designation with the Nevada Secretary of State setting forth the terms of the Preferred Stock with respect to which Depositary
Shares are issued; (iii)&nbsp;the due execution, authentication, issuance and delivery of the Depositary Shares, upon payment of the consideration therefor provided for in a definitive purchase, underwriting, or similar agreement, as applicable, or
the Prospectus or a Prospectus Supplement approved by the Board of Directors of the Company, and otherwise in accordance with the provisions of the applicable Deposit Agreement and such definitive purchase, underwriting, or similar agreement, as
applicable; and (iv)&nbsp;the conditions in the applicable Deposit Agreement have been satisfied, the Depositary Shares will be validly issued and will entitle the holders thereof to the rights specified in the Depositary Receipts and such Deposit
Agreement for such Depositary Receipts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Warrants, assuming (i)&nbsp;the taking of all necessary corporate action by the Board of
Directors of the Company to approve the execution and delivery of a Warrant Agreement and issuance of the Warrants; (ii)&nbsp;the due execution, countersignature, issuance and delivery of such Warrants upon payment of the consideration therefor
provided for in a definitive purchase, underwriting, or similar agreement, as applicable, or the Prospectus or a Prospectus Supplement approved by the Board of Directors of the Company, and otherwise in accordance with the provisions of the
applicable Warrant Agreement and such definitive purchase, underwriting, or similar agreement, as applicable; and (iii)&nbsp;the conditions in the applicable Warrant Agreement have been satisfied, such Warrants will constitute valid and legally
binding obligations of the Company enforceable against the Company in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Purchase Contracts, assuming (i)&nbsp;the taking of all necessary corporate action by the
Board of Directors of the Company to approve the execution and delivery of a Purchase Contract; (ii)&nbsp;the due execution, countersignature, issuance and delivery of such Purchase Contracts upon payment of the consideration therefor provided for
in a definitive purchase, underwriting, or similar agreement, as applicable, or the Prospectus or a Prospectus Supplement approved by the Board of Directors of the Company, and otherwise in accordance with the provisions of the applicable Purchase
Contract and such definitive purchase, underwriting, or similar agreement, as applicable; and (iii)&nbsp;the conditions in the applicable Purchase Contract have been satisfied, such Purchase Contracts will constitute valid and legally binding
obligations of the Company enforceable against the Company in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Units, assuming (i)&nbsp;the taking of all necessary corporate action by the Board of
Directors of the Company to approve the execution and delivery of a Unit Agreement and issuance of the Units; (ii)&nbsp;the due execution, countersignature, issuance and delivery of the Units upon payment of the consideration therefor provided for
in a definitive purchase, underwriting, or similar agreement, as applicable, or the Prospectus or a Prospectus Supplement approved by the Board of Directors of the Company, and otherwise in accordance with the provisions of the
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g280081g43g40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March
23, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
applicable Unit Agreement and such definitive purchase, underwriting, or similar agreement, as applicable; and (iii)&nbsp;the conditions in the applicable Unit Agreement have been satisfied, such
Units will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions above are subject to (i)&nbsp;the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium, and other
similar laws now or hereafter in effect relating to or affecting creditors&#146; rights generally; (ii)&nbsp;the effects of general equitable principles, including, without limitation, concepts of materiality, reasonableness, good faith and fair
dealing, and the possible unavailability of specific performance or injunctive relief, whether enforcement is considered in a proceeding in equity or law; (iii)&nbsp;the discretion of the court before which any proceeding for enforcement may be
brought; and (iv)&nbsp;the unenforceability under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution
is contrary to public policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion letter is limited to the matters stated herein, and no opinions may be implied or inferred
beyond the matters expressly stated herein. We assume no obligation to supplement this opinion letter if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinions expressed herein after the
date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not express any opinion herein concerning any law other than the laws of the State of New York and the federal laws of
the United States. With respect to our opinions above, we have, without any investigation on our part, assumed the accuracy, and to the extent necessary in connection with the opinions contained herein, relied upon the opinion dated as of the date
hereof furnished to you by Greenberg Traurig, LLP as to matters of Nevada law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby expressly consent to (i)&nbsp;any reference to
the name of our firm in the Registration Statement; and (ii)&nbsp;the inclusion of this opinion letter as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is
required by Section&nbsp;7 of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:61%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:61%; font-size:10pt; font-family:Times New Roman"><B>DLA Piper LLP (US) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:61%; font-size:10pt; font-family:Times New Roman">/s/ DLA Piper LLP (US) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d280081dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have issued our report dated March&nbsp;3, 2021 with respect to the consolidated financial statements of TherapeuticsMD, Inc. included in the Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this
Registration Statement, and to the use of our name as it appears under the caption &#147;Experts.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Miami, Florida </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;23, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d280081dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 1: Newly Registered and Carry Forward Securities</U></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Security Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Security<BR>Class&nbsp;Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Amount<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Maximum<BR>Aggregate<BR>Offering<BR>Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Fee<BR>Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Amount<BR>of<BR>Registration<BR>Fee</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Carry<BR>Forward<BR>Form<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Carry<BR>Forward<BR>File<BR>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Carry<BR>Forward<BR>Initial<BR>effective<BR>date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Filing<BR>Fee<BR>Previously<BR>Paid In<BR>Connection<BR>with<BR>Unsold<BR>Securities<BR>to be<BR>Carried<BR>Forward</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" COLSPAN="32" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:10pt"><B>Newly Registered Securities</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees&nbsp;to&nbsp;be&nbsp;Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Common<BR>stock,<BR>par value<BR>$0.001 per<BR>share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Preferred<BR>stock, pay<BR>value<BR>$0.001 per<BR>share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Debt</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Debt<BR>Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Depositary<BR>Shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Warrants</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Purchase<BR>Contracts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Units</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Unallocated<BR>(Universal)<BR>Shelf</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Unallocated<BR>(Universal)<BR>Shelf</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">$209,377,660</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$92.70<BR>per<BR>$1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">$19,409.30(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees to
be Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Common<BR>stock, par<BR>value<BR>$0.001 per<BR>share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees
Previously Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Common<BR>stock, par<BR>value<BR>$0.001 per<BR>share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">$59,377,660</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$109.10<BR>per<BR>$1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">$6,478.10(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$209,377,660</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$19,409.30</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$6,478.10</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$8,916.42(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$4,014.78</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Pursuant to Instruction 2.A(iii)(b) of Item 16(b) of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> this information is
not required to be included. An indeterminate amount of the securities of each identified class is being registered as may from time to time be offered under this registration statement at indeterminate prices, along with an indeterminate number of
securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold under this registration statement, as shall have an aggregate initial offering price up to $209,377,660. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The securities registered pursuant to this registration statement include unsold securities previously registered on this registration statement on
March&nbsp;4, 2021 (the &#147;Original Registration Statement&#148;). The Original Registration Statement registered the offer and sale of up to $100,000,000 in shares of the registrant&#146;s common stock that may be issued and sold under an
amended and restated sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. The registrant previously paid a fee of $10,910 related to such $100,000,000 in shares of common stock. Of such shares of common stock, $59,377,660 remain unsold (the
&#147;Unsold Securities&#148;). The registrant has determined to include in this registration statement all of the Unsold Securities and the registration fee in the amount of $6,478.10 related thereto is applied to the registrant&#146;s total
registration fee. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Pursuant to Rule 457(p), the registrant hereby partially offsets the registration fee required in connection with this filing by
$8,916.42, which represents the remaining balance from the $32,450 registration fee previously paid by the registrant with respect to an aggregate $250,000,000 of securities previously registered under a universal shelf on a post-effective amendment
to a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-226452)</FONT> (the &#147;Prior Registration Statement&#148;), initially filed with the Securities and
Exchange Commission on February&nbsp;24, 2020, which is terminated and of which $68,693,563 aggregate offering amount was unsold. Pursuant to Rule 457(p) under the Securities Act, the $19,409.30 filing fee currently due in connection with this
filing is offset in part against the $8,916.42 remaining balance for such unsold securities under the Prior Registration Statement. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) The Prior
Registration Statement included an indeterminate number and amount of Common Stock, Preferred Stock, Debt Securities, Depository Shares, Warrants, Purchase Contracts and Units of the registrant that could be issued at currently indeterminable prices
and could be issued upon conversion, redemption, repurchase, exchange or exercise of any securities registered thereunder, which together had a maximum aggregate initial offering price of $250,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U><B>Table 2: Fee Offset Claims and Sources</B> </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registrant</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>or Filer</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Form<BR>or<BR>Filing<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>File</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Initial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Filing</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Filing</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offset<BR>Claimed</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security Type<BR>Associated with<BR>Fee Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Title<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Unsold<BR>Securities<BR>Associated with<BR>Fee Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Unsold<BR>Aggregate<BR>Offering<BR>Amount<BR>Associated with<BR>Fee Offset<BR>Claimed</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offset</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Source</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="23" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="23" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Rule 457(p)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fee Offset</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Claims</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">TherapeuticsMD,<BR>Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">333-226452</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;24,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$8,916.42</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Unallocated</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(4)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$68,693,563</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$68,693,563</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fee Offset</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sources</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">TherapeuticsMD,<BR>Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">333-226452</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">February&nbsp;24, 2020</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$8,916.42(3)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g280081g03s03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g280081g03s03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1/V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $]J^4((X0DE-! 0      %,< @   @  ' )0  AR<C,Y,#DX.1P"!0 Z
M36EC<F]S;V9T(%=O<F0@+2!46$U$("T@4$]305-27U,M,T%34B S+C0N,C%?
M+3$X.3,X-34Q,"UV-0 X0DE-!"4      !":B4#288P>E1HA THVNR*$.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      -!    !@
M    -P   :@    & &< ,  S ', ,  S     0
M   !              &H    -P                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    -P    !29VAT;&]N9P   :@    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   #<     4F=H=&QO;F<   &H     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      E:     0   *     5
M   !X   )V    D^ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  5 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M     P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0
M  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,04
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  ,! 0          "0H " $"!P,%!@0+_\0 4!    8! @0#!0,%"P@* P
M 0(#! 4&!P@1  D2(0H3,105(D%1%C)A%Q@C<8$9-S@Y0E)W>+&VMQHF)S96
M=J'1)"@I.F-R=9&2\;*UP?_$ !T!  (# 0$! 0$            &! 4' 0,(
M @G_Q !3$0 " 0,# @,$! 8/ PH' 0 ! @,$!1$ $B$&,1,B00<446$R<8&1
M%2,UH;'P"!8D)3,T0G)S=;.TP='Q-E)T%Q@F0T1EI+*UX3=%4U5V@H6C_]H
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M4EWJC>*AV":A5I"6=LF2.YEQ,6514<]PJJ>BI4,D]1($1>P X+.3\$7+,/\
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ME>ZYP)A3CP0,XRS%PR?':R!@I!/?1E-.^J'!&J_';/*FGG*%<RE2'BYVBDI
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M33)<'BMC3%8RG6RX&D752D,A+3I%2U&)F%V"3-*>C%"'?)M"+BN9$AE%DU"
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M-6?#B*EAO\"944R@DKN'*DL ,,;YXHL5*M&+\<VC&*+)KC>ST:J6*@-H^(&
MCF]*FX%A*5=-G!F:M#PS0(1RQ*VC/9&@,4MFP-T?**@%14)*E14+4/(9DED]
MX9W$CF4,4?+9;<=R$DYR223JXI&A:EIFI41:>2&,TR)&T2")E#1D(P0J C*
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M!(.?CP",:3Y^O.GH96B26JJ<-CQ((%>)N,[E=GC.T<CE>2#ACD'5N-+W-TT
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M^[U.L@]G7Y=K/ZKJ/[Y0Z?(1^X'ZQXR0=V^O_ :VC05/$-?Q3>I -AV&8P>
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M9TB8HKE1>59XUWV S04=B#Y)UKU!&Q;WF.0)AF@-'31AN<862*"%B>,8$F[
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MI]1@^O?OZ=M5_L[ %EJQC_YK-WY_['0GUSQ\!V&F25$DP*( 4.Q0$.XB._6
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M6!,P;=P<D+V1@<@5D5CZIJ+W1W.MHI9)VN%'-/4$T40_%,G.R!5A0@0QDD(
MWF,F<DDHGBN.VG;2J(@("7,UT,0#;CMM0S% 0[CMN @)3% I@ 0W^,3&,O\
ML] 6LN&#A4HP #R2%D 4X))]2,D_#/'9C]I2YH;;E2,UDA/F&<LG;(\I!VC*
M_$%B.2-$RY!F*:_C3E:Z=%XIB@A)9)&\Y3M+M(A4U)6<LMVG&3%X[\O8JCAI
M4X:LPI%!#K%M$MNL3*%,<U+U=.TU_K0QRL!BAC! .U/"67:,Y)\\KG)R06(!
MP!J_Z*@6#IZC=<AJIIJB4@GS.9#"#WX BAC3 P"%Y&2=%$S'DVGX-Q9D;,5Z
M<'84O%U)L^0;2Y;D(LZ)"56(=S4F#)L=1/VI^NW9&38M0, NWQVZ &*=0#"O
MTT#U%1%31*-T[J@Q_O$@!B!WV]SP>!\AIDJJB.DIYJJ0^6GC>1_B55>1N/)+
M $#)';O@D:1+9ZG>;=SRL^W:C:=+W/X8P_7!+(OZQ4+[-8PQ?C*IR3MVUKZ6
M5;M541MN0K)-BV<F%@LQGUI&482[VNU&"@F+XT;K;T?3G25%$]QA6IJ6.&J#
M"LTDDI120@EW!%"[1L3:@/F*[V9M8VM=U)U=6U,%#+-34R'<E.DXAI8J=G(1
MGDC :61G5W,C%W9" I946,6M0\-[S"HM#WW!:_JLVMQ0!<QT+)FR+!-Y^C.!
M?M0T!Q*& %T]Q=C#%4'<P@U !\OBM;K:S$>$UI;P<[MW@4^3G:!D A><?[Q'
M QSG4\= W]2DD=WIHZA7/*258(4@'!D4ANQX! P#N!SSH(&OC3YJ[TQZO,;X
MPUGY:4S5E%I7,?RU<NZF1K;E$BF.G]QL36"CFMCO<?&6=NV9RL;/@E#R#)'V
M BO_ $</97"8<--KKK?7VRHFMD/N\*O.DB")(?W0U*'D)6/@DH806R22N,XT
MHWJANEKKX8+I5&JJ46!X93--/BG\2?PUWU!9R!+'(ZJ0%7=PH);+:'BB2%+R
M[: 8 V*&J[&YC 'W0'\F^9Q*(E^90$H@)";=6X 8!  VS_H JEZG8C(6VU!(
M/;'O-,YSG/\ *PWIG&,XXUIGM&(%DIV8;E_"4((!*DYHZQ!@@@C QR#GUYUW
M/PZB54)RJL*FKX,R3"MTS4K=P1 HJGM(Y0M -C2'EF!078THM2*050,X".%B
M&PH@F 0NLA+^'JDON"&&E$0)! C:!'(5AR1XK2D$G*DE00%4";T*(_VNTH7;
MXGCU338SQ()F5<^F? $(.  P 9@6+$G.23* >@[E,8 ^(PB'J E$1VZ@ 1$"
MF$-Q)TB.YMQX5!P, G X[DYQ\23S]N>?F-.)Y.<#[  !GX   ?9C2M/BLT:U
M^:5IP7<%;#<4]1#A&#Z@*+P*POC&YJ6SV<!$JGLAY-E2TWH)& A5QC3' % 0
M-P_= ;S<*_&?"]QPQY W^*"G/8$()NQ!\V?AK./:4(A:[>Q*B<7 ^&>-PB-+
M.)B/7:'%.S#D>4$9P0>;4T;@7PI$@)!>#+CC:[E3.([./L@;6/-E?**]A$K(
M*89VL8HA\,8&QC] "/'M-L'M!4[@5]XC#<@#Q/<8TDY/J7#$GDAA@8P,1XPZ
M^S=P8R-JRG8N<^[I>'; R1A#3[L#(7PSR",@@[Y7,]SB(:AY2)RR4)):D.+?
M$J93-$5?3;8'1+,$*8\*#Q?,T3)3Z:1HDRYV1(XR4*=471@ZWYG8E:K]%TPU
M53"^L0[1N("7N  B#L?^S'9N#EBQ8[R"H;*A0%+IR3J6*.I:Q"0QB0BL$4-O
MDRRY2$-[XC2>51R(SSDEAO)+%)+=_%D; (LK@!^PG <=Z#@ %.G8W2!JR.Y0
MWV((=A "F'<P;\4"0^SS&=_)!4DR7KD;CC !('&!Y0,XS\RQ&;VD9R6G# [O
MXM8_7M_U!],9^8/&>=4WU9Z-/$%:Y%:"MJFPG;LI+XQ^T@4A8C+2G25H4EL-
M GGR&<X[?4Y61(]4K<'T$FU'R3$&IS1GLIW#WS[6VW+HVT,WX.JA"961I ?P
MA(&,6XQG]TD[2I9L[0 PPK%A@"KN=JZWO C>OI7JC3!Q"[K:X2AF*>(I6!J<
M2@^'&0)$D ((!4,V2^<TJDY#QKX>#".-\LPSF R+0*MI+I-PA'CQB_=1$U5R
M0T&JP4=QCEXQ<F; R3:F4;NG"0   "IU Z@6>GY(9^L*N>!@T,_ODD;!74?C
M-KL=KDD>9R3SM[XP -,W4D,]-T)24]1&R3TRT$3J7CD*B-F1=S1,ZDA5  W%
MB?I<YS9CPRYP-RT$@*8IA)J!RN50=PV*(M:B<H; (F YDE$SE >PE,4P?>[Q
M.NU*WYB?Y5) P^HF0?I!^KMZ:L/9^1^ I #VN%0#\B8J=L?<PTP6H8=C&[A\
M(  &#N4XC\!3 &X])C  F'??N4 V 1$4P\ G[<?S>1^<G3PO+ ?4,_)C@_HT
M@AE@Y3^)XBQ(<IRAK+PB3J*.X 9.IT0ARB("(=9#E,4X=A(<#$$ ,40XU^ _
M]!)/+M_>J7CGUE<GOSR2?]-8C.2>OTR=W[\0 'CL)Z0 <<< ?6>YYTZ-KD_@
M2:Q@^7YK&H/M\OWI;=_R_9W^H\9C9?RK:S_WE1#_ /W@_P SK6[W^1[L/^ZJ
MX_\ AI_\M*N>$O*'VSUOE[@!:O@/I !$-@)+9;Z0[" [=QW#T,/<P"/#Y[03
MBGMG]-5#[XH_\ASWXUG7LT\TEW))_@J!N#@;B]9DD# YV@=NPQVXTZ<DF4R?
M<!VW] ,8 [>G8! -OJ&VPCN([B(\9F.&;'&&P/EP-:OC(&>>!ZGX:2K\684"
MY#T3 '8 IF;_ )B/I,8X /41^0!QIWL]_@;K_24OS_ZNJ^.LE]IO\+:_Z*I_
MM(==SYUSB=1Y$6@-.*%R$:Y<Z/4;*"'F>6:))ICO#EJ5V)#  -O?K>'.43@)
M0?IQXA^D G$7I4(>K;ON(#!ZXQD^A_"<?B'X$F$2*.. Q(PP5A,ZL\3]IM@"
M<*[VE93Q@1K;I2<@@XRYC((((95YT0OPY?V6_<LL2F@S-"S)\A9F/=A:@D*Q
M[3^4.:*W4> 38?;/L:-1.(G*"GL'LH=/0('-3=:^*;_4-+D P4HCSZH(1D@@
M#O*93_@/2^Z$:$]-T@C"AA/6F51](/[U*%#? B#P1@=EVCM@:.JB0IR"!BB&
MQPW*!AZ2B  8 *8H$ Y2"(=)NGY!ON8N_"J?3G/ _P!"?C]_PTX<'/<8../+
MZ>F,<$??WUY!13'?X1[AL(=1P 0^@@!MA#Y=P'L(AZ"(#S]<^H^0/<#Y Z[Z
M@_#[!]9'8GYD$ZH1S$.7[ASF)X./AG*+J1K,I#RA;7C;(D$BBXG:#<4FSE@2
M419N%$4)J%D&SHT?8:ZY7;I2C51!9H]B)MA#S4=;6:\5-EJC4TX64.%66&1B
MJN%)(;>,.&!/!#$@=@,DFEOMDI;[2+3U)>,Q,S0S1J"8RZ&-U*GRE'0L"".>
MX.5&%"9[D]\Z#EVV>9N6CR^6"]5M%R=\ZFM.F1EH20FF#+;V8]UPM:7T8O:W
MZQ4DC?9F-C,F-"+"4B:S[J./&C)U'TQ>D6*Y)%!,^-T=5$=@;Z.Y*I?,@Y.
M9 <\X!).LODZ6ZLL+&>U3R21*7*M0RAGV,Q?:]/,<L<^B)*,;0$& =6/T?\
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M&:IJH)R<>J]AG1C1TB])QG-LN,]JK8JV!O-'E9(O2>%B/$B;AB 1SVX/(!(
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MUJQ\$8(_>RF&.YSP.^?EZ9/<3F$#" &$/A 1[%$?4P !0$/4?Y0F$0 I0Z0
M1,8M=IFT);G,YNAL8:+K=357R);9FN3A:%6F *)F<JL6TLQL%NDA;?HE#1S6
M!C%8I9T BBWDYZ&(J(^>F4[?T31355]@F10L=&C3,Y!VO(ZO'#"2<@&0EB",
M'"G&#R,-_9!=1TUE]GM=;VD4UW44\%NI(]PWK!#-%5W&<H!N:*.FB%.Q RLM
M7 5\V->?DM8FD\9:&ZO*3395F^RS=;3E9)JN!B+)14HA#5:OK^A"F:RL%4(Z
M<CC%*4%(Z4:*G("RBH<?GK6KBJK[,L+;TI(8Z0/D$-L:24@$=Q&9C$.YPG))
MR=?O]CY8Y[-[.:6:H5T>^W.X7Q(Y$9'6GG\"BIG*, 0*FGH(JM,#!2H5E)!&
MBS  !Z?41_:(B(_\1_9Z!VX4M;?K/!HUR?.O[S.6_P"B^_\ ]U9;CVIOXS!_
M21_VL>HU;_$JK^@F_L)=)%>%6_AI:@/ZK4G_ (KXPXU3V@_DVC_XY/[O4ZR#
MV=?EVL_JNH_OE#I\A'[@?K'C)!W;Z_\  :VC05?$-_Q3&I/_ -7PA_COC;AF
MZ0_V@HOYE;_<:G2AUW_LQ</Y]%_?:?58?"T?Q=^3/ZW.1?\ "7!7%AUY^68?
MZNI_[:IU!]G?Y%J_ZUF_N=!ID=7T-_Y0_P#S#A*'TA_-?] T^^J_SE_\PT@5
MKS_[S;4/ZX/+Y_NCICXU^T_[ S?U=>/[6X:Q6]__ ! @_KKI_P#L*/337.0T
M*26OK1?:L;4M%LKE^@RS3*N'TW2R+1"5MU>9RT<]J*[Y<4D6Q+G5YB>@6"KQ
MRC%-;"X@Y.4,5M'@<J#TW>%LUT6>0;J>:)8*D8SB,D$.H. 65L;CDD+VQGG1
M>J+.UYM3PPA6JJ:0U5,CG"/(H92CG!/F4G:.V\ G@9"Y/)HYSU<T,U>2T0:X
M(FY46D4:W61*C79S6II],XDD7\TX<VO'&1J8V8*6MM$-K2O*R3!_&Q<G,PLM
M*R$;(Q2\*9N]@G'J;IIKLPO-HDBE]XC1Y$) CE"C:OA,ISXP50K*?*<*<@AM
MR)TMU8EFB:U7J&:GACFDV3 ;FHY'8,]-)#M\0PJVZ995#$"4IM 4!&([[SQ^
M5]0ZFYM2NJVIVSRVAG#.NT&!MUMMTHMY/F(L4(5C  $8[7$Q !:Q+PL<U..\
M@[9H[J@G1=*]02N$_!S1*_T99741Q^I,@!WX&.X&#]8T]3=8=.Q1&47 2E5W
M"***0R2@]A'N4*&)XVN0W'.,C5(N71SO<O<P/7#=\1U/2_*(Z:#5\[^O71@L
M0UJQ2A$(R"K.UYBF59$U3=-LB/"IQD;6JPJI(P3U-NSB%KHW:3TT:SO72]-9
MK;!-+<4:X%\20JN$D5E/$.2S;<@X<@JQ#9P -M18>KZF^7:2""VO[AM)$K'\
M;2;"6$M22 A$N[9X2,'0KG#%ANX/XK42FTYZ41*.Y39IN0 8"@0#D-1#&W "
MB.Y3C\0B(_$(B(!TB4.)OL^&:ZX[AVI8EY[[6=@<^F3M'( [9&"23 ]I3?O?
M;=OT3532# X+!$ 9<^8#S'N23ZYP,&*Y+H '*YT9[  ?Z*C>@;!_K38OD'"Y
MU.2;]<B?_K*/3LL,8';Y ?,]SSIJZ3 '3MK [> _YYY2?SDZ[1S%<+VS4/HC
MU0X7HB8.;K?L,V^+J,?U))^][&T9'E8:#$ZZS= I;!(L6L&*BZGD(#( JL0Z
M0*;0K1514=THJF4^6&4%U]&5O+SGMM/.1]OP,V^T<M?9[A20\RSP,(QDCS("
MW=>3N'&#QQW'.DW.03S(,'Z"KKGC!6JQ20QC!94FJPZ9WY]!S+HM+NE'">@I
M.IY"C63%Q8XMG($DRD;2"D49O7Y:.E&T\5HWDS/66E]962KN\='66\QSBG79
MX0<EG60B3*AFVDYPI;AVY#,0JA<JZ+O]!9)*R@N3- D^U3.XVF.IA+%X655W
M[ KALY."<8(SIIW*?.EY9N*JD\M+_5=CFZG1:JNF-8Q6[<Y&N,RX!+=*+:0]
M;3>A'/G*ADVR:EA=0<8T6.1-_)LB=:Q$&'I?J":1D6VRIV!:5U4*K';XHW$!
ME&22B G@G)R-:1/U9T_#&DQN44H8&1!2JTAD" _BSM&$D;;RSE1M(/IG2&>O
M76;9]>VN%#49,5:1I=4GI*EUW$M8DA,LO&8OJTZ\BX8QWY4R-9%Y(S9+'*S:
MT<HYC6=C?3,.R<J(1A0+K-JM<=HM#T22K/*@E>KD0C:U2]/)OPH^@ @C 4X.
M!N(RQUB]^NLMYN35TD30([1)3QN2S+3J9MF6/TR6+EF&5+[@A*@:;@\49_%V
M4(=MQ_.JQOL & -S#C?-'2 B(;)CU; !NXF 3% HF H\9]T%C\-3@Y*FVS@C
MT.:FC R>X[\?/YXQIGM%P;'2KWWW:G3'J<TM:1CUSD9XQC'PR- "Y/G-)N_+
M$"/KV>Z!=IO1_J-<2-TK4Y$L.M_ 6BL2CC'UBOV/T7:S6+LL>HZK:5<R!6%'
M["621AX6PQ2Z;E!2'MC?U'84OX+TDL,%UI$2*;Q"2L\4:92(QH2(R5<;)M@#
M'RDDJ3I+Z7ZEFL(C%9!+-:ZXR3#8 K13^*8'DB=EQ,RB!4D@$I50J;55F\S7
M<CSY^5A'TU2X$U4Q3XHM%'*%=C<=Y47N+MR5,# P3K:]'0?HN3+;-?.>IM(T
MIC$55D4&F[SC.QTEU%XOA"W;6<Y0O(OAJ#Y=\I5B5 96..& P2#G)TI^LNG%
M3<;@25&7C2"4S$[0VQ0R!-V#@Y. <G.!PI?K7U1YUY]NN#%N']/=#G8C'=9-
M(5G%57G$R*J5Z F7[%:_9MRTXBC2$9"(*,6,6I))-9!XQAHJ'B(*O.9^PR*S
MB8T:V6ZEZ1M=3/75"BHE0O4,I'F)4HM/ ">47S$/@.TDC98JL:IF5XN-9UE=
MZ:DH891"BM%3Q'82(Y68354[J 4=X]@,1<K&D0PJ2,QD>;KFC[%L'HO8:(%D
MG$EB=# BV!)!<"MVLI*0KZI*U:9GQ.0JC=K8Y1PN\L)W:9!\B;7,Z3 YBFZ<
MG>YU!NS7<$K*:OWH 8)*MM.PDJ%P0-IPH&W/EPQ!V*.U4ZVA;.S&2'W'W)G)
M*[CL*&3"\J2<G@@AAG.1I(?2/J"SAX?C7=D_#>H*D3EEQ!<P80EY;0#<6QKG
M38F4D/R=YXQ0I).D8^3%L@^E6ZL$M)HINBR<_49Q]&6*!;*0VJ7"AAZQM%//
M0F-:F,[XRTA/A/@&2.<;N(FXV\9\0$=@1K(K775G1EZJJ:KADJ(:AS[R$Q'X
MJAV,<T!;;$'4>;8-H\/N%W!RVC \[WE;S=3);TM7-'C&1VGMBT1.P=ZBK8U,
M5(IUFQJDZJI)Y=PD;]&4D<Q?H.3B!VCERFJBHKG4G3%]CD,7N,K%25\1=OA-
M@\-NR, YXW$';@D=LZ5'UATW(AE-R1 ?IQNL@EC? S&1L.648!VAAOW $XX%
M-E'Q(SJ]:K<,89T(:?+!J"HDM=&T';UY>+DX2_9:)) JT1C,00 N$EZBA$(G
M6GW%BO\ &%</5V(LI6!JM?82,^Z8H>B5@H*FJO-:E&XC9J?PBK0QD*"IJ&?S
M,"<C9$RMD=^V%R?KTSW&EIK-12UT3L%F4JWO4F6((IXX\JJA2C>)*"""00@
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M\:@QRH P7=@$G &2W SC!!.L:Z)O-+9*NK2O>1(IT$;OX4CE)*=Y"JLD4+.
MBO(V1WW@-NPK:<GTT\T?1QK#S/-X*TT9,D<G6FM8WF<G3\RPI=K@*C%PT39*
MI63L F+C"P#J3EG#ZWQRK8D)&2D:#-O(BZDV[UNDU<9I76&Z6R!:JOI? CDG
M6%0TB.S$QN^<Q,R@$(0!G(VD]B-:G;NHK3=:IJ*WU+32I225+-[O/"BJDD<>
MW%3'&Y9=P8E5*E7'F)& MOXLD3&R'HH$W^QV<-@V ! /?&-^P["(#WW'?Z"'
MKZBZ>SPY@NG.3OI,\8Y\*I/_ +Z0O:;_  MKXQ^*J<?/$D(S]ISH]EFTC06N
M3D]XBTW3#UM$R%WT@:?75+L3E,YTZMD&MXZI=AI4ZN**2KHL8E/QK)K/)M !
MV]K[F58-3IK.0,*DER>U=2558@+A+C7I+& /-#)43+(<\$%1AAR,E0 1D@N;
M6M+QTK1T+MM,EKM[1/DC9.E-&T3<<X)\I&""#@JPXTJ5RR>8AE3DO9\RSI4U
M=8WM[7%DM<"*7ZJ,FR2UMQC>VK5&+3R536RKIO$6^KVN"0BRRXLGR25CKS*M
M6BM2KE9FK#V+0K]9:?J:D@N5LGA>I,*+$SE@*B)"S"-@"$C97=QDH&[;F((U
MG%@OE1TE63V^YQ.8/&8SQQ[3,DY5$$\:%3O1HT10H;8=IVJ"=Q:K7Y['*R:4
MT;B&J^O+M?8S.20:-'R<I<EW()B<6 U4:2E+MGHJ%]G,9XT:QZ:YB@J^11 R
MI<]/2?4"R%&MSH"X3>98RBL<98<EB@SN)Y)Y &1C6C_MSZ;\!9VN6%*A@KT\
MZR.<9$:KL&7/ R,CD')')&!@GQ F;]7',9QQA?3+IKF+?IEG 7KL_#R#9FWR
MT6*6?L1ELZS$RF_-5J5"TAL!3%J#Y^^CI2/=.FKZRDLT[6FD$PU71U+;K--4
MW"O6&M1?$5L$09V@>[E6&YGWAL,JY8,N!_)TMT?7%;<K[!2T%LDEH)2%*95J
MCPMYWUSL,) B*5_$R-EMK $L05N+S6N=!+\M[.>!<;L,#R>2JS;XJ1M^3;'+
MEF*K'KUI5=2(C(+$EJ49.(*;NL0](:<M)';.2BV+!:"KZBC!_:1DH&KZ>Z86
M^4554>_1Q3)B.")"LC;Q@^))&"6$;AU52, E6[XU<]2=5R6*MI:=*)YH9%\:
M>:0-&CQ,S+X5,_8SQB,R.KAL!D/8^7KV'.?)RQ<NUQK,KZ@VV*)I5JDXDJ7F
M"L6"HV"&,< 4]E6D6[*9IDNLD)NE8]7MDXW !,H*Y"@;ICU72-_IW,?N)J%!
M WQ3QE"<=U5SO ^.0 .?D#)I.L^GJB-9&KEHW*Y,51$Z3+@GR/L&S<,$@ DD
M%21DG"OW/DUAZ=^8?J0TXT?1K$.,LVVGL;#0I7(5>JL@P=Y0G[_8JR2EX]JR
M$I'1L_8VM6D6$X:+>KQX1SN2OCXE?4<MEI!^X?>DK=662CK);HW@++)$XIY9
M(Y%@2-27F5CN16DX0@<@1#C6<]9W>W7RLHX+4!42K%)&\L$#":H,DF(XD+*)
M,0E7=F&T+XN5(<9#U&G3'TQB73S@W%5A>DDI[&>'\;8^FI!-519-_+4NCPE;
MD7J:RHBHJ1T\C%ERJF'=4%/-V+U]!<DK95GJZV="2DT]3)&3W*--E21G )7!
MP,??DG9*&!Z:@M]-)CQ(*2FBD .Y0Z0*& 8DE@#GDDG.1G &EZ>0/^^YJF_W
M5I_]Z+)QIWM$_@+?_P 6?[)-?'G[%_\ +O5_]64/]Y;309DB*?> ?Y0=CG+N
M'4([#TF#?O\ 7C*OB/CP?U]/LU]G_#D\'(P2.?G@\_;G'IK -T0$Q@)\1M^H
MW4;<=PV$=]]P,(  =0?%L4@;[$+MS'<9., 8W' QG&!G"XR3Y0.3GOKF!R<#
M)SG  SG /;U( !/?  [  :B4I#[%#8! 1V[[;B"F^V_IOZB ;!N(CZB(\<;U
M_FM_AH]3]0_2VE#>7IGG$NGCF(:I;KF6[QE!J\I$YKJ[*8E4GRR"\\]SC399
MI'$3CF3]QYBT?"2CD3&0 @$9CLH41$#;)U-05=QZ?MT-%!)/,D]!(RH!C8:.
MIBQDX499U!RP(\I!QNU\)^RGJ:Q]*^U#JFOZAKQ;:&>@OM''4NDLD354G4-M
MG2-EAIII PBIIF5MP0KX@9=PC),GEW5WRG]0+&$C\TY-Q)D=E7'3Q[!-K+$W
M)9&,=2"2*3Q9LFG"-@*HLD@BF8QP..R1>G8P;\)%#9^KJ'<]%1U,!G1%D(:#
M+A&# 8D)X$@)R%7/8C&1K?>H.NO8=U2M+'U!>+3=4H99Y*1:FFN^V%Y]JR,!
M'3(&++'&#OW*-JLO.3KJL'S(^7K58*)KM?U#4&)@:_%L(:&BVS*U V8QD8U2
M8L&+8IH%98$VK1NBBF B8PD3 -S'$1XCR=,]33RR226VH>65WD=VDBRSNQ9C
MR^.6).  HSVQC5U2>USV4T5-!1TG55LIZ2CIXJ>G@2"N5(:>GC6**-$-)XA2
M.-%4$9X7N6!UP3-/.ST<X\B'PX\E['FZU%343CH6L5V;K4-[=T&! DS:+I%P
M:+2/.8P^8]@XRQK)@)0(S7ZQ%&PHNAKY4NHJ(A0P@Y=YFC:5@!DB&.-G$C$8
M\K/'GG# C#+5_P#V170%L@<V:>JZEKRC>!2T%+4TM+XB[B!5UM?# T,;'CQ*
M6FK6&?X-N=HOL/X"U-<W;/<;J!U$L7]+TXP;CRHU)L@_BH5Y6FKOSST3%:#U
M3VZ37FE"JHVJ_ +M!$Q'!_;%'C"%K31FK+C;.CJ!J&W%9;I/YR2Y=D<+X8J)
MU8LL4@"$FF'DP%=$42L5QVP=,=8^W?J>/J3JI)K7TK1-LB"P-3PR4BS^*MKL
MHD'[K>64GWJ[R/+X(0K(2Z0TRM:U^)B8"&CH&!8LXN$A&3.(B(J/1*WCXN+C
M6B#..CF+=, 3;LF3)%!NU03*1-) B9"$*4H &4.[R.[R',C.SR'U+NQD9B/3
M)8G& !G@8QK[7IX(*6"&FIHTBIX(HX(88QMCABA18HXD7LJ1HBJH'  &,#@>
MYX_.O;4X-&OGK/ L+3!3E9EB*J1-AA9*#DR(JBBJ>/EV;F/?$263_2(*G;N#
M@FN'5T&#<H 8-^/TCM&Z.HRRD,.?4$,!\^0#]GSP?Q*BRQ/$_"NK*V,YVLI5
MO4 >4D>AYSZ# [=%W*DT?Z"<@V;)NG>N7"%M%NIZ]$G'-DO$W9VAZXM-1%A6
M01:2:@H-5?>,&P,#H@&7!-+HZP356 ]Q<^H+E=HDIZ^42+&XE0"&&/#*KINW
M1(I.0[#!.WUQG&J.U=-6NSU$E70Q,DDD30N[33/^+=XY#&%DD9<;HXVW;=XQ
MC=C<"2Y(-BB&Q@^+[I@]/A+N #L &#JW$#!V'?8/38*7X_/_ " _PU?ZKSJH
MTS8KU@X5MFGS-<=,RN-KJK77,\Q@IAW R2RM7LL7:XHS>58"#MMY,O",%5 (
M8J:R9105 Z:JB9I=#6U%OJ4JZ4JDT8<([!6QXD;1N-CY0YC=ERP.-V1A@"(-
MRM])=*22BK%D>"4H71&9-WANLB'>F'!5U5O*PSC!R"0?D]&.BS!6A+%4OA[3
MW$3T-29N]2V0G[6Q6.0L[X]FF(2MUY^LG(20BX3;#'56(23:EV2(JDLL4 ,X
M/QZ7&YU=VG6IK&#RI$L((1$&Q&=EX0!2<R-SC/IZ:\K5::.S4\E-1*Z123M4
M,'=G/B/''&2"Q) V1(,9QD$^NK8*=0F$H=_@ 0 .D-QW,/2(F,&XF !$H !0
M 4QZS@4P!Q '?/RQ]_?[_P VK/ZN#W!^8Y''R/WZ&'DGE)Z-\L:O&&M^Y5FZ
MN=0$;>\8Y%;3#*]S3"O?:?$#"H1U+<FK**@,#,V;>D5]-ZR%,2OU$%E'!5/:
ME?,O(>H;G3VXVJ&4>XM'-$T?@PDB.H,C3)XC)XGF,LAW;MR[_*P 4*O3]-6J
MJN:W:>-O?TFIZA7\:8*9J0(L$GAJXCRBHB[-H1MH+HQ+%B=D(10 ,<.HQ!,
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MK<+)O&CQTP>O5X]4K5.LN/4=UN:-%42I% P&Z"GB\%&P6(+$EI6!W8*F3PR
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MA3#N(;CMMON(#MOOMV'TW'?_ .N <'([_KZ=M!Y&#V_T_P AK7R4_P":(!L
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/DG].MN#1J<&C4X-&O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g280081g43g40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g280081g43g40.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MKB<OE# 4^(<QJX/,\.H4ZL9.CBL#AY0A.I&4Z<91Q$ZL.24:D5."E.?*W+]
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1 "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g280081g43s48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g280081g43s48.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MRT\42O+)LCBC)9G9FHV^0[2LM;6/L;6=-_8AT;]G3PA^T*_[+/B">R\6^/\
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M>*J!+XWZ'1_\$HO^3H+S_LF'BO\ ].?AN@)['ZF_$>^CT#_@H1\!=0\3[(-
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'!M^ENQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g280081g51s75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g280081g51s75.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1164&AO=&]S:&]P(#,N,  X0DE-! 0
M    %#J^47@X0DE-! 0      %,< @   @  ' )0  AR<C,Y,#DX.1P"!0 Z
M36EC<F]S;V9T(%=O<F0@+2!46$U$("T@4$]305-27U,M,T%34B S+C0N,C%?
M+3$X.3,X-34Q,"UV-0 X0DE-!"4      !":B4#288P>E1HA THVNR*$.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      -!    !@
M    (P   0T    & &< -0 Q ', -P U     0
M   !              $-    (P                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    (P    !29VAT;&]N9P   0T    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   ",     4F=H=&QO;F<   $-     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      FY     0   *     5
M   !X   )V    F= !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  5 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M     P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0
M  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!
M8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  C 0T# 1$  A$! Q$!_\0
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M91$CRZC[%,I'IC"KE51-JA1@A1U9G1/R8! P=W(%.'>)Q  $I1X H@!?S#N
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MDD_Q4IY^XN3X/\Q\'SUS:'CZC7,<?PT8XXX.FULC^1^1U:F5  $>  .!( <
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M6RQ8M)>:!)8L7!75M>J_8WBC>N3YVK!^]E6BNIW?3O2I1U;2*Z49\QJ\ 0&
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M<,[I%CD[:1*QI=]+F8JJLBK6A-KU_1-2_"6-.JM3M.A%Z(9]%2L@2$IC 9G
M+.0H)7"D<8Z?=OZ=KNDO:JZE;6[IT8!I2.6:T79 TB$.TCK"@&Q$9VVON*#D
MY OISBQ?KH9EV2ONWV[N7L96ZI7]['8JU1QS=(6J2E-IZ)%G24G$5FT-9B.<
M0%;[FM8EUH.N*3SR5BGTQ<)\LA,L3O:S4;<?:U738M-TVK9@E@#6+LT9DDED
M.&)=PGM#,Q$9+']VHQP !%:73'>5V_8U+4K56>M,R0Z;!-[EC).'].<E(3#@
MQL(54DKO=B6ST?WIY]/O9G1_*>1&5KWFR3L9K,_IS!GC/%N1FSM]/U>SJS K
MO)%W)SCRPGB6$%$-19Q[2F3$%%V9Y89)[.5*-6A8QQ(2.LZS3U6"(Q:/#2N;
MSZUB%@!( 2% "JI_)LR7W<AB%!P1;Z'H=[2+4XFUJ>]2]#;!6GWDHV<EB&=H
MUP<J#'MS^9B,X&CI+%=,S=U?MML49$BDYJG7?2V.A)IF)>'*22[G!RB#YDN<
MA_A)>/?H,Y:'?HD*I'246B]3$RB)!0?"U+2[0T2Y Y2S6UIGA9#L1_=J)=)0
M,;MVU2 2?: 1RHQPM]%TWN/Z\=_:'JL0FHZE]/HJUF.10SC<.UW22LT@<1S5
MW,5F"8(7AG3>C*S'/>TRV.=Z,V/+NC&V]Q3AXO"D%/9(P7DN9.9-C<<0-DI"
M<6AXP%0^\>O6;)!S*0$(Q4DG)%TK136QTC52,:N?G6]+&OP4-=T9$,EZ2"EJ
M%=%"BO>*(K3.%7&UL%Y'^2WJ$$$L?3Z>=W2?3:YW#]->^KWI1=MT[.K]M:K,
M"1J&A();/X>#<VZ:78':G "TAECN4$(-2*+K"\&T"V[>*;+=2;.$0[91SO%>
M5Z;J;0I?A3^#J-&52T1QK7\.H*J OEA/*,&;D2_#/; _N4Z@0C1:NJ)^NH6H
M]%;3NV=-9&=+=&QJEE=P9[/KH=F1AB"=@*ECA$1<L!PM[<TN[W\.]/J]W%&R
M59-!UZAV1ITR^HM32X]/NH-02-R\8D](O'$80B2W)-2NJB,T#'*M*RE#H>98
M, %Y'#.X(]P<>0,QR,(CR !_-X$0_L \\>OG61&>_*&P'8^HZ'E6YX,U;<IS
MY0<JJG@( N,#IE].R5_V=-?()!7MWO[:<G(Q6U7!!))X^"#SY&!CJ9W2,*7_
M "[]=/E+_P"#R2/L'N.8\A\C[>X_7TC[O '<6H@   U< < ?P5;XZO/H/Q]*
M.T\<936<_KGN'5B?[GD_?J76?<0UG/.(LC8AM;-!Y"WJL2$&H"R"2_X=(+H=
M\/-- .001DX23(SEHQP(@=K(,62Z1B*=H^DFGW6T^[!;C9U:&1-QC9D?9N4O
M'E"IPZOAEW ,#@\'KH/<V@4^Z= U;0+RQM7U6I+58RQI(L4DB,(K05U<>M5E
M].Q"^TLDL2.I#(I X.A[DV?O^E:<!/.57A<2Y*M6.85==4ZZH0@,H2Y,VHK*
M"8YD(TUO6C&28F[&K%FV:(E(W02(6I[[K+!KK.%5&M5TGD15"A'26:L!A0%R
M8ZZ.2  2Q)YSUQ__ &<-7L:I].E@G=Y8]'UF_IM621F9WKR15-6!9F9GPLFI
MR11HQ/IQQI&N%50#$>HSKOG54^K_ .U39._\@X__ .-V.O5_+_W K_\ F9?_
M ,R?KFL/_P!1KG_EXO\ ];6ZM3J^YO[D_P"!_4!UT@_XO_M'_P#7567[.X4I
MME>LAW%*;C9&F<=P /'_ &]VF]N0'Z!^P>K[O( T^W01D&M.I!Y!4PZ=E2/D
M')X/')^_7.>Q_P#YEW:?E;\!4_*D3:D00?@@\@CYZFC]HQ /\JK,@\!S_'&&
MAYX#GD,FUX0'GWY ?(?0?(>EG9)/[?J<GF&SGGS_  [G_, _S /QTU[^_P"[
M5H?!GJ9'W_B$/^9)_J>@\]7[%=JLG1AZ2>9(AK,.ZQAK$NN32]J0PG*ZAXG(
M>OU#8Q=D47 #)L4FLY7F5=:R"O'W$S9XIH4IPD3&3H>VYHT[IUZ%W19);=XP
M(V#ZACM397GCDO\ D)]P!." >IKNJM++VKVQ<C#L:4.GM)\HPFHQ;=^1@J9(
M420DX(D7/VZF=ACHFXEV!Q=2LR8FZHV\ENQ]D*"86*N3;#*4<LDL@]3 %6+M
M- O#"8C'15(F<AW )R$/+,W<8Z3;OFKDH+K/<\U.>2K9[?TJ*:.23?ZE=0&#
M.S(R 1 9*D'< "Q+,?<2.FM/M."_6CN5>X]8EKV$,L>RP'*[R699"[LQ*/N!
MR<J1M\  ;+THZ7&HN ^H(C?ZKOCD_8+:;7RJR3ZWXKO]SI=ILL?7K_3K-06B
MED,A'A8DVT8A8%'H1R+\XUYT_K:\L5HTG(,TAX:KKUZ[I JOI4-*A<FB>.6*
M/: \+/EE?8IRYR 1@E>!N7/7MI7;NETM:6>/6YK^J48Y'EKS6*S2&*6O)$$D
MB ,P0&:-P&<J72-\!B@70_2RAHUUUY.K).N&J:DK$AD&-CGIDBJ&:M)W+U06
MDDD3F 3I_%*0L6(G()0423-W !0 "[NONS=H]N9RH98<KD@$+44(=H(!)4A]
MQ&<DY\Y.CVXG_P 9]SL>6WV0KD98*UL$J&.2%4;4"@X"JH&!C$Y?M!6SV7]7
M.G^]FL*3LU4+3E7+-/P[*7>MN5V4_3JM8:Y=;3-OX.5;#\1"2,F6G-ZP$PU*
M608-; \7C%V<L$>[03]FTJM[6H1:PZ0PO,L) 999%**-RD$$@.\F2"0T889*
MC#SO6_=TW2 U%I(Y)[E>"2Q&SI)! ?59FC=6!4EHXXP P!WE2>3U'O5W[/9T
MX;-@+&=VR46^9]NN1*-6+U,93'*MJA(V8D[A",9YW(5>/IDE#L@@559 '$2>
M;/-RJK$$UY20>N3+*GWKW>6LQ6IH:\<-.*.:5(H&@ 9 KD98D '>07   4-@
M>,]+=,['T&6C7L2O-<FEKQSS6H[+K%(\J^HS!8WXP6VMO+EG5F)]P 'GTT\1
M:Z8#^T&95PUJU89.RX=QYB"_0,9(REC:6I5"R-ZE15;[#-IMFS8_&M:Y<5YR
MO"HHB*S9S%JM#+O%$3NUW.O6KUSLZO8U!0EN:PC2JJ>D 5GL1Q'T^"I:%8R<
M@$DD\9(Z3]O5:5/O>U7T]A)3AI,8'#I+[C!7:0^HGM)65Y5R/<N"K'.>LZZ.
M^S>+<0]7WJ@85R%,Q-:G-B=B,I(8WF9ITU9,Y>XXZSQEQR>BLW[@R1/QJUQU
MQ=2$*S442"2<U<T<55:4=PS)SK]QZ=/9[;T.[7B:84]/J":*,9D8258R7  W
M,!D%R<C_ !/P#UZ]KZG7I]SZ[2L21P_M"]:,4[G;&+$-J9_29F8X,BN&4^W)
MSA2QW&UEGG..--:\0WS-N6[-&U>B8^K\C8)J3>.$$S.1:H@9C#1#994AI:P3
MK]1M$P$,T!5Y*2[UK'MB+.UTP4@:52>]8CK5H)7=W0L-IS&H49+'Q[5P.2%!
MP =_'71[]ZMI]2:[9GBCCBCD.2X_>,Y=MJKSRS'&WEFSG!&<4_>F/K)E7,_1
MIZIEEKM=?M7FRDM99/%=99-EQ4LRF(XO^)Y%I6D 2$KYO.3;M[C^.*F7_KTO
M!248HFW*D10>C:YJ%>KW%VZFY72C&!9)P5C>TJPA.3@%(PLB_ )!]N>N7=OZ
M=+?[6[DE19]VHR-)4P&3U%H2-.-J8& \QDA; PX0>?'7G=(SIMXFWKU3A;77
MNH!MIC3(-%EIRKY.PGC[(;*)A: ]">E7E:=14"NF$@WKUNK2[:6:OSM?AEK
MK88Y)R=[#2"!?KN+7)=,O30_LC3KE:00B"W9B]4S(L$:YG8HP=E(*H221&J
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M+C)!-5=*G?VCRSR+'7-*,;F #JLD5ZO$HL* ,--)F1=RX5L-D'VV/=GLST#
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M#O&QB-S152#N'#%\L3\C!XP.O'L50FH=RQD !K,&P9C&T"QJ9;'AO(!YY)P
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MER/&"%&<+QQKZ5:;9U?Z"7='I[?Q6JZ1WGIM4;HX@+-X7ZT!9VP /4E&6?@
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E]'1TN ^@?L'HZ.EVE]^ Y'W'@//HZ.G   .   #Z!X#T='7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g280081g52s52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g280081g52s52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<64&AO=&]S:&]P(#,N,  X0DE-! 0
M    %OJ^6((X0DE-! 0      %,< @   @  ' )0  AR<C,Y,#DX.1P"!0 Z
M36EC<F]S;V9T(%=O<F0@+2!46$U$("T@4$]305-27U,M,T%34B S+C0N,C%?
M+3$X.3,X-34Q,"UV-0 X0DE-!"4      !":B4#288P>E1HA THVNR*$.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      -!    !@
M    +@   -\    & &< -0 R ', -0 R     0
M   !              #?    +@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    +@    !29VAT;&]N9P   -\    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   "X     4F=H=&QO;F<   #?     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      QY     0   *     A
M   !X   />    Q= !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  A * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M     P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0
M  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!
M8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&
M)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(!
M @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R
M@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#T;J_5L'I.#9G9S_3HJ@0!+G./T*:F?GVO_-7E?6?K_P!?ZC:XT7'IN*#[
M*J##X_-];)^FY_\ Q>RM7?\ &=U1V3UNOIC7'T<!@<YO8W7#?N_L4>GM_P",
M5G_%ET'&R[<CK.4P6#%>*<1KH+18&^I==M_?K8^OT5-&(C'CD+892E*?!$UW
M+RN/]9/K!0_?1U3*#@=Q#K7/$^+J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( "X WP,!$0 "$0$#$0'_Q  >   # 0 # 0 #
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MP=<E;WSDSZLT=*D?L@F"?'3.,:X V0[8T#ZXLV(.:SIN@3D2L]GQ 9 DD_\
MKF8.FL]#8DP0:(QN%1IM3-4?BS(T1]B;$1%"=(W-#0VDI4"0DK'(X2 2)TXA
M\  .V1VYTJ+*UFHLR9G.G7]^GW ;=.H0E"!3 Q]VF/N^.,?'R+41IHL=JJ@Y
M5NK_ $&;;D0I,_HY"2R/AB\M.6\-A2U$F5 8@< /)J)YZI-D! 1ZO(^8;9VC
MURQJARTK%O6SD1,>$9$9ZZ1(SMKO&32X4N7?4.8HS(3D &=>D9STUC6-@NJW
M*.[ P%0:2(0--&.(.IEV1#E\SN/RI$?N,!^G8<"!/YSW_P#ZT<?"/X'P_'S&
MPGYKV#0VQOGIV,G,@QIYS UP8S*]-_EJ@C&C70S#=&=E!1PYYN^Q-ML&:.-!
M]=!L4L!"V8AK=D*2DT#5J=N6H4;- O=T2M8-50B&!-;FV]=TO!N#DD\K+J1^
MMR"#(\">9G!G,> #?JXT[18$VIJ0VYKA:D9/^BAAT "1Q=T<N?$$R3@;1'6(
MLY+]0UY;962@"7JI?="8,<.:1Y9IB=$#@N*%>\N !V)9V1J*4O;HI ,)&=$L
M'.=JR^>4[>T<OJV VRK$DQ C.<:@QH1/E&[8Q<7)[1:4HYFL]X #$24DPHI]
MKE9/]HIXID27)>('T^1#3GJ8T_P"WZ4E#$8[I8MK!F1 G1T$&<J .DE9@7KE
M0<GKG!U(64*G-5V$%615@&<;*FX[U;YE<#5D5OE13O&<N8SD^_0GX"-G'?\
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MQD3TG2,F-DDI)'O.?.1C7K$:=1IG8OMW[;BJ[NN#29;RM,"I'(]0-KQ=T]=
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M4>M5[%O7JS]G;J\ -)ZXD &1Y1!&DO;T:CBK3;4N]7K54LCT #Q0C(F # 2
M<D\.9!.IQJ&CSC;30/>N+P6BNIQ@6D^?QZ'EH"ZS3*UL8M Y,S,2E)(YPG*
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MA$_&!Y;%;5N]:+15-=DU-&K4I<M55VM6IQ4020@"JM6(!US)P0,%GM*>L*0
M1I[  >8^@?\ EV"['=E#7PW'N@743=F<WHNI;Z5OEP+A.M#W)WA-<R<M92I:
MF0HFM,"=N1.Y:%*10@0IB1+**S]6 TU@&  ^SWHO;!LAHV=BG0HB**.RI$)F
M)D]F#TP,ZZD@'9:?;H;OW%U6>.FE>I6<'BK5 ]>4R3V-&AA%*O3I?54*29X!
M/#!Z$<[IOW,.A+2C>6,WSLW;-W9;BP\I^*CSNYW F\@2MH2-K/8'$2FA\>7%
MOJK!F=7-"E/,*J/3DJ>$*ZQ :A\W#>2\W*A4:/'8JMU@$([&C3(Q($TZ:,21
MQ:S B-OUOW6L=J=TGC%D4UJ(<FDNNZ>.NQ-101%(.7%4)BBI2>/ZSB)/&4F-
MFQ@EJI)'-0#6!)0!6(4C4 \7^\-&<8 0]X9]<[ MF79;.OC=A:<MX3#D31=M
MG.8ITRT+J8?=B* D332, %(TT(1//15E/T?4?>+&!VXT@FCS4YA1Q1!I1>T7
MM_9G 6SJ#L5R:U"J.*G4  QPX@S.01."1L$O=BM]\I4J;VB..F0*;FD>!S1Q
M$TUE*DK'_9UTU*4IIGLYI4^"7RZOAF9M!7?IHMJSBSZWUKP+3C(+4N[&L3D9
M\SJFR:O1*H[';)5*&GN/IV%Y1Z0@I$+LZ"9(PZ3XR#/*@S&H'AJ=I[5]&JBD
M<-VI <.#\FI!$*(3 +A0$=3U$X$[?OM7X969S=TI)D^KB,,2 A862<#%:1U?
M5AZ8?O.28OG3 4D.JSD*C*%P9$<Y\]OJ_2(!A%G1H"9=)'6,0U,=.LZYG.WJ
MEZ-UD F[4ID $6U)GI)!<@=",  8P3I2#H6W/.DG0?21((#&S9S=BA&:G4W@
MN#2C=Y?04I+X5A,?3 CH98>4?ZC'$"(\T.SB<Y>J5=MXKI=P$.7!30) Y6B.
MR;1K]5*N/3^N55]PU+W9MW+994D-: 573$.JQ[1Q)\*D)X, ":2:>@D;%;J[
MTA6UUIV4<K"7A.DU$%>79@?72B*R56P."U3'7BAV;4)RLE*=56U$KBR%8I1
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$2K;_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g280081g75s75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g280081g75s75.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %L:^6# X0DE-! 0      %,< @   @  ' )0  AR<C,Y,#DX.1P"!0 Z
M36EC<F]S;V9T(%=O<F0@+2!46$U$("T@4$]305-27U,M,T%34B S+C0N,C%?
M+3$X.3,X-34Q,"UV-0 X0DE-!"4      !":B4#288P>E1HA THVNR*$.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M     #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      -!    !@
M    -@   /P    & &< -P U ', -P U     0
M   !              #\    -@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    -@    !29VAT;&]N9P   /P    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   #8     4F=H=&QO;F<   #\     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    $.$))300,      Q%     0   )\    B
M   !X   /\    PI !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  B )\# 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#TW+S,?#QK,K)M%-%+=UMKC : O..L?XTNH6VNKZ+2W'H!TOO&^QW\IM4B
MNIO]?U$_^-'K%EN=1T6MT4X[1D9 'YUKOYEKO^*K_2?]<53_ !??5;%ZS??G
M]09ZN'B$,KI,AMEI&]WJ1])E#-OZ/\_>IH0B(\<M6&<Y&7!#3N6MCP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M%$$R%2-1@9$687$7&!HS.$*AL<$9)"<T8W.2E.'P\?_$ !P!  (" P$!
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MFR>5&D #$N!N-V?YH)H$$D4 :Y#\7U5FWCA>-ONJXJ@\\K,QQ4Y_^Y_5.?\
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ML HWR1B @9\N*#8)QRJF:M](JB)RJFI*UVX3E5[HO"HSP05W4%';D<>W)[@
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MTDW:PW^.@G9)UKL<WR15:4AZEY,E);#Z1FG4=.Q,RVN;'$CK9%MS\5+VKU(
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M7*&V]*E/NNNDYR1.$BKR@ @UMU.=\C/S9G)8SY3O*: W%C;&@ $LC@*%"]E
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MFGB;%T_&:LB9^#D$=TQN03)1.Z0;HCW%#[VBO,)UXQ?7#<';P-+XC53H1I!
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M1=;C1K3ZXTSLM(F\7J*33VZIY6/2L:QV.%'!"LEQUA2&61K6XW03T;EIQP$
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M=O*TY'2S7G$F,LQ&-<1<@KXZOOQ9M9;0W!09-=/84)$0I#8^G*5M>76R-KE
M,T+JP,W(T[(&3BRO#*$,>Y::T/<%7W(?Q()]+'7#J6#BZEBG%S(4FA,B/M.Y
M"'2]I#Q%)%^85@&_:!Z&X7T]/EE(G(Z/70B!F MIG.0KU-]*=*FZ3I.=:$O/
M(=*<?*$OB;_C=KWIFD?^[B/]J7_7\C?4%_$SPZ=Q^H#@G_CI_0?^UKGUX^8H
M]$0VG[,M#-E> 3],] <8/%\1M+YW(IT*782+60_:/L1X9/E,E KY=+#0" D1
M=*@/*J*=/B%S\_)U'(.3ER>;*4";BB)\ LA=J*JT"37'4]I^G8>EX_U7!A$,
M&\R;"SRG>42/<7F:20G9&@LMZ7W))EDH&G'?N0HI+RO=?RJ+QV_EQXX^N[H7
M&J'DV[ -9-0LMU-U%T-J<BS;-[,[G([YZSMFI4V>+;+(N"(2599$6F6FT$ 1
M>@>A2455%F<?Q!K.)#%CP:AD)##7E)N#!?S8$MS_ #B?SZ@\CPWHF7/D9.1I
MV+)-E2++-((8T+2(B1JP"*JI21H"J!5;;9%DD^)BWDF^7)@N78YF>-[>,?AW
M^*7E7DM%,_:5P7V-S3O-2J^4VT<IUHD;F,,R7&S$@)YM'$1"5>?F\2:Y-$\4
MFH3M'*CQNOF.+1^'4D$, P[[6![T1WZ\7PWH4,D$D6EXB/ R21,(EM7AYC)#
M;@]$!B) RD@6#7):(D4U:3K=4N#YZ53J#E%%4[*J?E$_A\?WKXANIWK$\GQ2
MBRZJM<:RFIK\@Q^XKY,.TI[5AJ976$=^.;+D>9"D,O-/-&!$)=2JYP7*&A)X
M]4E&5D9E9*VL"01Q7>[]!WOK%U61/+=5>.F!5@"&#?>#"OC##@[KXX[$]*S[
MR_IK-O.37UWJ%H+JE?Z'MVZN6+V#.T#&6XC!F2W_ %)04J+:4UG5PG#X4(8R
M9##">UEL![*>:9X[U&#^3Y4&/F(@_6$&*8GFR3'4?X?9WWZ7FI_1YIV4XEP<
MA\!G4 0LARL56LCS CRQY&^CV.28QW5%LV'N=Y#F;1+.QACN$QAYB!*:BBXY
MAMH#SR&G/J\)9.(Q_P"TAO<+RJ.HOQ/CQVAK_)C=KOZV"?>K./QQZ@CG]_0X
MWT;Y0 /\,8_(X_D$GH#R?Y;\CP/2N>_1!]M7TR^G^56=7=:O[D\BOZ+K:ES,
M:P[#(N.N3610''(3M_/NK>0#;O*@;T:OCR$!>6S;-$+Q&9OT@Y94IBX44!;]
MMY/.9!7908U0CG]M&X]>>)7!^CG#20'/SYLE%D#&/'C7%5A9'EDNV2^SW*NL
MA('Q@<=-)[9]G.@.T3!PP#0/3R@P>H!I@;.9"B@=UD3[(*/W=];N-G.GR'5Y
M)XG7B!Q?D.>_@"S,[*SYFFRIFF<]B] +[;46D4CM\*CL..!3$P=/Q--QUAPX
M$@C4$T@)9RP^+S)'+22[Z&_S'<MR"2.O@W=;,=%]Z^F;&D.NM9;V^%U=Y69,
MW"I;Z?1.R[2$:FR<Q^#Z;KC32J2M IDHJO8D[JN6GZCE:7D#)PY?+E"/&&9(
MWI'H, K*5L@"C0(/:N_6.JZ;AZMA28.;$9<:1D9T$T\)8QOO0F2"2*0$/R=K
M@$6#8^'H;0_3C>6:BHO^3[-E]R\_^(&0)VX+_P!=?RG_ /?S.'QIX@/;,4?_
M  V(?_L#H>_B#X8X_D$G'_IVH\_C_*^B);0]AVWS8MAV087M\QR70TF2VRW-
MVU;V<N[DSYY1QC^J_-F&4DQ%L1 &B,FVT1.@1\0FHZKFZQ,N3G.DDJIL5D18
M@%LV-L8519YNK^?N0Z7I&!H\#8V!$T,)=I2K2/,2[DAB7G,DA!W$;=^T"@!0
M6I1Y-C,#*,;R#%K5I'J?):>VH;:.CK@F_66D,Z^4R#HHAMD<:6^*&/N O3)%
M]JHO /A*D=U((^55[W[>H/4@PW!@?VN_I_91_P!P]N@DK].;Y9_"(&G68H4<
M(Y(JY_?_ +PVD DZE1U"Z2,C(U,G3+J5$(45>2@^,=?-?RP<=OY/BBOE?DV1
M^-]!Y\">&:). _ H5G:AP!Z _6K%T-U<M7Q%JZGYH]Y?&WO0N7H>]@M3=LSM
MO5#D&+:86=A?39T^GQ/+'AF7..RGGU,K*"<L&WHWW1$4<FVT;1! 1&&R-2R\
ME\AY60_6G$DX$:J'D >G 4!4-R,3L"CGL:%$.-IF)B)B)CJZ+A0G'QMTCRF.
M$K$I0M*7>0$00\R,YN-6!#63-Z,R2-]E$/>?8..G]2\+PH)QVX[(B(G'9/'!
%U(=?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
